<PAGE> 1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 26, 1998
REGISTRATION NO. 333-
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------------
INTEGRATED SURGICAL SYSTEMS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 1850 RESEARCH PARK DRIVE 60-0232575
(STATE OR OTHER JURISDICTION OF DAVIS, CALIFORNIA 95616-4884 (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION) TELEPHONE: (530) 792-2600
TELECOPIER: (530) 792-2690
</TABLE>
(ADDRESS AND TELEPHONE NUMBER OF PRINCIPAL EXECUTIVE OFFICES)
-------------------------
DR. RAMESH C. TRIVEDI
CHIEF EXECUTIVE OFFICER AND PRESIDENT
INTEGRATED SURGICAL SYSTEMS, INC.
1850 RESEARCH PARK DRIVE
DAVIS, CALIFORNIA 95616-4884
TELEPHONE: (530) 792-2600
TELECOPIER: (530) 792-2690
(NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE,
OF AGENT FOR SERVICE)
-------------------------
A COPY OF ALL COMMUNICATIONS, INCLUDING COMMUNICATIONS SENT TO THE AGENT FOR
SERVICE SHOULD BE SENT TO:
JACK BECKER, ESQ.
SNOW BECKER KRAUSS P.C.
605 THIRD AVENUE
NEW YORK, N.Y. 10158-0125
TELEPHONE: (212) 687-3860
TELECOPIER: (212) 949-7052
APPROXIMATE DATE OF PROPOSED SALE TO THE PUBLIC: As soon as practicable
after the effective date of this registration statement.
-------------------------
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this form are to be offered or
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [X]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
-------------------------
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
- ---------------------------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------------------------
PROPOSED MAXIMUM PROPOSED MAXIMUM
TITLE OF EACH CLASS OF AMOUNT TO BE AGGREGATE OFFERING AGGREGATE AMOUNT OF
SECURITIES TO BE REGISTERED REGISTERED PRICE PER SECURITY(1) OFFERING PRICE(1) REGISTRATION FEE(2)
<S> <C> <C> <C> <C>
- ---------------------------------------------------------------------------------------------------------------------------------
Common Stock, $0.1 par value................... 1,760,000(2) $2.875(3) $5,060,000 $1,406.08
Common Stock, $.01 par value................... 44,000(4) $2.875(3) 126,500 35.17
Common Stock, $.01 par value................... 5,000(5) $2.875(3) 14,375 4.00
-------------------
Total Registration Fee................ $1,445.85
- ---------------------------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) Estimated solely for the purpose of calculating the registration fee
pursuant to Rule 457 promulgated under the Securities Act of 1933.
(2) Represents shares that may be acquired by the Selling Securityholders named
herein (the "Selling Securityholders") upon conversion of the 3,520 shares
of the Registrant's Series A Convertible Preferred Stock (the "Series A
Preferred Stock"), assuming a conversion price of $2.00 per share. The
number of shares of Common Stock issuable upon conversion of the Series A
Preferred Stock is equal to the quotient of (x) the product of $1,000 and
the number of shares to be converted, and (y) 85% of the lowest sale price
of the Common Stock on the Nasdaq SmallCap Market (or the principal market
on which the Common Stock is than traded) for the five day trading period
prior to the date of conversion. The conversion price would have been $2.34
if the date of conversion was October 23, 1998. Includes an indeterminate
number of shares which may become issuable in the event of a stock split,
stock dividend or similar transaction involving the Common Stock pursuant to
the antidilution provisions of the Series A Preferred Stock.
(3) Calculated solely for the purpose of determining the registration fee
pursuant to Rule 457(g)(3) based upon the closing price of the Common Stock
on the Nasdaq SmallCap Market on October 23, 1998.
(4) Represents shares issuable upon exercise of warrants (the "Warrants") issued
to the Selling Securityholders in connection with the issuance and sale of
the Series A Preferred Stock. Includes an indeterminate number of shares
which may become issuable in the event of a stock split, stock dividend or
similar transaction involving the Common Stock pursuant to the antidilution
provisions of the Warrants.
(5) Represents shares issued to a registered broker-dealer in connection with
the issuance and sale of the Series A Preferred Stock and the Warrants.
-------------------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT
SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID
SECTION 8(a), MAY DETERMINE.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
PRELIMINARY PROSPECTUS, SUBJECT TO COMPLETION, DATED OCTOBER 26, 1998
1,809,000 SHARES
INTEGRATED SURGICAL SYSTEMS, INC.
COMMON STOCK
The securityholders named below under the caption "Selling Securityholders" are
offering and selling up to 1,809,000 shares of the common stock of Integrated
Surgical Systems, Inc. under this Prospectus, including up to 1,804,000 shares
that they may acquire upon conversion of 3,520 shares of Series A Convertible
Preferred Stock and 44,000 shares that they may acquire upon exercise of
warrants. The Selling Securityholders acquired the shares of Series A
Convertible Preferred Stock, the warrants and the other 5,000 shares of common
stock that they are offering for sale under this Prospectus in the private
financing described below under the caption "The Company -- Recent
Developments -- Preferred Stock Financing."
The Selling Securityholders may offer their shares of common stock in the manner
described below under the caption "Plan of Distribution" in public or private
transactions on or off the Nasdaq SmallCap Market, at prevailing market prices
or privately negotiated prices. Sales may be made through brokers, dealers or
other agents who may receive compensation in the form of commissions, discounts
or concessions. The Selling Securityholders and participating brokers or dealers
may be deemed to be "underwriters" within the meaning of the Securities Act and
any commission, discount or concession they receive may be deemed to be
underwriting compensation.
The common stock is quoted on The Nasdaq SmallCap Market under the symbol
"RDOC", and is listed on the Pacific Exchange Incorporated under the symbol
"ROB". The common stock also has been admitted for trading on the European
Association of Securities Dealers' Automated Quotation system under the symbol
"RDOC". On October 21, 1998, the closing sale price of one share of common stock
on The Nasdaq SmallCap Market was $3.00.
Integrated Surgical Systems, Inc. will not receive any proceeds from the sale of
the common stock, but will receive the exercise price of the warrants.
THE COMMON STOCK IS A SPECULATIVE INVESTMENT AND INVOLVES A HIGH DEGREE OF RISK.
YOU SHOULD READ THE DESCRIPTION OF CERTAIN RISKS UNDER THE CAPTION "RISK
FACTORS" COMMENCING ON PAGE 8 BEFORE PURCHASING THE COMMON STOCK.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE COMMISSION OR
ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS
PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
-------------------------
THE DATE OF THIS PROSPECTUS IS , 1998
INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A
REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY
OFFERS TO BUY BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE
REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE
AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY
SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE
WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES
LAWS OF ANY STATE.
<PAGE> 3
AVAILABLE INFORMATION
We file reports, proxy statements and other information with the Securities and
Exchange Commission (the "Commission). You may read and copy any document we
file at the Public Reference Room of the Commission at Judiciary Plaza, 450
Fifth Street, N.W., Washington, D.C. 20549 and at the Regional Offices of the
Commission at Seven World Trade Center, Suite 1300, New York, New York 10048 and
at 500 West Madison Street, Suite 1400, Chicago, Illinois 60661-2511. Please
call 1-800-SEC-0330 for further information concerning the Public Reference
Room. Our filings also are available to the public from the Commission's website
at www.sec.gov. We distribute to our stockholders annual reports containing
audited financial statements.
INFORMATION INCORPORATED BY REFERENCE
The Commission allows us to "incorporate by reference" the information we file
with it, which means that we can disclose important information to you by
referring to those documents. The information incorporated by reference is
considered to be part of this Prospectus, and information we file later with the
Commission will automatically update and supersede this information. We
incorporate by reference the documents listed below and any future filings we
make with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the
Securities Exchange Act of 1934 (the "Exchange Act"):
1. The Company's Annual Report on Form 10-KSB for the fiscal year ended
December 31, 1997.
2. The Company's Proxy Statement dated March 26, 1998.
3. The Company's Quarterly Reports on Form 10-QSB for the fiscal quarters
ended March 31, 1998 and June 30, 1998.
4. The description of the Company's common stock contained in the
Company's Registration Statement on Form 8-A (File No. 1-12471) under
Section 12 of the Exchange Act.
You may request a copy of these filings, at no cost, by writing or calling us
at:
INTEGRATED SURGICAL SYSTEMS
1850 Research Park Drive
Davis, California 95616-4884
Attention: Corporate Secretary
Telephone: (530) 792-2600
-------------------------
This Prospectus is part of a registration we filed with the Commission. You
should rely only on the information or representations provided in this
Prospectus. We have authorized no one to provide you with different information.
No offer of the common stock will be made in any state where the offer is not
permitted. You should not assume that the information in this Prospectus is
accurate as of any date other than the date on the cover of this Prospectus.
2
<PAGE> 4
CAUTIONARY STATEMENT FOR PURPOSES
OF THE "SAFE HARBOR" PROVISIONS OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
THIS PROSPECTUS AND THE DOCUMENTS INCORPORATED HEREIN BY REFERENCE CONTAIN
FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES
ACT OF 1933 AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, CONCERNING
OUR FUTURE OPERATIONS. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ESTIMATE
THE HAPPENING OF FUTURE EVENTS, ARE NOT BASED ON HISTORICAL FACT AND ARE
"FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY
THE USE OF FORWARD-LOOKING TERMINOLOGY SUCH AS "BELIEVES", "INTENDS",
"PROJECTS", "FORECASTS", "PREDICTS", "MAY", "WILL", "EXPECTS", "ESTIMATES",
"ANTICIPATES", "PROBABLE", "CONTINUE" OR SIMILAR TERMS, VARIATIONS OF THOSE
TERMS OR THE NEGATIVE OF THOSE TERMS. THE "RISK FACTORS" INCLUDED IN THIS
PROSPECTUS UNDER THE CAPTION "RISK FACTORS" CONSTITUTE CAUTIONARY STATEMENTS
IDENTIFYING IMPORTANT FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER
MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS. THE FORWARD-LOOKING
STATEMENTS CONTAINED IN THIS PROSPECTUS AND THE DOCUMENTS INCORPORATED HEREIN BY
REFERENCE HAVE BEEN COMPILED BY OUR MANAGEMENT BASED UPON ASSUMPTIONS THEY
CONSIDER REASONABLE. THESE ASSUMPTIONS ARE SUBJECT TO SIGNIFICANT BUSINESS,
ECONOMIC AND COMPETITIVE UNCERTAINTIES AND CONTINGENCIES, MANY OF WHICH ARE
BEYOND OUR CONTROL. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE CURRENTLY
ANTICIPATED DUE TO A NUMBER OF FACTORS, INCLUDING THOSE IDENTIFIED UNDER "RISK
FACTORS" AND ELSEWHERE IN THIS PROSPECTUS. ACCORDINGLY, THERE CAN BE NO
ASSURANCE THAT SUCH STATEMENTS, ESTIMATES AND PROJECTIONS WILL BE REALIZED. THE
FORECASTS AND ACTUAL RESULTS WILL LIKELY VARY AND THOSE VARIATIONS MAY BE
MATERIAL. WE MAKE NO REPRESENTATION OR WARRANTY AS TO THE ACCURACY OR
COMPLETENESS OF SUCH STATEMENTS, ESTIMATES OR PROJECTIONS CONTAINED IN THIS
PROSPECTUS OR THAT ANY FORECAST CONTAINED IN THIS PROSPECTUS WILL BE ACHIEVED.
THESE FORWARD-LOOKING STATEMENTS HAVE BEEN COMPILED AS OF THE DATE OF THIS
PROSPECTUS OR THE DATE OF THE DOCUMENTS INCORPORATED HEREIN BY REFERENCE, AS THE
CASE MAY BE, AND YOU SHOULD EVALUATE THEM WITH CONSIDERATION OF ANY CHANGES
OCCURRING AFTER THE DATE OF THIS PROSPECTUS OR THE DOCUMENTS INCORPORATED HEREIN
BY REFERENCE IN WHICH SUCH FORWARD-LOOKING STATEMENTS APPEAR. WE DO NOT INTEND
TO UPDATE THESE FORWARD-LOOKING STATEMENTS. WE CANNOT GIVE YOU ANY ASSURANCE
THAT ANY OF THE ASSUMPTIONS RELATING TO THE FORWARD-LOOKING STATEMENTS SPECIFIED
IN THIS PROSPECTUS OR THE DOCUMENTS INCORPORATED HEREIN BY REFERENCE WILL PROVE
TO BE ACCURATE. WE URGE YOU AND YOUR ADVISORS TO REVIEW THESE FORWARD-LOOKING
STATEMENTS, TO CONSIDER THE ASSUMPTIONS UPON WHICH THEY ARE BASED AND TO
ASCERTAIN THEIR REASONABLENESS.
3
<PAGE> 5
THE COMPANY
At Integrated Surgical Systems, Inc., we develop, assemble, market and service
image-directed, computer-controlled robotic products for orthopaedic and
neurosurgical applications. Our principal orthopaedic product is the ROBODOC(R)
Surgical Assistant System (the "ROBODOC System"), consisting of a
computer-controlled surgical robot and our ORTHODOC(R) Presurgical Planner (the
"ORTHODOC"), and our principal neurosurgical product is the NeuroMate
System.(TM)
The ROBODOC System has been used for primary total hip arthroplasty ("THA")
surgery on over 3,000 patients in Europe. We believe our "active" robotic system
is the only available system that can accurately perform key segments of
surgical procedures with precise tolerances generally not attainable by
traditional manual surgical techniques. The ROBODOC System also allows the
surgeon to prepare a preoperative plan specifically designed for the
characteristics of the individual patient's anatomy. We cannot market the
ROBODOC System in the United States until we obtain clearance or approval from
the U.S. Food and Drug Administration (the "FDA").
The ORTHODOC is a computer workstation that utilizes our proprietary software
for preoperative surgical planning. The ORTHODOC is part of the ROBODOC System,
but we also market the ORTHODOC separately. We received 510(k) clearance from
the FDA to market the ORTHODOC in the United States on a stand-alone basis in
January 1997.
Over 1,800 neurosurgical procedures have been performed with the NeuroMate
System in Europe and Japan. We believe that the NeuroMate System, which uses its
proprietary robotic arm design and control systems designed specifically for use
in the operating room, is the only image-guided, computer-controlled
stereostatic robot currently in use to precisely position and hold critical
tool's used in the performance of neurosurgical procedures. We began marketing
the NeuroMate System in the United States in the fourth quarter of 1997. The
NeuroMate System received 510(k) clearance form the FDA for marketing in the
United States in May 1997.
We were incorporated under the laws of the State of Delaware on October 1, 1990.
Our offices are located at 1850 Research Park Drive, Davis, California 95616,
and our telephone number is (530)792-2600.
RECENT DEVELOPMENTS
DIGIMATCH SINGLE SURGERY SYSTEM
We have developed and commenced marketing to our customers in Europe our
DigiMatch Single Surgery System, a pinless registration system that, in most
cases, eliminates the need for an initial surgery to place registration pins in
a patient's femur before using the ROBODOC System in THA surgery. More than 100
patient THA surgeries have been successfully performed at the
Berufsgenossenschaftliche Unfallklinic in Frankfurt, Germany.
We plan to amend our Investigational Device Exemption ("IDE") under which we
conducted clinical trials for the ROBODOC System in the United States to permit
us to perform a relatively small clinical study showing a correlation between
the ROBODOC System using the DigiMatch technology and the three pin system that
we used in our initial clinical evaluations. We have deferred the filing of our
pre-market approval ("PMA") application to market the ROBODOC System in the
United States so that we may incorporate our DigiMatch Single Surgery System,
and possibly other technical developments, as part of our PMA submission. We
believe, based upon our discussions with representatives of the FDA, that the
incorporation of the DigiMatch Single Surgery System will enhance our prospects
for obtaining FDA approval. However, we cannot give you any assurance as to when
or if the FDA will approve our PMA to market the ROBODOC System or that such
approval, if obtained, will not include unfavorable limitations or restrictions.
See "Risk Factors -- Available
4
<PAGE> 6
Clinical Data; Risk Versus Benefit Issues" and "Risk Factors -- Government
Regulation -- U.S. Regulation."
PREFERRED STOCK FINANCING
On September 10, 1998, we issued and sold 3,520 shares of Series A Convertible
Preferred Stock ("Series A Preferred Stock") and warrants ("Warrants") to
purchase 44,000 shares of our common stock, par value $.01 per share ("Common
Stock"), to two of the Selling Securityholders, each an institutional accredited
investor, for a total purchase price of $3,520,000, pursuant to a Preferred
Stock Purchase Agreement dated as of August 25, 1998 (the "Purchase Agreement").
The Series A Preferred Stock and Warrants were issued (and the Common Stock
issuable upon conversion or exercise thereof will be issued) pursuant to the
exemption from the registration requirements of the Securities Act of 1933 (the
"Securities Act") provided by Section 4(2) of the Securities Act and Regulation
D promulgated by the Commission under that Section.
The Series A Preferred Stock is convertible into shares of Common Stock, at the
option of the holder thereof, commencing December 9, 1998, subject to certain
limitations, discussed below. The number of shares of Common Stock issuable upon
conversion of the Series A Preferred Stock is equal to the quotient of (x) the
product of $1,000 (the stated value of each share of Series A Preferred Stock)
and the number of shares of Series A Preferred Stock to be converted and (y) 85%
of the lowest sale price of the Common Stock on the Nasdaq SmallCap Market
during the five trading days preceding the date of conversion (the "Market
Price"), but in no event more than $4.96 (the "Conversion Price"). The lowest
sale price of one share of Common Stock for the five trading days immediately
preceding October 23, 1998 was $2.75. Accordingly, the Conversion Price on that
date would have been $2.34.
Holders of Series A Preferred Stock may convert 25% of their shares commencing
December 9, 1998, 50% of their shares commencing January 8, 1999, 75% of their
shares commencing February 7, 1999 and 100% of their shares commencing March 9,
1999. No holder may convert the Series A Preferred Stock to the extent such
conversion would result in the holders in the aggregate acquiring more than
1,127,674 shares of Common Stock (the "Maximum Shares"), representing 20% of the
number of shares of Common Stock outstanding on September 10, 1998 (the date
upon which the Series A Preferred Stock and the Warrants were issued), unless
and until our stockholders approve the issuance of the Series A Preferred Stock
to the Selling Securityholders pursuant to the Purchase Agreement. Until we
obtain such stockholder approval, a holder requesting conversion may only
receive cash equal to the product of (i) the number of shares of Common Stock in
excess of the Maximum Shares otherwise issuable upon conversion and (ii) the
closing price of the Common Stock on the date of conversion. We may require
holders to convert all (but not less than all) of the Series A Preferred Stock
at any time after August 24, 2001, or buy out all outstanding shares, at the
then Conversion Price.
Holders of Series A Preferred Stock are not entitled to dividends and have no
voting rights, unless required by law or with respect to certain matters
relating to the Series A Preferred Stock.
We may redeem the Series A Preferred Stock upon written notice to the holders of
the Series A Preferred Stock at any time after the earlier of January 10, 1999
and the closing of a registered firm commitment underwritten secondary offering
of our equity securities, at a redemption price equal to the greater of $1,500
per share and the Market Price of the shares of Common Stock into which such
shares of Series A Preferred Stock could have been converted on the date of the
notice of redemption.
The Conversion Price and the number of shares of Common Stock issuable upon
conversion is subject to adjustment in the event of a stock split, stock
dividend, reorganization, reclassification or
5
<PAGE> 7
issuances of shares of Common Stock (or securities convertible into or
exercisable or exchangeable for Common Stock) prior to , 1999 [the
first anniversary of the effective date of the registration statement of which
this Prospectus is a part] at less than the then Conversion Price in
transactions exempt from the registration requirements of the Securities Act if
the Company grants the purchasers of such shares (or other securities) the right
to demand registration of such shares.
The Warrants are exercisable at any time during the period commencing March 5,
1999 and ending March 5, 2002, at an exercise price of $4.31, subject to
adjustment in the event of a stock split, stock dividend, reclassification,
recapitalization, merger, consolidation or certain dispositions of assets.
6
<PAGE> 8
RISK FACTORS
The shares of Common Stock offered hereby are speculative and involve a high
degree of risk, including, but not limited to, the risk factors described below.
Each prospective investor should carefully consider the following risk factors
before making an investment decision.
HISTORY OF LOSSES; ACCUMULATED DEFICIT; ANTICIPATED FUTURE LOSSES. Since its
inception, we have incurred losses. We incurred a net loss of approximately
$4,478,000 (on net sales of approximately $4,934,000) for the fiscal year ended
December 31, 1997 and a net loss of approximately $3,449,000 (on net sales of
approximately $2,280,000) for the fiscal year ended December 31, 1996. We
incurred a net loss of approximately $4,531,000 (on net sales of approximately
$3,411,000) for the six months ended June 30, 1998, as compared to a net loss of
approximately $1,688,000 (on net sales of approximately $1,380,000) for the six
months ended June 30, 1997. At June 30, 1998, our accumulated deficit was
approximately $28,110,000 as a result of continuing losses. We expect to
continue to incur operating losses until such time, if ever, as we derive
significant revenues from the sale of our products. Our ability to operate
profitably depends upon market acceptance of our orthopaedic and neurosurgical
products, our development of an effective sales and marketing organization, and
our development of new products and improvements to existing products. We cannot
give you any assurance that we will obtain FDA approval to market the ROBODOC
System in the United States or that our products will achieve market acceptance
in the United States, Europe and other foreign markets to generate sufficient
revenues to become profitable.
LIMITED OPERATING HISTORY. Although commercial sales of the ROBODOC System have
been made in Europe and Japan, we have engaged only in clinical testing of the
ROBODOC System in the United States, and our ability to market the ROBODOC
System in the United States is dependent upon FDA approval. See "Risk
Factors -- Government Regulation." Accordingly, you must evaluate us in light of
the uncertainties, delays, difficulties and expenses commonly experienced by
companies with limited operating experience, which generally include
unanticipated problems and additional costs relating to the development and
testing of products, product approval or clearance, regulatory compliance,
commencement of production, product introduction and marketing, and competition.
Many of these factors may be beyond our control, including but not limited to
unanticipated results of product tests requiring modification in product design,
changes in applicable government regulations or the interpretation thereof,
market acceptance of our products and development of competing products by
others. In addition, our future performance also will be subject to other
factors beyond our control, including general economic conditions and conditions
in the healthcare industry or targeted commercial markets. See "Risk
Factors -- Dependence on Principal Product," "-- Uncertainty of Market
Acceptance," "-- Competition," "-- Available Clinical Data; Risk Versus Benefit
Issues" and "-- Government Regulation."
LENGTHY SALES CYCLE. Since the purchase of a ROBODOC System or NeuroMate System
(each, a "System," and collectively, the "Systems") represents a significant
capital expenditure for a customer, the placement of orders may be delayed due
to customers' internal procedures to approve large capital expenditures. We
anticipate that the period between initial contact of a customer for a System
and submission of a purchase order by that customer could be as long as 9 to 12
months. Furthermore, the current lead time required by the supplier of the robot
for either the ROBODOC System or the NeuroMate System is approximately four
months after receipt of the order. Although we generally intend to require a
deposit upon receipt of an order for a System, we may be required to expend
significant cash resources to fund our operations until the balance of the
purchase price is paid. Accordingly, we may not recognize a significant portion
of the sales price of a System until a fiscal quarter subsequent to the fiscal
quarter in which we incurred marketing and sales expenses associated with an
order.
7
<PAGE> 9
CHALLENGES OF GROWTH. We plan to expand our sales and marketing, research and
development and technical personnel to increase and support sales of Systems and
to develop additional surgical applications for our orthopaedic and
neurosurgical systems. Our anticipated growth will likely result in new and
increased responsibilities for management personnel and place significant strain
upon our management, operating and financial systems and resources. To
accommodate such growth and compete effectively, we must continue to implement
and improve our operational, financial, management and information systems,
procedures and controls, and to expand, train, motivate and manage our
personnel. We cannot give you any assurance that our personnel, systems,
procedures and controls will be adequate to support our future operations. If we
fail to implement and improve our operational, financial, management and
information systems, procedures or controls, or to expand, train, motivate or
manage our employees, our business, financial condition and results of
operations could be materially and adversely affected.
DEPENDENCE ON PRINCIPAL PRODUCT. For the near term, we expect to derive most of
our revenues from sales of the ROBODOC System. Accordingly, our potential future
success and financial performance will depend almost entirely on our ability to
successfully market the ROBODOC System. If we are unable to obtain the requisite
regulatory approvals or to achieve commercial acceptance of the ROBODOC System,
our business, financial condition and results of operations will be materially
and adversely affected. We have not obtained, and we cannot give you any
assurance that we will obtain, clearance or approval to market the ROBODOC
System in the United States. See "Risk Factors -- Government Regulation."
UNCERTAINTY OF MARKET ACCEPTANCE. To successfully commercialize our Systems we
must commit substantial marketing efforts and expend significant funds to inform
potential customers, including hospitals and physicians, of the distinctive
characteristics and advantages of using the Systems instead of traditional
surgical tools and procedures. Since the Systems employ innovative technology,
rather than being an improvement of existing technology, and represent a
substantial capital expenditure, we expect to encounter resistance to change,
which we must overcome to successfully market our products. If our Systems do
not achieve significant market acceptance, our business, financial condition and
results of operations would be materially and adversely affected.
COMPETITION. The principal competition for the ROBODOC System is manual surgery
performed by orthopaedic surgeons, using surgical power tools and manual
devices. The providers of these instruments are the major orthopaedic companies,
which include Howmedica, Inc. (a subsidiary of Stryker Corporation), located in
New York; Zimmer, Inc. (a subsidiary of Bristol-Myers Squibb Company), located
in Indiana; Johnson & Johnson Orthopaedics, Inc. (a subsidiary of Johnson &
Johnson), located in New Jersey; DePuy, Inc. (a subsidiary of Johnson & Johnson)
located in Indiana; Biomet, Inc., located in Indiana; and Osteonics, Inc. (a
subsidiary of the Stryker Corporation), located in New Jersey. MAQUET, a
manufacturer of operating tables located in Germany, has announced that it
intends to market a device similar to the ROBODOC System. The principal
competition for the NeuroMate System are frame-based and frameless navigators,
which are manually operated. Approximately twenty navigator models have been
introduced, including those by Radionics, Sofamor-Danek and Ohio Medical
Surgical products, all located in the United States; Elekta, located in Sweden;
and Fischer Leibingher and Brain Lab, both located in Germany. In general, there
are companies in the medical products industry capable of developing and
marketing computer-controlled robotic systems for surgical applications, many of
whom have significantly greater financial, technical, manufacturing, marketing
and distribution resources than us, and have established reputations in the
medical device industry. Furthermore, we cannot give you any assurance that IBM
or the University of California, which developed the technology embodied in the
ROBODOC System and hold patents relating thereto, will not enter the market or
license the technology to other companies.
8
<PAGE> 10
We cannot give you any assurance that future competition will not have a
material adverse effect on our business. The cost of the Systems represents a
significant capital expenditure for a customer and accordingly may discourage
purchases by certain customers.
AVAILABLE CLINICAL DATA; RISK VERSUS BENEFIT ISSUES. We conducted a randomized
clinical trial for the ROBODOC System in the United States at three centers. Of
the 120 patients enrolled in the U.S. clinical study, 71 hips received treatment
with the ROBODOC System and 65 hips in a control group received conventional THA
surgery. In addition, a group of at least 1,400 patients have received treatment
with the ROBODOC System at the Berufsgenossenschaftliche Unfallklinic in
Frankfurt, Germany, although not as a part of the formal U.S. clinical study and
without comparison to randomized control patients.
In order to obtain FDA clearance or approval, we must demonstrate that the
ROBODOC System is safe and effective, and we may be required to show a clinical
benefit to patients. We believe that a reduced incidence of intraoperative
fractures with the ROBODOC System compared to conventional THA surgery would
offer an important benefit. The number of patients enrolled in the U.S. clinical
study is less than the 300 patients (150 ROBODOC System; 150 control group) we
initially requested to study in our Investigational Device Exemption ("IDE")
application to the FDA. Nonetheless, over 3,000 primary THA surgeries have been
performed with the ROBODOC System in the U.S. clinical trial and the European
treatment population without a single intraoperative fracture. Since the
observed fracture rate in the control group in the U.S. clinical trial was lower
than anticipated, the data from this study are not sufficient to establish a
statistically significant reduction in intraoperative fractures compared to the
control group. Nevertheless, the data from both the U.S. and the European group
of patients suggest that the ROBODOC System reduces intraoperative fractures
when compared to the fracture rate of approximately 3 to 28 percent for
conventional THA surgery reported in the scientific and medical literature.
However, we cannot give you any assurance that the FDA will agree that the
ROBODOC System offers a clinically significant reduction in intraoperative
fractures, in the absence of a controlled trial demonstrating such a reduction,
or that such a reduction is of clinical benefit to patients.
The FDA has advised us that it believes long-term functional assessments are the
primary endpoints for evaluating the safety and effectiveness of the ROBODOC
System. Our preliminary review of the functional assessment data from the U.S.
clinical trial shows equivalence between the ROBODOC System and conventional THA
surgery. We believe that achieving better implant fit and alignment in the
femoral cavity are significant factors in the success of cementless THA surgery,
although the FDA has questioned whether fit is an appropriate endpoint and has
not addressed alignment.
Our most recent statistical analysis of fit and alignment parameters from the
3-month radiographs showed that the ROBODOC System surgeries produced better fit
and alignment when compared to conventional THA surgeries. We believe a more
accurate fit of the prosthesis reflects the implant manufacturers' design goals
for implant cavity preparation. We also reviewed 24-month radiographs evaluating
prosthesis stability. We cannot give you any assurance that the FDA will accept
our data that demonstrates the ROBODOC System achieves better implant fit,
alignment and stability, or that the FDA will agree that better fit and
alignment are significant surgical endpoints. In addition, we cannot give you
any assurance that the FDA will agree that the greater surgery time and blood
loss associated with the ROBODOC System does not pose a significant safety
concern or create an unfavorable risk/benefit ratio. Further, we cannot give you
any assurance that the FDA will not require us to obtain additional clinical
data from a randomized, controlled trial to resolve any concern about the
risk/benefit ratio offered by the ROBODOC System. If we must obtain such
additional data, the FDA review process could be prolonged by several years.
In February 1995, a law firm specializing in FDA regulatory matters examined an
interim report of preliminary data and concluded that it was doubtful that the
FDA would find that the device was
9
<PAGE> 11
safe and effective for its intended use, or provided a therapeutic benefit,
sufficient to permit PMA approval, if the FDA were presented with the then
existing preliminary data or future data qualitatively similar to the
preliminary data. We believe that the additional data analyzed subsequent to the
law firm's February 1995 report address many of the concerns identified in that
report. These data and analyses include non-radiographic clinical follow-up data
from the U.S. trial, preliminary analysis and review by an outside radiologist
and an outside biostatistician of 3-month, 12-month and 24-month radiographic
films from the U.S. clinical trial. We cannot give you any assurance that the
data, once fully analyzed and reviewed, will demonstrate that the ROBODOC System
is safe and effective for its intended use, provides a clinical benefit, or has
an acceptable risk/benefit ratio in light of increased surgery time and
intraoperative blood loss. In addition, our Director of Regulatory Affairs and
Quality Assurance resigned in September 1996 and subsequently has asserted that
one of the reasons for his resignation was his concern, similar to that
expressed in the February 1995 law firm report, about the adequacy of our
clinical data to support product approval. See "Risk Factors -- U.S.
Regulation -- FDA Review Process for ROBODOC System."
If the FDA concludes that the existing clinical data are insufficient to
establish the safety and efficacy of the ROBODOC System, the FDA could require
us to obtain additional clinical data from a randomized, controlled trial, which
could significantly delay completion of the PMA review process, and accordingly
have a material adverse effect on our business, financial condition and results
of operations.
GOVERNMENT REGULATION.
SUMMARY. Our products are subject to continued and pervasive regulation by the
FDA and foreign and state regulatory authorities. In the United States, we must
comply with food and drug laws and with regulations promulgated by the FDA.
These laws and regulations require us to obtain various authorizations prior to
marketing our products in the United States, and we cannot give you any
assurance that our products will receive these authorizations. Our manufacturing
facilities and practices also are subject to FDA regulations. In each foreign
market, our products may be subject to substantially different regulations. If
we fail to comply with U.S. or applicable foreign regulations, our business
could be materially and adversely affected.
U.S. REGULATION.
GENERAL. Pursuant to the Federal Food, Drug, and Cosmetic Act, as amended, and
regulations thereunder (collectively, the "FDC Act"), the FDA regulates the
clinical testing, manufacture, labeling, sale, distribution and promotion of
medical devices in the United States. Noncompliance with applicable requirements
can result in, among other things, fines, injunctions, civil penalties, recall
or seizure of products, total or partial suspension of production, failure of
the government to grant pre-market clearance or pre- market approval for
devices, withdrawal of marketing clearances or approvals, and criminal
prosecution. The FDA also has the authority to request recall, repair,
replacement or refund of the cost of any device that we manufacture or
distribute. If we fail to comply with regulatory requirements, including any
future changes to such requirements, our business, financial condition and
results of operations could be materially and adversely affected.
FDA REVIEW PROCESS FOR ROBODOC SYSTEM. Before a new device can be introduced
into the U.S. market, the manufacturer must obtain FDA permission to market
through either the 510(k) pre-market notification process for medical devices
which are substantially similar to other approved medical devices or the
costlier, lengthier and less certain pre-market approval ("PMA") application
process. Following a pre-filing meeting with representatives of the FDA in early
1998, we stated that we intended to file our PMA to market the ROBODOC System
with the FDA in the second quarter of 1998. As a result of further discussions
with representatives of the FDA as part of the pre-
10
<PAGE> 12
submission review process (which process is intended to expedite the FDA's
formal pre-market approval process), we have deferred the filing of the PMA so
that we may incorporate our DigiMatch Single Surgery System, and possibly other
technical developments, as part of the PMA submission. We believe, based upon
our discussions with representatives of the FDA, that the incorporation of the
DigiMatch Single Surgery System will enhance our prospects for obtaining FDA
approval. However, we cannot give you any assurance as to when or if the FDA
will grant PMA approval to the ROBODOC System or that such approval, if
obtained, will not include unfavorable limitations or restrictions. See "Risk
Factors -- Available Clinical Data; Risk Versus Benefit Issues."
New surgical applications for the ROBODOC System generally will require FDA
clearance or approval of a new 510(k) submission or a PMA supplement or,
possibly, a new PMA application. We also are likely to require additional FDA
approvals, supported by additional clinical data, before incorporating new
imaging modalities such as ultrasound and MRI or other different technologies in
the ROBODOC System.
NO ASSURANCE OF APPROVALS; SUBSEQUENT REVIEW OF APPROVALS, ETC. We cannot give
you any assurance that any of our current or future products will obtain
required FDA approvals on a timely basis, or at all, or that we will have the
necessary resources to obtain such approvals. If any of our products are not
approved for use in the United States, we will be limited to marketing them in
foreign countries. Furthermore, approvals that have been or may be granted are
subject to continual review, and later discovery of previously unknown problems
can result in product labeling restrictions or withdrawal of the product from
the market.
ADVERSE EFFECT OF DELAYS OR LOSS OF APPROVALS. If we experience delays in the
receipt of, or fail to receive, FDA approvals or clearances, or lose any
previously received approvals or clearances, or the FDA imposes limitations on
intended use as a condition of such approvals or clearances, our business,
financial condition and results of operations could be materially and adversely
affected.
REQUIREMENT TO FOLLOW GOOD MANUFACTURING PRACTICES. Assuming we obtain the
necessary FDA approvals and clearances for our products, in order to maintain
such approvals and clearances we must, among other things, register our
establishment and list our devices with the FDA and with certain state agencies,
maintain extensive records, report any adverse experiences on the use of our
products and submit to periodic inspections by the FDA and certain state
agencies. The FDC Act also requires devices to be manufactured in accordance
with the Quality System Regulation ("QSR"), which sets forth good manufacturing
practices ("GMP") requirements with respect to manufacturing and quality
assurance activities. The QSR revises the previous GMP regulation and imposes
certain enhanced requirements that are likely to increase the cost of
compliance, including design controls.
MODIFICATIONS TO CLEARED DEVICES. We have made certain minor modifications to
the ORTHODOC and the NeuroMate System which we do not believe require the
submission of new 510(k) notices. However, we cannot give you any assurance that
the FDA would agree with any of our determinations not to submit a new 510(k)
notice for any of these changes or would not require us to submit a new 510(k)
notice for any of the changes made to the device. If the FDA requires us to
submit a new 510(k) notice for any device modification, we may be prohibited
from marketing the modified device until the 510(k) notice is cleared by the
FDA.
FOREIGN REGULATION. The introduction of our products in foreign markets has
subjected and will continue to subject us to foreign regulatory clearances,
which may be unpredictable and uncertain, and which may impose substantial
additional costs and burdens. The ROBODOC and NeuroMate Systems satisfy the
appropriate international electromedical safety standards and comply with the
requirements of the Electromagnetic Compatibility Directive, thus allowing us to
apply the CE Mark under the European Directives and to distribute the ROBODOC
and NeuroMate Systems throughout
11
<PAGE> 13
the European Union. Outside the European Union, international sales of medical
devices are subject to the regulatory requirements of each country. The
regulatory review process varies from country to country. Many countries also
impose product standards, packaging requirements, labeling requirements and
import restrictions on devices. We cannot give you any assurance that any of our
products will receive further approvals or clearances, if required on a timely
basis, or at all.
UNCERTAINTY REGARDING PATENTS AND PROTECTION OF PROPRIETARY TECHNOLOGY.
SUMMARY. Certain technology underlying our products is the subject of a United
States patent issued to IBM, which IBM has agreed not to enforce against the
manufacture and sale of the Company's products. We have been issued three
patents and filed nine patent applications covering various aspects of our
technology. Third party claims to the technology used in our products could, if
valid, require us to obtain licenses to the technology; those licenses may not
be available on acceptable terms. The technology used in our products could be
(a) disclosed by our employees despite their confidentiality obligations or (b)
independently developed or otherwise acquired by potential competitors.
GENERAL. Our ability to compete successfully may depend, in part, on our
ability to obtain and protect patents, protect trade secrets and operate without
infringing the proprietary rights of others. Our policy is to seek to protect
our proprietary position by, among other methods, filing U.S. and foreign patent
applications relating to our technology, inventions and improvements that are
important to the development of our business. We have been issued three patents
and filed nine patent applications covering various aspects of its technology.
In addition, IBM has agreed not to assert infringement claims against us with
respect to an IBM patent relating to robotic medical technology, to the extent
such technology is used in our products. IBM has granted us a non-exclusive
royalty-free perpetual license for the underlying software code for the ROBODOC
System. Significant portions of the ROBODOC System and ORTHODOC software are
protected by copyrights.
We cannot give you any assurance that our pending or future patent applications
will mature into issued patents, or that we will continue to develop our own
patentable technologies. Further, we cannot give you any assurance that any
patents that may be issued to us effectively protect our technology or provide a
competitive advantage for our products or will not be challenged, invalidated,
or circumvented in the future. In addition, we cannot give you any assurance
that competitors, many of which have substantially more resources than us and
have made substantial investments in competing technologies, will not obtain
patents that will prevent, limit or interfere with our ability to make, use or
sell our products either in the United States or internationally.
SECRECY OF PATENT APPLICATIONS UNTIL PATENTS ISSUED. Patent applications in the
United States are maintained in secrecy until patents' issue, and patent
applications in foreign countries are maintained in secrecy for a period after
filing. Publication of discoveries in the scientific or patent literature tends
to lag behind actual discoveries and the filing of related patent applications.
Patents issued and patent applications filed relating to medical devices are
numerous and we cannot give you any assurance that current and potential
competitors and other third parties have not filed or in the future will not
file applications for, or have not received or in the future will not receive,
patents or obtain additional proprietary rights relating to products or
processes that we use or propose to use.
ABSENCE OF INFRINGEMENT STUDY. Our patent counsel has not undertaken any
infringement study to determine if our products, patents and pending patent
applications infringe on other existing patents due to our belief that an
infringement study would not be cost-effective, nor offer sufficient protection
against potential infringement claims, if and when made. The medical device
industry has been characterized by substantial competition and litigation
regarding patent and other proprietary rights. We intend to vigorously protect
and defend our patents and other proprietary rights relating to our proprietary
technology. Litigation alleging infringement claims against us (with or without
merit), or
12
<PAGE> 14
instituted by us to enforce patents and to protect trade secrets or know-how
owned by us or to determine the enforceability, scope and validity of the
proprietary rights of others, is costly and time consuming. If any relevant
claims of third-party patents are upheld as valid and enforceable in any
litigation or administrative proceedings, we could be prevented from practicing
the subject matter claimed in such patents, or could be required to obtain
licenses from the patent owners of each patent, or to redesign our products or
processes to avoid infringement. We cannot give you any assurance that such
licenses would be available or, if available, would be available on terms
acceptable to us or that we would be successful in any attempt to redesign our
products or processes to avoid infringement. Accordingly, an adverse
determination in a judicial or administrative proceeding or failure to obtain
necessary licenses could prevent us from manufacturing and selling our products,
which would have a material adverse effect on our business, financial condition
and results of operations.
POSSIBILITY OF DISCLOSURE OR DISCOVERY OF PROPRIETARY INFORMATION. Although we
require each of our employees, consultants, and advisors to execute
confidentiality and assignment of inventions and proprietary information
agreements, we cannot give you any assurance that these agreements will provide
effective protection for our proprietary information in the event of
unauthorized use or disclosure of such information. Furthermore, we cannot give
you any assurance that our competitors will not independently develop
substantially equivalent proprietary information and techniques or otherwise
gain access to our proprietary technology, or that we can meaningfully protect
our rights in unpatented proprietary technology.
LIMITED PRODUCTION EXPERIENCE. Our success will depends in part on our ability
to assemble our products in a timely, cost-effective manner and in compliance
with GMP, and manufacturing requirements of other countries, including the
International Standards Organization ("ISO") 9000 standards and other regulatory
requirements. The assembly of our products is a complex operation involving a
number of separate processes and components. Our production activities to date
have consisted primarily of assembling limited quantities of systems for use in
clinical trials and systems for commercial sale. We do not have experience in
assembling our products in larger commercial quantities. Furthermore, as a
condition to receipt of PMA approval, our facilities, procedures and practices
will be subject to pre-approval and ongoing GMP inspections by FDA.
Manufacturers often encounter difficulties in scaling up manufacturing of new
products, including problems involving product yields, quality control and
assurance, component and service availability, adequacy of control policies and
procedures, lack of qualified personnel, compliance with FDA regulations, and
the need for further FDA approval of new manufacturing processes and facilities.
We cannot give you any assurance that production yields, costs or quality will
not be adversely affected as we seek to increase production, and any such
adverse effect could have a material adverse effect on our business, financial
condition and results of operations.
DEPENDENCE ON SUPPLIER FOR ROBOT. Although we have multiple sources for most of
our components, parts and assemblies used in the ROBODOC and NeuroMate Systems,
we are dependent on Sankyo Seiki of Japan for the ROBODOC System robot arm and
Audemars-Piguet of Switzerland for the supply of the customized NeuroMate robot.
Although we can obtain the robot for either the ROBODOC System or the NeuroMate
System from other suppliers, with appropriate modifications and engineering
effort, we cannot give you any assurance that delays resulting from the required
modifications or engineering effort to adapt alternative components would not
have a material adverse effect on the Company's business, financial condition
and results of operations.
RELIANCE ON FOREIGN SALES. From inception through September 30, 1998,
substantially all of our sales (other than clinical sales in the United States
pursuant to an exemption in the rules and regulations of the FDA for
investigational devices) have been to customers in Germany, Austria, France and
Japan. We believe that until such time, if ever, as we receive approval from the
FDA to
13
<PAGE> 15
market the ROBODOC System in the United States, substantially all of our sales
for the ROBODOC System will be derived from customers in foreign markets.
Foreign sales are subject to certain risks, including economic or political
instability, shipping delays, fluctuations in foreign currency exchange rates,
changes in regulatory requirements, custom duties and export quotas and other
trade restrictions, any of which could have a material adverse effect on our
business. To date, payment for substantially all ROBODOC Systems in Europe has
been fixed in U.S. Dollars. However, we cannot give you any assurance that in
the future customers will be willing to make payment for our products in U.S.
Dollars. If the U.S. Dollar strengthens substantially against the foreign
currency of a country in which we sell our products, the cost of purchasing our
products in U.S. Dollars would increase and may inhibit purchases of our
products by customers in that country. We are unable to predict the nature of
future changes in foreign markets or the effect, if any, they might have on us.
UNCERTAINTY CONCERNING THIRD PARTY REIMBURSEMENT. We expect that our ability to
successfully commercialize our products will depend significantly on the
availability of reimbursement for surgical procedures using our products from
third-party payors, such as governmental programs, private insurance and private
health plans. Reimbursement is a significant factor considered by hospitals in
determining whether to acquire new equipment. Notwithstanding FDA approval, if
granted, third-party payors may deny reimbursement if the payor determines that
a therapeutic medical device is unnecessary, inappropriate, not cost-effective
or experimental or is used for a nonapproved indication. Although we are not
aware of any potential customer that has declined to purchase the ROBODOC System
based upon third party reimbursement policies, cost control measures adopted by
third-party payors may have a significant effect on surgeries performed with the
ROBODOC System or as to the levels of reimbursement. We cannot give you any
assurance that levels of reimbursement, if any, will not be decreased in the
future, or that future legislation, regulation, or reimbursement policies of
third-party payors will not otherwise adversely affect the demand for our
products or our ability to sell our products on a profitable basis. Fundamental
reforms in the healthcare industry in the United States and Europe that could
affect the availability of third-party reimbursement continue to be proposed,
and we cannot predict the timing or effect of any such proposal. If third-party
payor coverage or reimbursement is unavailable or inadequate, our business,
financial condition and results of operation could be materially and adversely
affected.
DEPENDENCE ON KEY PERSONNEL. Our business and marketing plan was formulated by,
and is to be implemented under the direction of, Dr. Ramesh C. Trivedi, Chief
Executive Officer and President. Dr. Trivedi is employed pursuant to an
employment agreement that may be terminated by either Dr. Trivedi or us at any
time. Our growth and future success also will depend in large part on the
continued contributions of key technical and senior management personnel, as
well as our ability to attract, motivate and retain highly qualified personnel
generally and, in particular, trained and experienced professionals capable of
developing, selling and installing the Systems and training surgeons in their
use. Competition for such personnel is intense, and we cannot give you any
assurance that we will be successful in hiring, motivating or retaining such
qualified personnel. None of our executive or key technical personnel, other
than Dr. Trivedi, is employed pursuant to an employment agreement. The loss of
the services of Dr. Trivedi or other senior management or key technical
personnel, or the inability to hire or retain qualified personnel, could have a
material adverse effect on our business, financial condition and results of
operations.
OWNERSHIP OF SHARES BY MANAGEMENT. Our executive officers and directors own
(directly or indirectly) 1,065,792 shares of Common Stock, or approximately 20%
of the outstanding shares of Common Stock. Although these securityholders may or
may not agree on any particular matter that is the subject of a vote of the
stockholders, these securityholders may be effectively able to control the
outcome of any issues which may be subject to a vote of securityholders,
including the election of
14
<PAGE> 16
directors, proposals to increase the authorized capital stock, or the approval
of mergers, acquisitions, or the sale of all or substantially all of our assets.
NEED FOR ADDITIONAL FINANCING. Although we believe that we have sufficient
funding to finance our operations through 1999, we cannot give you any assurance
that additional financing will not be needed at an earlier date. This will
depend upon our ability to generate sufficient sales of our products and the
timing of required expenditures. We cannot give you any assurance that if we
need additional financing in the future, such financing will be available on
acceptable terms, if at all.
PRODUCT LIABILITY. The manufacture and sale of medical products exposes us to
the risk of significant damages from product liability claims. Although we
maintain product liability insurance against product liability claims in the
amount of $5 million per occurrence and $5 million in aggregate, we cannot give
you any assurance that the coverage limits of our insurance policies will be
adequate or that such insurance can be maintained at acceptable costs. Although
we have not experienced any product liability claims to date, a successful claim
brought against us in excess of our insurance coverage could have a materially
adverse effect on our business, financial condition and results of operations.
LIMITATION ON DIRECTOR LIABILITY. Our certificate of incorporation provides
that a director shall not be personally liable to the company or its
stockholders for monetary damages for breach of fiduciary duty as a director,
with certain exceptions under Delaware law. This may discourage stockholders
from bringing suit against a director for breach of fiduciary duty and may
reduce the likelihood of derivative litigation brought by stockholders on behalf
of the company against a director. In addition, our by-laws provide for
mandatory indemnification of directors and officers.
ABSENCE OF DIVIDENDS. Since inception, we have has not paid any dividends on
the Common Stock and do not anticipate paying such dividends in the foreseeable
future. We intend to retain earnings, if any, to finance our operations.
POSSIBLE VOLATILITY OF MARKET PRICE FOR THE COMMON STOCK. From time to time and
in particular during the last several months, the stock market generally, and
the securities of technology companies in particular, have experienced a high
level of price and volume volatility, and market prices for the securities of
many companies have experienced wide price fluctuations not necessarily related
to the operating performance of such companies. We believe that factors such as
announcement of developments related to our business, announcements of
technological innovations or new products by us or our competitors, sales of our
Common Stock in the public market, and shortfalls or changes in the our
financial results from analysts' expectations could cause the price of the
Common Stock to fluctuate substantially. Our operating results and various
factors affecting the medical device industry generally also may significantly
impact the market price of the Common Stock.
SHARES ELIGIBLE FOR FUTURE SALE. As of October 15, 1998, there were 5,638,372
shares of Common Stock outstanding. Except for 1,039,792 shares of Common Stock
(representing approximately 18.4% of the outstanding Common Stock) owned by EJ
Financial Investments V, L.P. ("EJ Financial"), which may be sold in accordance
with the volume limitations of Rule 144, substantially all of the outstanding
shares of Common Stock are transferable without restriction under the Securities
Act. An additional 7,616,374 shares of Common stock are issuable upon conversion
of the Series A Preferred Stock (at an assumed conversion price of $2.00 per
share) and the exercise of outstanding options and warrants, including warrants
to purchase 2,274,066 shares of Common Stock issued to International Business
Machines Corporation ("IBM") at exercise prices ranging from $.01 to $.07 (the
"IBM Warrants"). Substantially all of such shares (other than the shares
issuable upon exercise of the IBM Warrants), when issued, may be immediately
resold in the public market pursuant to effective registration statements under
the Securities Act or pursuant to Rule 144. In April 1998, we amended the IBM
Warrants to permit IBM to exercise them without the payment of cash for a
15
<PAGE> 17
lesser number of shares, based upon the difference between the market price of
the Common Stock at the time of exercise and the exercise price (a "cashless
exercise"), in which case such shares could be sold immediately under Rule 144
since under applicable Commission interpretations, the holding period under Rule
144 for shares acquired as a result of a cashless exercise of warrants includes
the period for which the Selling Shareholder owned the warrants. In
consideration for such cashless exercise right, IBM agreed not to exercise the
IBM Warrants before January 1, 1999, and to limit sales of shares acquired upon
exercise thereof to the volume limitations of Rule 144, whether or not
applicable, and granted us or our designee a right of first refusal with respect
to such sales. In addition, the former securityholders of Innovative Medical
Machines International, S.A., which we acquired in September 1997 in exchange
for shares of Common Stock, have agreed to limit the number of shares of Common
Stock they may sell under a currently effective registration statement: (i) from
September 6, 1998 through December 5, 1998, an aggregate of 100,000 shares plus
1% of the total number of shares of Common Stock traded on Nasdaq during the
preceding three month period; and (ii) from December 6, 1998 through March 5,
1999, an aggregate of 100,000 shares plus 1% of the total number of shares of
Common Stock traded on Nasdaq during the preceding three month period; and (iii)
thereafter, in accordance with the volume limitation of Rule 144.
Securityholders (including EJ Financial and IBM) owning or having rights to
acquire, and with registration rights covering, 4,030,649 shares of Common
Stock, have agreed that they will not exercise such registration rights prior to
May 21, 1999. Holders of the underwriter's warrants issued in connection with
our initial public offering in November 1996 have demand and piggyback
registration rights concerning the shares of Common Stock and warrants issuable
upon exercise of those underwriters' warrants and a holder of certain other
warrants to purchase 25,000 shares of Common Stock has piggyback registration
rights (fully subordinated to the registration rights of the other holders of
the Company's securities) covering those shares. In addition, the holders of
warrants to purchase 150,000 shares of Common Stock issued in connection with
our European offering in November 1997 have demand and piggyback registration
rights covering those shares.
We cannot give you any assurance as to the effect, if any, that future sales of
Common Stock, or the availability of shares of Common Stock for future sales,
will have on the market price of the Common Stock from time to time. Sales of
substantial amounts of Common Stock (particularly shares issued upon conversion
of the Series A Preferred Stock), or the possibility of such sales, could
adversely affect the market price of the Common Stock and also impair our
ability to raise capital through an offering of equity securities in the future.
DILUTIVE EFFECT OF CONVERSION OF SERIES A PREFERRED STOCK. The conversion of
the Series A Preferred Stock at a discount to the then prevailing market price
of the Common Stock would result in the issuance of up to 1,760,000 shares of
Common stock, or approximately 23.8% of the outstanding shares (at an assumed
conversion price of $2.00 per share), and consequently could have an immediately
adverse effect on the market price of the Common Stock, and will have a dilutive
impact on other stockholders. See "The Company -- Recent
Developments -- Preferred Stock Financing."
POSSIBLE ADVERSE EFFECT OF OTHER ISSUANCES OF PREFERRED STOCK. Our certificate
of incorporation authorizes the issuance of 1,000,000 shares of "blank check"
preferred stock, with designations, rights and preferences determined from time
to time by the Board of Directors. Accordingly, the Board of Directors is
empowered, without further stockholder approval, to issue preferred stock with
dividend, liquidation, conversion, voting or other rights that could adversely
affect the voting power or other rights of the holders of the Common Stock. In
the event of issuance, the preferred stock could be used, under certain
circumstances, as a method of discouraging, delaying or preventing a change in
control of the company, since the terms of the preferred stock that might be
issued could effectively restrict our ability to consummate a merger,
reorganization, sale of all or substantially all of its assets, liquidation or
other extraordinary corporate transaction without the approval of the holders of
the
16
<PAGE> 18
preferred stock. The Series A Preferred Stock is the only series of preferred
stock outstanding. The terms of the Series A Preferred Stock are summarized
under the caption "The Company -- Recent Developments -- Preferred Stock
Financing."
EFFECT OF ISSUANCE OF COMMON STOCK UPON EXERCISE OF WARRANTS AND OPTIONS. As of
October 15, 1998, there were outstanding options and warrants to purchase
5,856,374 shares of Common Stock, including the IBM Warrants, exercisable to
purchase 2,274,066 shares (or approximately 28.7% of the outstanding shares) at
exercise prices ranging from $.01 to $.07; 1,304,558 shares issuable upon
exercise of stock options granted pursuant to the Company's employee stock
option plans at exercise prices ranging from $.07 to $3.00 per share; 1,795,750
shares issuable upon exercise of the warrants issued in the Company's initial
public offering at an exercise price of $6.00 per share; and 482,000 shares
issuable upon the exercise of warrants at exercise prices ranging from $4.31 to
$8.25 per share.
The exercise of warrants or options and the sale of the underlying shares of
Common Stock (or even the potential of such exercise or sale) could have an
adverse effect on the market price of the Common Stock, and will have a dilutive
impact on other stockholders. Moreover, the terms upon which we will be able to
obtain additional equity capital may be adversely affected since the holders of
outstanding warrants and options can be expected to exercise them, to the extent
they are able, at a time when we would, in all likelihood, be able to obtain any
needed capital on terms more favorable than those provided in such warrants or
options.
ANTITAKEOVER PROVISIONS OF DELAWARE BUSINESS COMBINATION STATUTE. We are
subject to Section 203 of the Delaware General Corporation Law ("DGCL"), which
limits transactions between a publicly held company and "interested
stockholders" (generally, those stockholders who, together with their affiliates
and associates, own 15% or more of a company's outstanding capital stock). This
provision of the DGCL also may have the effect of deterring certain potential
acquisitions of the company. See "Description of Securities -- Statutory
Provisions Affecting Stockholders."
RISKS ASSOCIATED WITH FORWARD-LOOKING STATEMENTS INCLUDED IN THIS
PROSPECTUS. This Prospectus contains certain forward-looking statements based
on current expectations that involve numerous risks and uncertainties.
Assumptions relating to the foregoing involve judgments with respect to, among
other things, future economic, competitive and market conditions and future
business decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond our control. Although we believe that
these assumptions underlying the forward-looking statements are reasonable, any
of the assumptions could prove inaccurate and, therefore, there can be no
assurance that the forward-looking statements included in this Prospectus will
prove to be accurate. In light of the significant uncertainties inherent in the
forward-looking statements included herein, the inclusion of such information
should not be regarded as a representation by us or any other person that our
objectives and plans will be achieved.
17
<PAGE> 19
SELLING SECURITYHOLDERS
The following table sets forth the names of the Selling Securityholders, the
number of shares of Common Stock beneficially owned by each Selling
Securityholder as of October 15, 1998, and the number of Shares that each may
offer, and the number of shares of Common Stock beneficially owned by each
Selling Securityholder upon completion of the Offering, assuming all of the
Shares are sold. The number of Shares sold by each Selling Securityholder may
depend upon a number of factors, including, among other things, the market price
of the Common Stock. None of the Selling Securityholders has, or within the past
three years has had, any position, office or other material relationship with us
or any of our predecessors or affiliates.
<TABLE>
<CAPTION>
SHARES OF SHARES OF SHARES OF
COMMON STOCK COMMON STOCK COMMON STOCK
BENEFICIALLY OWNED OFFERED IN THE BENEFICIALLY OWNED
BEFORE OFFERING(1) OFFERING(1)(2) AFTER OFFERING
NAME OF SELLING -------------------- ---------------- ------------------
SECURITYHOLDER NUMBER PERCENT(3) NUMBER NUMBER PERCENT
--------------- ------- ---------- ---------------- ------- --------
<S> <C> <C> <C> <C> <C>
The Shaar Fund Ltd.(4).............. 315,000(5) * 1,291,500 0 --
AMRO International, S.A.(6)......... 125,000(5) * 512,500 0 --
Trinity Capital Advisors, Inc.(7)... 5,000 * 5,000 0 --
</TABLE>
- -------------------------
* Less than one percent (1%).
(1) Unless otherwise indicated, each person has sole investment and voting power
with respect to the shares indicated. For purposes of computing the
percentage of outstanding shares held by each Selling Securityholder on
October 15, 1998, any security which such person has the right to acquire
within 60 days after such date is deemed to be outstanding for the purpose
of computing the percentage ownership for such person, but is not deemed to
be outstanding for the purpose of computing the percentage ownership of any
other person.
(2) Represents shares that may be acquired upon conversion of the Series A
Preferred Stock, at an assumed conversion price of $2.00 per share, and upon
the exercise of the Warrants. The Series A Preferred Stock is not
convertible for any number of shares of Common Stock in excess of that
number which would (i) render a Selling Securityholder the beneficial owner
of more than five percent of the then issued and outstanding shares of
Common Stock, or (ii) result in the issuance of an aggregate of 1,127,674
shares of Common Stock, representing 20% of the number of shares of Common
Stock issued and outstanding on September 10, 1998, the date upon which the
Series A Preferred Stock and Warrants were issued.
(3) Calculated based upon 5,638,372 shares of Common Stock outstanding on
October 15, 1998.
(4) The address of the principal business office of the Selling Securityholder
is Citco Building, Wickhams Cay, P.O. Box 662, Road Town, Tortola B.V.I.
(5) Represents 25% of the shares of Common Stock issuable upon conversion of the
Series A Preferred Stock on October 15, 1998, at an assumed conversion price
of $2.00 per share. The Series A Preferred Stock is convertible into Common
Stock commencing December 9, 1998 as to 25% of the shares, commencing
January 8, 1999 as to 50% of the shares, commencing February 7, 1999 as to
75% of the shares, and commencing March 9, 1999 as to 100% of the shares.
The Warrants are not exercisable until March 9, 1999.
(6) The address of the principal business office of the Selling Securityholder
is c/o Ultrafinance, Grossmunster Platz 26, Zurich CH 8022.
(7) The address of the principal business office of the Selling Securityholder
is 211 Sutter Street, Suite 2000, San Francisco, California 94104.
(8) These shares were acquired by the Selling Securityholder, a registered
broker-dealer, for services rendered in connection with the issuance and
sale of the Series A Preferred Stock to the other Selling Securityholders.
We are registering the Shares for resale by the Selling Securityholders in
accordance with registration rights granted to the Selling Securityholders. We
will pay the registration and filing fees, printing expenses, listing fees, blue
sky fees, if any, and fees and disbursements of our counsel in connection with
this offering, but the Selling Securityholders will pay any underwriting
discounts, selling commissions and similar expenses relating to the sale of the
Shares, as well as the fees and expenses
18
<PAGE> 20
of their counsel. In addition, we have agreed to indemnify the Selling
Securityholders, underwriters who may be selected by the Selling Securityholders
and certain affiliated parties, against certain liabilities, including
liabilities under the Securities Act, in connection with the offering. The
Selling Securityholders may agree to indemnify any agent, dealer or
broker-dealer that participates in transactions involving sales of the Shares
against certain liabilities, including liabilities under the Securities Act. The
Selling Securityholders have agreed to indemnify us and our directors and
officers, as well as any person controlling the company, against certain
liabilities, including liabilities under the Securities Act. Insofar as
indemnification for liabilities under the Securities Act may be permitted to our
directors or officers, or persons controlling the company, the Company has been
informed that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and
is therefore unenforceable.
19
<PAGE> 21
PLAN OF DISTRIBUTION
The Selling Securityholders (or, subject to applicable law, their pledgees,
donees, distributees, transferees or other successors in interest)may sell
Shares from time to time in public transactions, on or off The Nasdaq SmallCap
Market, or private transactions, at prevailing market prices or at privately
negotiated prices, including but not limited to the following types of
transactions:
- ordinary brokerage transactions and transactions in which the broker
solicits purchasers;
- a block trade in which the broker-dealer so engaged will attempt to sell
the Shares as agent but may position and resell a portion of the block as
principal to facilitate the transaction;
- purchases by a broker or dealer as principal and resale by such broker or
dealer for its account pursuant to this Prospectus; and
- face-to-face transactions between sellers and purchasers without a
broker-dealer.
The Selling Securityholders also may sell Shares that qualify under Section 4(1)
of the Securities Act or Rule 144.
In effecting sales, brokers or dealers engaged by the Selling Securityholders
may arrange for other brokers or dealers to participate in the resales. The
Selling Securityholders may enter into hedging transactions with broker-dealers,
and in connection with those transactions, broker-dealers may engage in short
sales of the Shares. The Selling Securityholders also may sell Shares short and
deliver the Shares to close out such short positions, except that the Selling
Securityholders have agreed that they will not enter into any put option or
short position with respect to the Common Stock prior to the date of the
delivery of a conversion notice. The Selling Securityholders also may enter into
option or other transactions with broker-dealers which require the delivery to
the broker-dealer of the Shares, which the broker-dealer may resell pursuant to
this Prospectus. The Selling Securityholders also may pledge the Shares to a
broker or dealer and upon a default, the broker or dealer may effect sales of
the pledged Shares pursuant to this Prospectus.
Brokers, dealers or agents may receive compensation in the form of commissions,
discounts or concessions from Selling Securityholders in amounts to be
negotiated in connection with the sale. The Selling Securityholders and any
participating brokers or dealers may be deemed to be "underwriters" within the
meaning of the Securities Act in connection with such sales and any such
commission, discount or concession may be deemed to be underwriting
compensation.
Information as to whether underwriters who may be selected by the Selling
Securityholders, or any other broker-dealer, is acting as principal or agent for
the Selling Securityholders, the compensation to be received by underwriters who
may be selected by the Selling Securityholders, or any broker-dealer, acting as
principal or agent for the Selling Securityholders and the compensation to be
received by other broker-dealers, in the event the compensation of such other
broker-dealers is in excess of usual and customary commissions, will, to the
extent required, be set forth in a supplement to this Prospectus (the
"Prospectus Supplement"). Any dealer or broker participating in any distribution
of the Shares may be required to deliver a copy of this Prospectus, including
the Prospectus Supplement, if any, to any person who purchases any of the Shares
from or through such dealer or broker.
We have advised the Selling Securityholders that during such time as they may be
engaged in a distribution of the Shares they are required to comply with
Regulation M promulgated under the Exchange Act. With certain exceptions,
Regulation M precludes any Selling Securityholder, any affiliated purchasers and
any broker-dealer or other person who participates in such distribution from
bidding for or purchasing, or attempting to induce any person to bid for or
purchase any security which is the subject of the distribution until the entire
distribution is complete. Regulation M also
20
<PAGE> 22
prohibits any bids or purchases made in order to stabilize the price of a
security in connection with the distribution of that security. All of the
foregoing may affect the marketability of the Common Stock.
LEGAL MATTERS
The validity of the shares of Common Stock offered hereby has been passed upon
by Snow Becker Krauss P.C., 605 Third Avenue, New York, New York 10158.
EXPERTS
The consolidated financial statements of Integrated Surgical Systems, Inc. at
December 31, 1997 and for the years ended December 31, 1996 and 1997, appearing
in our Annual Report (on Form 10-KSB) for the year ended December 31, 1997 have
been audited by Ernst & Young LLP, independent auditors, as set forth in their
report thereon incorporated herein by reference. Such consolidated financial
statements are incorporated herein by reference in reliance upon such report
given upon the authority of such firm as experts in accounting and auditing.
21
<PAGE> 23
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The expenses payable by the Company in connection with the issuance and
distribution of the securities being registered are estimated below:
<TABLE>
<S> <C>
SEC registration fee........................................ $ 1,445.85
Listing fees................................................ 15,000.00
Legal fees and expenses..................................... 10,000.00
Printing expenses........................................... 5,000.00
Accounting fees............................................. 3,500.00
Miscellaneous............................................... 54.15
----------
Total............................................. $35,000.00
==========
</TABLE>
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Article VI of the Registrant's by-laws provides that a director or officer shall
be indemnified against expenses (including attorneys' fees), judgments, fines
and amounts paid in settlement (provided such settlement is approved in advance
by the Registrant) in connection with certain actions, suits or proceedings,
whether civil, criminal, administrative or investigative (other than an action
by or in the right of the corporation -- a "derivative action") if he acted in
good faith and in a manner he reasonably believed to be in or not opposed to the
best interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his conduct was unlawful. A
similar standard of care is applicable in the case of derivative actions, except
that indemnification only extends to expenses (including attorneys' fees)
incurred in connection with the defense or settlement of such an action, except
that no person who has been adjudged to be liable to the Registrant shall be
entitled to indemnification unless a court determines that despite such
adjudication of liability but in view of all of the circumstances of the case,
the person seeking indemnification is fairly and reasonably entitled to be
indemnified for such expenses as the court deems proper.
Article 6.5 of the Registrant's by-laws further provides that directors and
officers are entitled to be paid by the Registrant the expenses incurred in
defending the proceedings specified above in advance of their final disposition.
provided that such payment will only be made upon delivery to the Registrant by
the indemnified party of an undertaking to repay all amounts so advanced if it
is ultimately determined that the person receiving such payments is not entitled
to be indemnified.
Article 6.4 of the Registrant's by-laws provides that a person indemnified under
Article VI of the by-laws may contest any determination that a director,
officer, employee or agent has not met the applicable standard of conduct set
forth in the by-laws by petitioning a court of competent jurisdiction.
Article 6.6 of the Registrant's by-laws provides that the right to
indemnification and the payment of expenses incurred in defending a proceeding
in advance of its final disposition conferred in the Article will not be
exclusive of any other right which any person may have or acquire under the
by-laws, or any statute or agreement. or otherwise.
Finally, Article 6.7 of the Registrant's by-laws provides that the Registrant
may maintain insurance, at its expense, to reimburse itself and directors and
officers of the Registrant and of its direct and
II-1
<PAGE> 24
indirect subsidiaries against any expense, liability or loss, whether or not the
Registrant would have the power to indemnify such persons against such expense,
liability or loss under the provisions of Article VI of the by-laws. The
Registrant maintains and has in effect such insurance.
Article 11 of the Registrant's certificate of incorporation eliminates the
personal liability of the Registrant's directors to the Registrant or its
stockholders for monetary damages for breach of their fiduciary duties as a
director to the fullest extent provided by Delaware law. Section 102(b) (7) of
the DGCL provides for the elimination off such personal liability, except for
liability (i) for any breach of the director's duty of loyalty to the Registrant
or its stockholders, (ii) for acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law, (iii) under
Section 174 of the DGCL or (iv) for any transaction from which the director
derived any improper personal benefit.
Insofar as indemnification for liabilities arising under the Securities Act of
1933 (the "Securities Act") may be permitted to directors, officers or persons
controlling the Registrant pursuant to the foregoing provisions, the Registrant
has been informed that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act
and is therefore unenforceable.
ITEM 16. EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION
- ------- -----------
<C> <C> <S>
4.1 -- Preferred Stock Purchase Agreement, as amended.
4.2 Certificate of Designations for Series A Convertible
-- Preferred Stock.
4.3 -- Form of Warrant.
4.4 -- Form of Registration Rights Agreement.
5.1 -- Opinion of Snow Becker Krauss.
23.1 -- Consent of Snow Becker Krauss P.C. (included in Exhibit 5.1)
23.2 -- Consent of Ernst & Young LLP, independent auditors.
</TABLE>
ITEM 17. UNDERTAKINGS.
(a) RULE 415 OFFERING
The undersigned small business issuer hereby undertakes that it will:
(1) File, during any period in which it offers or sells securities, a
post-effective amendment to this registration statement to:
(i) Include any prospectus required by section l0(a) (3) of the
Securities Act.
(ii) Reflect in the prospectus any facts or events which, individually
or in the aggregate, represent a fundamental change in the
information set forth in the registrant statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not
exceed that which was registered) and any deviation from the low
or high end of the estimated maximum offering range may be
reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price represent no more than a 20% change in the
maximum aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective registration statement.
II-2
<PAGE> 25
(iii) Include any material information with respect to the plan of
distribution not previously disclosed in the registration
statement or any material change to such information in the
registration statement.
(2) For determining any liability under the Securities Act, each such
post-effective amendment shall be deemed a new registration statement
relating to the securities offered therein, and the offering of such
securities at that time to be the initial bona fide offering thereof.
(3) Remove from registration by means of a post-effective amendment any of
the securities being registered that remain unsold at the termination
of the offering.
(e) REQUEST FOR ACCELERATION OF EFFECTIVE DATE
Insofar as indemnification for liabilities arising under the Securities Act of
1933 (the "Securities Act") may be permitted to directors, officers and
controlling persons of the small business issuer pursuant to the foregoing
provisions, or otherwise, the small business issuer has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is
against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the small business issuer of the expenses
incurred or paid by a director, officer, or controlling person of the small
business issuer in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the
securities being registered, the small business issuer will, unless in the
opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.
II-3
<PAGE> 26
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, hereunto duly
authorized, in the City of Davis, State of California, on October 26, 1998.
<TABLE>
<S> <C>
INTEGRATED SURGICAL SYSTEMS, INC.
By /s/ RAMESH C. TRIVEDI By: /s/ MARK W. WINN
------------------------------------------------
---------------------------------------------------- Mark W. Winn
Ramesh C. Trivedi Chief Financial Officer
Chief Financial Officer (Principal Financial and
and President (Principal Accounting Officer)
Executive Officer)
</TABLE>
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints Ramesh
C. Trivedi and Mark Winn, and each of them, his true and lawful
attorneys-in-fact and agents, with power of substitution and resubstitution, for
him and in his name, place and stead, in any and all capacities, to sign any and
all amendments (including post-effective amendments) to this registration
statement, and to file the same, with exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, hereby
ratifying all that said attorneys-in-fact and agents or his substitute or
substitutes, or any of them, may lawfully do or cause to be done by virtue
hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration
Statement has been signed by the following persons in the capacities indicated
on October 26, 1998.
<TABLE>
<CAPTION>
SIGNATURES TITLE
---------- -----
<S> <C>
/s/ RAMESH C. TRIVEDI Chief Executive Officer,
- ----------------------------------------------------- President and Director
Ramesh C. Trivedi (Principal Executive Officer)
/s/ MARK W. WINN Chief Financial Officer
- ----------------------------------------------------- (Principal Financial and
Mark W. Winn Accounting Officer
/s/ JAMES C. MCGRODDY Chairman of the Board of
- ----------------------------------------------------- Directors
James C. McGroddy
/s/ JOHN N. KAPOOR Director
- -----------------------------------------------------
John N. Kapoor
/s/ PAUL A. H. PANKOW Director
- -----------------------------------------------------
Paul A. H. Pankow
/s/ GERALD D. KNUDSON Director
- -----------------------------------------------------
Gerald D. Knudson
Director
- -----------------------------------------------------
Patrick G. Hays
</TABLE>
II-4
<PAGE> 27
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION PAGE
- ------- ----------- ----
<C> <C> <S> <C>
4.1 -- Preferred Stock Purchase Agreement, as amended.
4.2 Certificate of Designations for Series A Convertible
-- Preferred Stock.
4.3 -- Form of Warrant.
4.4 -- Form of Registration Rights Agreement.
5.1 -- Opinion of Snow Becker Krauss.
23.1 -- Consent of Snow Becker Krauss P.C. (included in Exhibit 5.1)
23.2 -- Consent of Ernst & Young LLP, independent auditors.
</TABLE>
<PAGE> 1
Exhibit 4.1
PREFERRED STOCK PURCHASE AGREEMENT
BETWEEN
INTEGRATED SURGICAL SYSTEMS, INC.
AND
THE INVESTORS SIGNATORY HERETO
PREFERRED STOCK PURCHASE AGREEMENT dated as of August 25, 1998 (the
"Agreement"), between the persons signatory hereto (each an "Investor"), and
Integrated Surgical Systems, Inc., a corporation organized and existing under
the laws of the State of Delaware (the "Company").
WHEREAS, the parties desire that, upon the terms and subject to the
conditions contained herein, the Company shall issue and sell to the Investors,
and the Investors shall purchase, an aggregate of $4,000,000 of the Preferred
Stock (as defined below) and (ii) Warrants (as defined below) to purchase an
aggregate of 50,000 shares of the Common Stock.
WHEREAS, such investments will be made in reliance upon the
provisions of Section 4(2) ("Section 4(2)") of the United States Securities Act
of 1933, as amended, and Regulation D ("Regulation D") and the other rules and
regulations promulgated thereunder (the "Securities Act"), and/or upon such
other exemption from the registration requirements of the Securities Act as may
be available with respect to any or all of the investments in Common Stock to be
made hereunder.
NOW, THEREFORE, the parties hereto agree as follows:
ARTICLE I
CERTAIN DEFINITIONS
Section 1.1. "Bid Price" shall mean the closing bid price (as reported by
Bloomberg L.P.) of the Common Stock on the Principal Market.
Section 1.2. "Capital Shares" shall mean the Common Stock and any shares of any
other class of common stock whether now or hereafter authorized, having the
right to participate in the distribution of earnings and assets of the Company.
Section 1.3. "Capital Shares Equivalents" shall mean any securities, rights, or
obligations that are convertible into or exchangeable for or give any right to
subscribe for any Capital Shares of the Company or any warrants, options or
other rights to subscribe for or purchase Capital Shares or any such convertible
or exchangeable securities.
<PAGE> 2
Section 1.4. "Closing" shall mean the closing of the purchase and sale of the
Preferred Stock pursuant to Section 2.1.
Section 1.5. "Closing Date" shall mean the date on which all conditions to
closing have been satisfied and the Closing shall have occurred.
Section 1.6. "Common Stock" shall mean the Company's common stock, par value
$.01 per share.
Section 1.7. "Conversion Shares" shall mean the shares of Common Stock issuable
upon conversion of the Preferred Stock.
Section 1.8. "Damages" shall mean any loss, claim, damage, liability, costs and
expenses (including, without limitation, reasonable attorney's fees and
disbursements and costs and expenses of expert witnesses and investigation).
Section 1.9. "Effective Date" shall mean the date on which the SEC first
declares effective a Registration Statement registering the resale of the
Registrable Securities as set forth in Section 6.1.
Section 1.10. "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder.
Section 1.11. "Legend" See Section 8.1.
Section 1.12. "Market Price" on any given date shall mean the single lowest
price at which a trade of the Common Stock is executed (as reported by Bloomberg
L.P.) on any Trading Day during the five Trading Days prior to the date for
which Market Price is to be determined.
Section 1.13. "Material Adverse Effect" shall mean any effect on the business,
Bid Price, operations, properties, prospects, or financial condition of the
Company that is material and adverse to the Company and its subsidiaries and
affiliates, taken as a whole, and/or any condition, circumstance, or situation
that would prohibit or otherwise interfere with the ability of the Company to
enter into and perform any of its obligations under this Agreement, the
Registration Rights Agreement, the Escrow Agreement, or the Warrant in any
material respect.
Section 1.14. "NASD" shall mean the National Association of Securities Dealers,
Inc.
Section 1.15. "Outstanding" when used with reference to shares of Common Stock
or Capital Shares (collectively the "Shares"), shall mean, at any date as of
which the number of such Shares is to be determined, all issued and outstanding
Shares, and shall include all such Shares issuable in respect of outstanding
scrip or any certificates representing fractional interests in such Shares;
provided, however, that "Outstanding" shall not mean any such Shares then
directly or indirectly owned or held by or for the account of the Company.
Section 1.16. "Person" shall mean an individual, a corporation, a partnership,
an association, a trust or other entity or organization, including a government
or political subdivision or an agency or instrumentality thereof.
2
<PAGE> 3
Section 1.17. "Preferred Stock" shall mean the Company's Series A Convertible
Preferred Stock, par value $.01 per share issued pursuant to the Certificate of
Designations attached hereto as Exhibit A.
Section 1.18. "Principal Market" shall mean the NASDAQ National Market, the
NASDAQ Small-Cap Market, the American Stock Exchange or the New York Stock
Exchange, whichever is at the time the principal trading exchange or market for
the Common Stock.
Section 1.19. "Purchase Price" shall mean one thousand dollars ($1,000) per
share.
Section 1.20. "Registrable Securities" shall mean the Conversion Shares and the
Warrant Shares until (i) the Registration Statement has been declared effective
by the SEC, and all Conversion Shares and Warrant Shares have been disposed of
pursuant to the Registration Statement, (ii) all Conversion Shares and Warrant
Shares have been sold under circumstances under which all of the applicable
conditions of Rule 144 (or any similar provision then in force) under the
Securities Act ("Rule 144") are met, (iii) all Conversion Shares and Warrant
Shares have been otherwise transferred to holders who may trade such shares
without restriction under the Securities Act, and the Company has delivered a
new certificate or other evidence of ownership for such securities not bearing a
restrictive legend or (iv) such time as, in the opinion of counsel to the
Company, all Conversion Shares and Warrant Shares may be sold without any time,
volume or manner limitations pursuant to Rule 144(k) (or any similar provision
then in effect) under the Securities Act.
Section 1.21. "Registration Rights Agreement" shall mean the agreement regarding
the filing of the Registration Statement for the resale of the Registrable
Securities, entered into between the Company and the Investor on the
Subscription Date annexed hereto as Exhibit C.
Section 1.22. "Registration Statement" shall mean a registration statement on
Form S-3 (if use of such form is then available to the Company pursuant to the
rules of the SEC and, if not, on such other form promulgated by the SEC for
which the Company then qualifies and which counsel for the Company shall deem
appropriate, and which form shall be available for the resale of the Registrable
Securities to be registered thereunder in accordance with the provisions of this
Agreement, the Registration Rights Agreement, and the Warrant and in accordance
with the intended method of distribution of such securities), for the
registration of the resale by the Investor of the Registrable Securities under
the Securities Act.
Section 1.23. "Regulation D" shall have the meaning set forth in the recitals of
this Agreement.
Section 1.24. "SEC" shall mean the Securities and Exchange Commission.
Section 1.25. "Section 4(2)" shall have the meaning set forth in the recitals of
this Agreement.
Section 1.26. "Securities Act" shall have the meaning set forth in the recitals
of this Agreement.
Section 1.27. "SEC Documents" shall mean the Company's December 31, 1997 Form
10-KSB, March 31, 1998 Form 10-QSB and any Form 8-K filed thereafter, and the
Proxy Statement for its 1998 Annual Meeting, in the form available via the SEC's
EDGAR System.
3
<PAGE> 4
Section 1.28. "Trading Day" shall mean any day during which the New York Stock
Exchange shall be open for business.
Section 1.29. "Warrant" shall have the meaning set forth in Section 2.2 and
substantially in the form of Exhibit B.
Section 1.30. "Warrant Shares" shall mean all shares of Common Stock or other
securities issued or issuable pursuant to exercise of the Warrant.
ARTICLE II
PURCHASE AND SALE OF COMMON STOCK
Section 2.1. Investment.
(a) The Company agrees to sell and the Investor agrees to purchase that
number of shares of Preferred Stock set forth on the signature page hereto at
the Purchase Price on the Closing Date.
(b) Upon the completion of the following conditions, the Preferred
Stock and the Warrant shall be released to the Investor and the Purchase Price
(after all fees have been paid as set forth in the Escrow Agreement attached
hereto as Exhibit D) shall be released to the Company, pursuant to the terms of
the Escrow Agreement:
(i) acceptance and execution by the Company and by the Investor,
of this Agreement and all Exhibits hereto;
(ii) delivery into escrow by Investor of good cleared funds of the
Purchase Price, as more fully set forth in the Escrow
Agreement;
(iii) all representations and warranties of the Investor and of the
Company contained herein shall remain true and correct as of
the Closing Date;
(iv) the Company shall have obtained all permits and qualifications
required by any state for the offer and sale of the Preferred
Stock and Warrants, or shall have the availability of
exemptions therefrom;
(v) the sale and issuance of the Preferred Stock and Warrant, and
the proposed issuance of the Common Stock underlying the
Preferred Stock and the Warrant shall be legally permitted by
all laws and regulations to which the Investor and the Company
are subject and there shall be no ruling, judgment or writ of
any court prohibiting the transactions contemplated by this
Agreement;
(vi) delivery of the original Warrant and Preferred Stock
certificates to the Escrow Agent;
4
<PAGE> 5
(vii) receipt by each Investor of an opinion of Snow Becker
Krauss P.C., counsel to the Company, in the form of Exhibit
E hereto
(viii) delivery to the Investor of the Irrevocable Instructions to
Transfer Agent in the form attached hereto as Exhibit F;
(ix) there not having occurred (i) any general suspension of
trading in, or limitation on prices listed for, the Common
Stock on the Nasdaq Small Cap Market, (ii) the declaration
of a banking moratorium or any suspension of payments in
respect of banks in the United States, (iii) the
commencement of a war, armed hostilities or other
international or national calamity directly or indirectly
involving the United States or any of its territories,
protectorates or possessions, or (iv) in the case of the
foregoing existing at the date of this Agreement, a
material acceleration or worsening thereof; and
(x) there not having occurred any event or development, and
there being in existence no condition, having or which
reasonably and forseeably could have a Material Adverse
Effect.
Section 2.2. The Warrant. On the Closing Date, the Company will issue to the
Investor a warrant exercisable beginning six months from the Subscription Date
and then exercisable any time over the three-year period there following, to
purchase the Investor's pro-rata share of an aggregate of 50,000 Warrant Shares
at the Exercise Price (as defined in the Warrant) in the form of Exhibit B
hereto. The Warrant Shares shall be registered for resale pursuant to the
Registration Rights Agreement.
Section 2.3. Liquidated Damages. The parties hereto acknowledge and agree that
the sum payable pursuant to the Registration Rights Agreement shall constitute
liquidated damages and not penalties. The parties further acknowledge that (a)
the amount of loss or damages likely to be incurred is incapable or is difficult
to precisely estimate, (b) the amounts specified in such Sections bear a
reasonable proportion and are not plainly or grossly disproportionate to the
probable loss likely to be incurred by the Investor in connection with the
failure by the Company to timely cause the registration of the Registrable
Securities and (c) the parties are sophisticated business parties and have been
represented by sophisticated and able legal and financial counsel and negotiated
this Agreement at arm's length.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF INVESTOR
Each Investor, severally and not jointly, represents and warrants to the Company
that:
Section 3.1. Intent. The Investor is entering into this Agreement for its own
account and the Investor has no present arrangement (whether or not legally
binding) at any time to sell the Common Stock to or through any person or
entity; provided, however, that by making the representations herein, the
Investor does not agree to hold the Common Stock for any minimum
5
<PAGE> 6
or other specific term and reserves the right to dispose of the Common Stock at
any time in accordance with federal and state securities laws applicable to such
disposition.
Section 3.2. Sophisticated Investor. The Investor is a sophisticated investor
(as described in Rule 506(b)(2)(ii) of Regulation D) and an accredited investor
(as defined in Rule 501 of Regulation D), and Investor has such experience in
business and financial matters that it is capable of evaluating the merits and
risks of an investment in Common Stock. The Investor acknowledges that an
investment in the Common Stock is speculative and involves a high degree of
risk.
Section 3.3. Authority. This Agreement and each Exhibit hereto which is required
to be executed by Investor has been duly authorized and validly executed and
delivered by the Investor and is a valid and binding agreement of the Investor
enforceable against it in accordance with its terms, subject to applicable
bankruptcy, insolvency, or similar laws relating to, or affecting generally the
enforcement of, creditors' rights and remedies or by other equitable principles
of general application.
Section 3.4. Not an Affiliate. The Investor is not an officer, director or
"affiliate" (as that term is defined in Rule 405 of the Securities Act) of the
Company.
Section 3.5. Absence of Conflicts. The execution and delivery of this Agreement
and any other document or instrument executed in connection herewith, and the
consummation of the transactions contemplated thereby, and compliance with the
requirements thereof, will not violate any law, rule, regulation, order, writ,
judgment, injunction, decree or award binding on Investor, or, to the Investor's
knowledge, (a) violate any provision of any indenture, instrument or agreement
to which Investor is a party or is subject, or by which Investor or any of its
assets is bound; (b) conflict with or constitute a material default thereunder;
(c) result in the creation or imposition of any lien pursuant to the terms of
any such indenture, instrument or agreement, or constitute a breach of any
fiduciary duty owed by Investor to any third party; or (d) require the approval
of any third-party (which has not been obtained) pursuant to any material
contract, agreement, instrument, relationship or legal obligation to which
Investor is subject or to which any of its assets, operations or management may
be subject.
Section 3.6. Disclosure; Access to Information. Investor has received all
documents, records, books and other publicly available information pertaining to
Investor's investment in the Company that have been requested by Investor. The
Company is subject to the periodic reporting requirements of the Exchange Act,
and Investor has reviewed or received copies of any such reports that have been
requested by it.
Section 3.7. Manner of Sale. At no time was Investor presented with or solicited
by or through any leaflet, public promotional meeting, television advertisement
or any other form of general solicitation or advertising.
6
<PAGE> 7
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to the Investor that, except as set forth on
the Schedule of Exceptions attached hereto:
Section 4.1. Organization of the Company. The Company is a corporation duly
incorporated and existing in good standing under the laws of the State of
Delaware and has all requisite corporate authority to own its properties and to
carry on its business as now being conducted except as set forth in Section 4.1
of the Schedule of Exceptions or as described in the Company's SEC Documents.
The Company does not have any subsidiaries and does not own more that fifty
percent (50%) of or control any other business entity except as set forth in the
SEC Documents. The Company is duly qualified as a foreign corporation to do
business and is in good standing in every jurisdiction in which the nature of
the business conducted or property owned by it makes such qualification
necessary, other than those in which the failure so to qualify could not
reasonably be expected to have a Material Adverse Effect.
Section 4.2. Authority. (i) The Company has the requisite corporate power and
authority to enter into and perform its obligations under this Agreement, the
Registration Rights Agreement, the Escrow Agreement, and the Warrant and to
issue the Preferred Stock, the Conversion Shares, the Warrant and the Warrant
Shares, (ii) the execution, issuance and delivery of this Agreement, the
Registration Rights Agreement, the Escrow Agreement, and the Warrant by the
Company and the consummation by it of the transactions contemplated hereby have
been duly authorized by all necessary corporate action and no further consent or
authorization of the Company or its Board of Directors or stockholders is
required, and (iii) this Agreement, the Registration Rights Agreement, the
Escrow Agreement, and the Warrant have been duly executed and delivered by the
Company and constitute valid and binding obligations of the Company enforceable
against the Company in accordance with their terms, except as such
enforceability may be limited by applicable bankruptcy, insolvency, or similar
laws relating to, or affecting generally the enforcement of, creditors' rights
and remedies or by other equitable principles of general application. The
Company has duly and validly authorized and reserved for issuance shares of
Common Stock sufficient in number for the conversion of 4,000 shares of
Preferred Stock (assuming a Conversion Price (as defined in the Certificate of
Designations) of $2.00) and for the exercise of the Warrants. The Company
understands and acknowledges the potentially dilutive effect to the Common Stock
of the issuance of the Conversion Shares and the Warrant Shares. The Company
further acknowledges that its obligation to issue Conversion Shares upon
conversion of the Preferred Stock and Warrant Shares upon exercise of the
Warrants in accordance with this Agreement and the Certificate of Designations
is absolute and unconditional regardless of the dilutive effect that such
issuance may have on the ownership interests of other stockholders of the
Company and notwithstanding the commencement of any case under 11 U.S.C. Section
101 et seq. (the "Bankruptcy Code"). In the event the Company is a debtor under
the Bankruptcy Code, the Company hereby waives to the fullest extent permitted
any rights to relief it may have under 11 U.S.C. Section 362 in respect of the
conversion of the Preferred Stock and the exercise of the Warrants. The Company
agrees, without cost or expense to the Investor, to take or consent to any and
all action necessary to effectuate relief under 11 U.S.C. Section 362.
7
<PAGE> 8
Section 4.3. Capitalization. The authorized capital stock of the Company
consists of 15,000,000 shares of Common Stock, par value $0.01, of which
5,630,950 shares are issued and outstanding as of June 30, 1998, and 1,000,000
shares of Preferred Stock, par value $0.01, of which no shares were issued and
outstanding as of June 30, 1998, 4,000 of which shares of Preferred Stock have
been properly designated as Series A Convertible Preferred Stock. Except as set
forth in Section 4.3 of the Schedule of Exceptions, there are no outstanding
Capital Shares Equivalents. All of the outstanding shares of Common Stock of the
Company have been duly and validly authorized and issued and are fully paid and
non-assessable.
Section 4.4. Common Stock. The Company has registered its Common Stock pursuant
to Section 12(b) or (g) of the Exchange Act and is in full compliance with all
reporting requirements of the Exchange Act, and the Company has maintained all
requirements for the continued listing or quotation of its Common Stock, and
such Common Stock is currently listed or quoted on the Principal Market. As of
the date hereof, the Principal Market is the NASDAQ Small Cap Market and the
Company has not received any notice regarding, and to its knowledge there is no
threat, of the termination or discontinuance of the eligibility of the Common
Stock for such listing.
Section 4.5. SEC Documents. The Company has delivered or made available to the
Investor true and complete copies of the SEC Documents. The Company has not
provided to the Investor any information that, according to applicable law, rule
or regulation, should have been disclosed publicly prior to the date hereof by
the Company, but which has not been so disclosed. As of their respective dates,
the SEC Documents complied in all material respects with the requirements of the
Exchange Act, and rules and regulations of the SEC promulgated thereunder and
the SEC Documents did not contain any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading. The financial statements of the Company included
in the SEC Documents complied in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC or
other applicable rules and regulations with respect thereto. Such financial
statements have been prepared in accordance with generally accepted accounting
principles applied on a consistent basis during the periods involved (except (i)
as may be otherwise indicated in such financial statements or the notes thereto
or (ii) as set forth in Section 4.5 to the Schedule of Exceptions) and fairly
present in all material respects the financial position of the Company as of the
dates thereof and the results of operations and cash flows for the periods then
ended. Neither the Company nor any of its subsidiaries has any indebtedness,
obligations or liabilities of any kind (whether accrued, absolute, contingent or
otherwise, and whether due or to become due) that would have been required to be
reflected in, reserved against or otherwise described in the financial
statements or in the notes thereto in accordance with GAAP, which was not fully
reflected in, reserved against or otherwise described in the financial
statements or the notes thereto or was not incurred in the ordinary course of
business consistent with the Company's past practices since the late date of the
financial statements.
Section 4.6. Exemption from Registration; Valid Issuances. The sale of the
Preferred Stock, the Conversion Shares, the Warrant and the Warrant Shares will
be properly issued pursuant to Rule 4(2), Regulation D and/or any applicable
state securities law. When issued, the Preferred Stock, the Conversion Shares
and the Warrant Shares will be duly and validly issued, fully paid,
8
<PAGE> 9
and non-assessable. Neither the sales of the Preferred Stock, the Conversion
Shares, the Warrant or the Warrant Shares pursuant to, nor the Company's
performance of its obligations under, this Agreement, the Registration Rights
Agreement, the Escrow Agreement, or the Warrant will (i) result in the creation
or imposition by the Company of any liens, charges, claims or other encumbrances
upon the Preferred Stock, the Conversion Shares, the Warrant Shares or any of
the assets of the Company, or (ii) entitle the holders of Outstanding Capital
Shares to preemptive or other rights to subscribe to or acquire the Capital
Shares or other securities of the Company. The Preferred Stock, the Conversion
Shares, and the Warrant Shares shall not subject the Investor to personal
liability by reason of the possession thereof.
Section 4.7. No General Solicitation or Advertising in Regard to this
Transaction. Neither the Company nor any of its affiliates nor any distributor
or any person acting on its or their behalf (i) has conducted or will conduct
any general solicitation (as that term is used in Rule 502(c) of Regulation D)
or general advertising with respect to any of the Preferred Stock, the
Conversion Shares, the Warrant or the Warrant Shares, or (ii) made any offers or
sales of any security or solicited any offers to buy any security under any
circumstances that would require registration of the Preferred Stock, the
Conversion Shares, the Warrant or the Warrant Shares under the Securities Act.
Section 4.8. Corporate Documents. The Company has furnished or made available to
the Investor true and correct copies of the Company's Articles of Incorporation,
as amended and in effect on the date hereof (the "Certificate"), and the
Company's By-Laws, as amended and in effect on the date hereof (the "By-Laws").
Section 4.9. No Conflicts. The execution, delivery and performance of this
Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby, including without limitation the issuance of the Preferred
Stock, the Conversion Shares, the Warrant and the Warrant Shares, do not and
will not (i) result in a violation of the Company's Articles of Incorporation or
By-Laws or (ii) conflict with, or constitute a material default (or an event
that with notice or lapse of time or both would become a default) under, or give
to others any rights of termination, amendment, acceleration or cancellation of,
any material agreement, indenture, instrument or any "lock-up" or similar
provision of any underwriting or similar agreement to which the Company is a
party, or (iii) result in a violation of any federal, state or local law, rule,
regulation, order, judgment or decree (including federal and state securities
laws and regulations) applicable to the Company or by which any property or
asset of the Company is bound or affected (except for such conflicts, defaults,
terminations, amendments, accelerations, cancellations and violations as could
not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect) nor is the Company otherwise in violation of, conflict with or
in default under any of the foregoing. The business of the Company is not being
conducted in violation of any law, ordinance or regulation of any governmental
entity, except for possible violations that either singly or in the aggregate
could not reasonably be expected to have a Material Adverse Effect. The Company
is not required under federal, state or local law, rule or regulation to obtain
any consent, authorization or order of, or make any filing or registration with,
any court or governmental agency in order for it to execute, deliver or perform
any of its obligations under this Agreement or issue and sell the Preferred
Stock or the Warrant in accordance with the terms hereof (other than any SEC,
NASD, NASDAQ or state securities filings that may be required to be made by the
Company subsequent to any Closing, any
9
<PAGE> 10
registration statement that may be filed pursuant hereto, and any shareholder
approval required by the rules applicable to companies whose common stock trades
on the NASDAQ Small Cap Market); provided that, for purposes of the
representation made in this sentence, the Company is assuming and relying upon
the accuracy of the relevant representations and agreements of the Investor
herein.
Section 4.10. No Material Adverse Change. Since March 31, 1998, no Material
Adverse Effect has occurred or exists with respect to the Company, except as
disclosed in the SEC Documents. No "Event of Default" (as defined in any
agreement or instrument to which the Company or any of its subsidiaries is a
party) and no event which, with notice, lapse of time or both, would constitute
an Event of Default (as so defined), has occurred and is continuing which could
have a Material Adverse Effect.
Section 4.11. No Undisclosed Liabilities. The Company has no liabilities or
obligations which are material, individually or in the aggregate, and are not
disclosed in the SEC Documents or otherwise publicly announced, other than those
incurred in the ordinary course of the Company's businesses since March 31,
1998, and which, individually or in the aggregate, could not reasonably be
expected to have a Material Adverse Effect.
Section 4.12. No Undisclosed Events or Circumstances. Since March 31, 1998, no
event or circumstance has occurred or exists with respect to the Company or its
businesses, properties, prospects, operations or financial condition, that,
under applicable law, rule or regulation, requires public disclosure or
announcement prior to the date hereof by the Company but which has not been so
publicly announced or disclosed in the SEC Documents.
Section 4.13. No Integrated Offering. Other than pursuant to an effective
registration statement under the Securities Act, the Company has not issued,
offered or sold the Preferred Stock, the Warrants or any shares of Common Stock
(including for this purpose any securities of the same or a similar class as the
Preferred Stock, the Warrants or Common Stock, or any securities convertible
into a exchangeable or exercisable for the Preferred Stock or Common Stock or
any such other securities) within the six-month period next preceding the date
hereof, and the Company shall not permit any of its directors, officers or
Affiliates directly or indirectly to take, any action (including, without
limitation, any offering or sale to any person or entity of the Preferred Stock,
Warrants or shares of Common Stock), so as to make unavailable the exemption
from Securities Act registration being relied upon by the Company for the offer
and sale to Investor of the Preferred Stock (and the Conversion Shares) or the
Warrants (and the Warrant Shares) as contemplated by this Agreement. No form of
general solicitation or advertising has been used or authorized by the Company
or any of its officers, directors or Affiliates in connection with the offer or
sale of the Preferred Stock (and the Conversion Shares) as contemplated by this
Agreement or any other agreement to which the Company is a party.
Section 4.14. Litigation and Other Proceedings. There are no lawsuits or
proceedings pending or to the best knowledge of the Company threatened, against
the Company, nor has the Company received any written or oral notice of any such
action, suit, proceeding or investigation, which could reasonably be expected to
have a Material Adverse Effect. Except as set forth in the SEC Documents, no
judgment, order, writ, injunction or decree or award has been issued by or, so
far
10
<PAGE> 11
as is known by the Company, requested of any court, arbitrator or governmental
agency which might result in a Material Adverse Effect.
Section 4.15. No Misleading or Untrue Communication. The Company, any person
representing the Company, and, to the best knowledge of the Company, any other
person selling or offering to sell the Preferred Stock or the Warrant in
connection with the transaction contemplated by this Agreement, have not made,
at any time, any oral communication in connection with the offer or sale of the
same which contained any untrue statement of a material fact or omitted to state
any material fact necessary in order to make the statements, in the light of the
circumstances under which they were made, not misleading.
Section 4.16. Material Non-Public Information. The Company has not disclosed to
the Investor any material non-public information that (i) if disclosed, would,
or could reasonably be expected to have, an effect on the price of the Common
Stock or (ii) according to applicable law, rule or regulation, should have been
disclosed publicly by the Company prior to the date hereof but which has not
been so disclosed.
Section 4.17. Insurance. The Company maintains property and casualty, general
liability, workers' compensation, environmental hazard, personal injury and
other similar types of insurance with financially sound and reputable insurers
that is adequate, consistent with industry standards and the Company's
historical claims experience. The Company has not received notice from, and has
no knowledge of any threat by, any insurer (that has issued any insurance policy
to the Company) that such insurer intends to deny coverage under or cancel,
discontinue or not renew any insurance policy presently in force.
Section 4.18. Environmental Matters.
1. The operations of the Company and each of its subsidiaries are
in material compliance with all applicable Environmental Laws and all permits
issued pursuant to Environmental Laws or otherwise;
2. to its knowledge, the Company and each of its subsidiaries has
obtained or applied for all material permits required under all applicable
Environmental Laws necessary to operate its business;
3. neither the Company nor either of its subsidiaries is the
subject of any outstanding written order of or agreement with any governmental
authority or person respecting (i) Environmental Laws, (ii) Remedial Action or
(iii) any Release or threatened Release of Hazardous Materials;
4. neither the Company nor either of its subsidiaries has
received, since December 31, 1997, any written communication alleging that it
may be in violation of any Environmental Law or any permit issued pursuant to
any Environmental Law, or may have any liability under any Environmental Law;
5. neither the Company nor either of its subsidiaries has any
current contingent liability in connection with any Release of any Hazardous
Materials into the indoor or outdoor environment (whether on-site or off-site);
11
<PAGE> 12
6. to the Company's knowledge, there are no investigations of the
business, operations, or currently or previously owned, operated or leased
property of the Company or either of its subsidiaries pending or threatened
which could lead to the imposition of any liability pursuant to any
Environmental Law;
7. there is not located at any of the properties of the Company
any (A) underground storage tanks, (B) asbestos-containing material or (C)
equipment containing polychlorinated biphenyls; and
8. the Company has provided to Investor all environmentally
related audits, studies, reports, analyses, and results of investigations that
have been performed with respect to the currently or previously owned, leased or
operated properties of the Company.
For purposes of this Section 4.18:
"Environmental Law" means any foreign, federal, state or local
statute, regulation, ordinance, or rule of common law as now or hereafter in
effect in any way relating to the protection of human health and safety or the
environment including, without limitation, the Comprehensive Environmental
Response, Compensation and Liability Act (42 U.S.C. Section 9601 et seq.), the
Hazardous Materials Transportation Act (49 U.S.C. App. Section 1801 et seq.),
the Resource Conservation and Recovery Act (42 U.S.C. Section 6901 et seq.), the
Clean Water Act (33 U.S.C. Section 1251 et seq.), the Clean Air Act (42 U.S.C.
Section 7401 et seq.), the Toxic Substances Control Act (15 U.S.C. Section 2601
et seq.), the Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C.
Section 136 et seq.), and the Occupational Safety and Health Act (29 U.S.C.
Section 651 et seq.), and the regulations promulgated pursuant thereto.
"Hazardous Material" means any substance, material or waste which
is regulated by the United States, Canada or any of its provinces, or any state
or local governmental authority including, without limitation, petroleum and its
by-products, asbestos, and any material or substance which is defined as a
"hazardous waste," "hazardous substance," "hazardous material," "restricted
hazardous waste," "industrial waste," "solid waste," "contaminant," "pollutant,"
"toxic waste" or toxic substance" under any provision of any Environmental Law;
"Release" means any release, spill, filtration, emission, leaking,
pumping, injection, deposit, disposal, discharge, dispersal, or leaching into
the indoor or outdoor environment, or into or out of any property;
"Remedial Action" means all actions to (x) clean up, remove, treat
or in any other way address any Hazardous Material; (y) prevent the Release of
any Hazardous Material so it does not endanger or threaten to endanger public
health or welfare or the indoor or outdoor environment; or (z) perform
pre-remedial studies and investigations or post-remedial monitoring and care.
Section 4.19. Labor Matters. Except as set forth in the Company's SEC Documents,
neither the Company nor any of its subsidiaries is a party to any labor or
collective bargaining agreement and there are no labor or collective bargaining
agreements which pertain to employees of the Company. No employees of the
Company are represented by any labor organization and none of
12
<PAGE> 13
such employees has made a pending demand for recognition, and there are no
representation proceedings or petitions seeking a representation proceeding
presently pending or, to the Company's knowledge, threatened to be brought or
filed, with the National Labor Relations Board or other labor relations
tribunal. There is no organizing activity involving the Company pending or to
the Company's knowledge, threatened by any labor organization or group of
employees of the Company. There are no (i) strikes, work stoppages, slowdowns,
lockouts or arbitrations or (ii) material grievances or other labor disputes
pending or, to the knowledge of the Company, threatened against or involving the
Company. There are no unfair labor practice charges, grievances or complaints
pending or, to the knowledge of the Company, threatened by or on behalf of any
employee or group of employees of the Company.
Section 4.20. ERISA Matters. The Company and its ERISA Affiliates are in
compliance in all material respects with all provisions of ERISA applicable to
it. No Reportable Event has occurred, been waived or exists as to which the
Company or any ERISA Affiliate was required to file a report with the Pension
Benefits Guaranty Corporation, and the present value of all liabilities under
all Plans (based on those assumptions used to fund such Plans) did not, as of
the most recent annual valuation date applicable thereto, exceed the value of
the assets of all such Plans in the aggregate. None of the Company or ERISA
Affiliates has incurred any Withdrawal Liability that could result in a Material
Adverse Effect. None of the Company or ERISA Affiliates has received any
notification that any Multiemployer Plan is in reorganization or has been
terminated within the meaning of Title IV of ERISA, and no Multiemployer Plan is
reasonably expected to be in reorganization or termination where such
reorganization or termination has resulted or could reasonably be expected to
result in increases to the contributions required to be made to such Plan or
otherwise.
For purposes of this Section 4.20:
"ERISA" means the Employee Retirement Income Security Act of 1974,
or any successor statute, together with the regulations thereunder, as the same
may be amended from time to time.
"ERISA Affiliate" means any trade or business (whether or not
incorporated) that was, is or hereafter may become, a member of a group of which
the Company is a member and which is treated as a single employer under Section
414 of the Internal Revenue Code of 1986, as amended (the "Internal Revenue
Code").
"Multiemployer Plan" means a multiemployer plan as defined in
Section 4001(a)(3) of ERISA to which the Company or any ERISA Affiliate (other
than one considered an ERISA Affiliate only pursuant to subsection (m) or (o) of
Section 414 of the Internal Revenue Code) is making or accruing an obligation to
make contributions, or has within any of the preceding five plan years made or
accrued an obligation to make contributions.
"PBGC" means the Pension Benefit Guaranty Corporation referred to
and defined in ERISA or any successor thereto.
"Plan" means any pension plan (other than a Multiemployer Plan)
subject to the provision of Title IV of ERISA or Section 412 of the Internal
Revenue Code that is maintained for employees of the Company or any ERISA
Affiliate.
13
<PAGE> 14
"Reportable Event" means any reportable event as defined in
Section 4043(b) of ERISA or the regulations issued thereunder with respect to a
Plan (other than a Plan maintained by an ERISA Affiliate that is considered an
ERISA Affiliate only pursuant to subsection (m) or (o) of Section 414 of the
Internal Revenue Code.
"Withdrawal Liability" means liability to a Multiemployer Plan as
a result of a complete or partial withdrawal from such Multiemployer Plan, as
such terms are defined in Part I of Subtitle E of Title IV of ERISA.
Section 4.21. Tax Matters.
1. Except as set forth on Schedule 4.21: the Company has filed all
Tax Returns which it is required to file under applicable Laws; all such Tax
Returns are true and accurate and have been prepared in compliance with all
applicable Laws; the Company has paid all Taxes due and owing by it (whether or
not such Taxes are required to be shown on a Tax Return) and have withheld and
paid over to the appropriate taxing authorities all Taxes which it is required
to withhold from amounts paid or owing to any employee, stockholder, creditor or
other third parties; and since December 31, 1997, the charges, accruals and
reserves for Taxes with respect to the Company (including any provisions for
deferred income taxes) reflected on the books of the Company are adequate to
cover any Tax liabilities of the Company if its current tax year were treated as
ending on the date hereof.
2. No claim has been made by a taxing authority in a jurisdiction
where the Company does not file tax returns that such corporation is or may be
subject to taxation by that jurisdiction. There are no foreign, federal, state
or local tax audits or administrative or judicial proceedings pending or being
conducted with respect to the Company; no information related to Tax matters has
been requested by any foreign, federal, state or local taxing authority; and,
except as disclosed above, no written notice indicating an intent to open an
audit or other review has been received by the Company from any foreign,
federal, state or local taxing authority. There are no material unresolved
questions or claims concerning the Company's Tax liability. The Company (A) has
not executed or entered into a closing agreement pursuant to Section 7121 of the
Internal Revenue Code or any predecessor provision thereof or any similar
provision of state, local or foreign law; or (B) has not agreed to or is
required to make any adjustments pursuant to Section 481 (a) of the Internal
Revenue Code or any similar provision of state, local or foreign law by reason
of a change in accounting method initiated by the Company or any of its
subsidiaries or has any knowledge that the IRS has proposed any such adjustment
or change in accounting method, or has any application pending with any taxing
authority requesting permission for any changes in accounting methods that
relate to the business or operations of the Company. The Company has not been a
United States real property holding corporation within the meaning of Section
897(c)(2) of the Internal Revenue Code during the applicable period specified in
Section 897(c)(1)(A)(ii) of the Internal Revenue Code.
3. The Company has not made an election under Section 341(f) of
the Internal Revenue Code. The Company is not liable for the Taxes of another
person that is not a subsidiary of the Company under (A) Treas. Reg. Section
1.1502-6 (or comparable provisions of state, local or foreign law), (B) as a
transferee or successor, (C) by contract or indemnity or (D) otherwise. The
Company is not a party to any tax sharing agreement. The Company has not
14
<PAGE> 15
made any payments, is obligated to make payments or is a party to an agreement
that could obligate it to make any payments that would not be deductible under
Section 280G of the Internal Revenue Code.
For purposes of this Section 4.21:
"IRS" means the United States Internal Revenue Service.
"Tax" or "Taxes" means federal, state, county, local, foreign, or
other income, gross receipts, ad valorem, franchise, profits, sales or use,
transfer, registration, excise, utility, environmental, communications, real or
personal property, capital stock, license, payroll, wage or other withholding,
employment, social security, severance, stamp, occupation, alternative or add-on
minimum, estimated and other taxes of any kind whatsoever (including, without
limitation, deficiencies, penalties, additions to tax, and interest attributable
thereto) whether disputed or not.
"Tax Return" means any return, information report or filing with
respect to Taxes, including any schedules attached thereto and including any
amendment thereof.
Section 4.22. Property. Neither the Company nor either of its subsidiaries owns
any real property. Each of the Company and its subsidiaries has good and
marketable title to all personal property owned by it, free and clear of all
liens, encumbrances and defects except such as do not materially affect the
value of such property and do not materially interfere with the use made and
proposed to be made of such property by the Company; and any real property and
buildings held under lease by the Company are held by it under valid, subsisting
and enforceable leases with such exceptions as are not material and do not
interfere with the use made and proposed to be made of such property and
buildings by the Company.
Section 4.23. Intellectual Property. Each of the Company and its subsidiaries
owns or possesses adequate and enforceable rights to use all patents, patent
applications, trademarks, trademark applications, trade names, service marks,
copyrights, copyright applications, licenses, know-how (including trade secrets
and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) and other similar rights and proprietary
knowledge (collectively, "Intangibles") necessary for the conduct of its
business as now being conducted. To the best of the Company's knowledge, neither
the Company nor any of its subsidiaries is infringing upon or in conflict with
any right of any other person with respect to any Intangibles. No claims have
been asserted by any person to the ownership or use of any Intangibles and the
Company has no knowledge of any basis for such claim.
Section 4.24. Internal Controls and Procedures. The Company maintains accurate
books and records and internal accounting controls which provide reasonable
assurance that (i) all transactions to which the Company is a party or by which
its properties are bound are executed with management's authorization; (ii) the
reported accountability of the Company's assets is compared with existing assets
at regular intervals; (iii) access to the Company's assets is permitted only in
accordance with management's authorization; and (iv) all transactions to which
the Company is a party or by which its properties are bound are recorded as
necessary to permit
15
<PAGE> 16
preparation of the financial statements of the Company in accordance with U.S.
generally accepted accounting principles.
Section 4.25. Payments and Contributions. Neither the Company nor any of its
directors, officers or, to its knowledge, other employees has (i) used any
Company funds for any unlawful contribution, endorsement, gift, entertainment or
other unlawful expense relating to political activity; (ii) made any direct or
indirect unlawful payment of Company funds to any foreign or domestic government
official or employee; (iii) violated or is in violation of any provision of the
Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any bribe,
rebate, payoff, influence payment, kickback or other similar payment to any
person with respect to Company matters.
Section 4.26. Related Party Transactions. Neither the Company nor any of its
officers, directors or "Affiliates" (as such term is defined in Rule 12b-2 under
the Exchange Act) has borrowed any moneys from or has outstanding any
indebtedness or other similar obligations to the Company. Other than the
investment in the Marbella, Spain clinic, neither the Company nor any of its
officers, directors or Affiliates (i) owns any direct or indirect interest
constituting more than a one percent equity (or similar profit participation)
interest in, or controls or is a director, officer, partner, member or employee
of, or consultant to or lender to or borrower from, or has the right to
participate in the profits of, any person or entity which is (x) a competitor,
supplier, customer, landlord, tenant, creditor or debtor of the Company or any
of its subsidiaries, (y) engaged in a business related to the business of the
Company or any of its subsidiaries, or (z) a participant in any transaction to
which the Company is a party (other than in the ordinary course of the Company's
business) or (ii) is a party to any contract, agreement, commitment or other
arrangement with the Company.
Section 4.27. No Misrepresentation. No representation or warranty of the Company
contained in this Agreement, any schedule, annex or exhibit hereto or any
agreement, instrument or certificate furnished by the Company to the Investors
pursuant to this Agreement, contains any untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to
make the statements therein, not misleading.
ARTICLE V
COVENANTS OF THE INVESTOR
Section 5.1. Compliance with Law. The Investor's trading activities with respect
to shares of the Company's Common Stock will be in compliance with all
applicable state and federal securities laws, rules and regulations and rules
and regulations of the Principal Market on which the Company's Common Stock is
listed.
Section 5.2. Short Sales. Neither the Investor nor its affiliates has the
intention of entering, or will enter into, on any date prior to the delivery of
a Conversion Notice, any put option, short position or other similar instrument
or position with respect to the Common Stock issuable pursuant to such
Conversion Notice.
16
<PAGE> 17
ARTICLE VI
COVENANTS OF THE COMPANY
Section 6.1. Registration Rights. The Company shall cause the Registration
Rights Agreement to remain in full force and effect and the Company shall comply
in all material respects with the terms thereof.
Section 6.2. Reservation of Common Stock. As of the date hereof, the Company has
reserved and the Company shall continue to reserve and keep available at all
times, free of preemptive rights, shares of Common Stock for the purpose of
enabling the Company to satisfy any obligation to issue the Conversion Shares
and the Warrant Shares; such amount of shares of Common Stock to be reserved
shall be calculated based upon the minimum Conversion Price therefor under the
terms of this Agreement and the Warrant respectively assuming for purposes of
this Section 6.2 a Conversion Price of $2.00. The number of shares so reserved
from time to time may be reduced by the number of shares actually delivered
hereunder and the number of shares so reserved may be increased or decreased to
reflect potential increases or decreases in the Common Stock that the Company
may thereafter be so obligated to issue by reason of adjustments to the Warrant.
Section 6.3. Listing of Common Stock. The Company hereby agrees to maintain the
listing of the Common Stock on a Principal Market, and as soon as required by
Nasdaq listing rules to list the Conversion Shares and the Warrant Shares. The
Company further agrees, if the Company applies to have the Common Stock traded
on any other Principal Market, it will include in such application the
Conversion Shares and the Warrant Shares, and will take such other action as is
necessary or desirable in the opinion of the investor to cause the Common Stock
to be listed on such other Principal Market as promptly as possible. The Company
will take all action to continue the listing and trading of its Common Stock on
the Principal Market (including, without limitation, maintaining sufficient net
tangible assets) and will comply in all respects with the Company's reporting,
filing and other obligations under the bylaws or rules of the Principal Market
and shall provide Investor with copies of any correspondence to or from such
Principal Market which questions or threatens delisting of the Common Stock,
within one business day of the Company's receipt thereof.
Section 6.4. Exchange Act Registration. The Company will cause its Common Stock
to continue to be registered under Section 12(b) or (g) of the Exchange Act,
will use its best efforts to comply in all respects with its reporting and
filing obligations under the Exchange Act, and will not take any action or file
any document (whether or not permitted by the Exchange Act or the rules
thereunder) to terminate or suspend such registration or to terminate or suspend
its reporting and filing obligations under said Act.
Section 6.5. Legends. The certificates evidencing the Common Stock to be sold by
the Investor pursuant to Section 9.1 shall be free of legends, except as set
forth in Article IX.
Section 6.6. Corporate Existence. The Company will take all steps necessary to
preserve and continue the corporate existence of the Company.
17
<PAGE> 18
Section 6.7. Notice of Certain Events Affecting Registration. The Company will
immediately notify the Investor upon the occurrence of any of the following
events in respect of a registration statement or related prospectus in respect
of an offering of Registrable Securities; (i) receipt of any request for
additional information by the SEC or any other federal or state governmental
authority during the period of effectiveness of the Registration Statement to be
supplied by amendments or supplements to the registration statement or related
prospectus; (ii) the issuance by the SEC or any other federal or state
governmental authority of any stop order suspending the effectiveness of the
Registration Statement or the initiation of any proceedings for that purpose;
(iii) receipt of any notification with respect to the suspension of the
qualification or exemption from qualification of any of the Registrable
Securities for sale in any jurisdiction or the initiation or threatening of any
proceeding for such purpose; (iv) the happening of any event that makes any
statement made in the Registration Statement or related prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue
in any material respect or that requires the making of any changes in the
Registration Statement, related prospectus or documents so that, in the case of
the Registration Statement, it will not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein not misleading, and that in the case
of the related prospectus, it will not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and (v) the Company's reasonable
determination that a post-effective amendment to the Registration Statement
would be appropriate; and the Company will promptly make available to the
Investor any such supplement or amendment to the related prospectus.
(a) Consolidation; Merger. The Company shall not, at any time after the
date hereof, effect any merger or consolidation of the Company with or into, or
a transfer of all or substantially all of the assets of the Company to, another
entity (a "Consolidation Event") unless the resulting successor or acquiring
entity (if not the Company) assumes by written instrument or by operation of law
the obligation to deliver to the Investor such shares of stock and/or securities
as the Investor is entitled to receive pursuant to this Agreement.
Section 6.8. Issuance of Preferred Shares and Warrant Shares. The sale of the
Preferred Stock and the issuance of the Warrant Shares pursuant to exercise of
the Warrant and the Conversion Shares upon conversion of the Preferred Stock
shall be made in accordance with the provisions and requirements of Section 4(2)
of Regulation D and any applicable state securities law. The Company shall make
all necessary SEC and "blue sky" filings required to be made by the Company in
connection with the sale of the Securities to the Investor as required by all
applicable Laws, and shall provide a copy thereof to the Investor promptly after
such filing.
Section 6.9. Limitation on Future Financing. The Company agrees that it will not
enter into any financing at a discount to Market Price until (i) six months from
the effective date of the Registration Statement, or (ii) each Investor gives
written approval for such additional financing; provided, however, anything to
the contrary appearing herein notwithstanding, neither this Section nor any
other provision hereof shall be construed to restrict or prohibit the Company's
right to restructure, amend or modify any financing facility existing on the
date hereof.
18
<PAGE> 19
ARTICLE VII
SURVIVAL; INDEMNIFICATION
Section 7.1. Survival. The representations, warranties and covenants made by
each of the Company and Investor in this Agreement, the annexes, schedules and
exhibits hereto and in each instrument, agreement and certificate entered into
and delivered by them pursuant to this Agreement, shall survive the Closing and
the consummation of the transactions contemplated hereby. In the event of a
breach or violation of any of such representations, warranties or covenants, the
party to whom such representations, warranties or covenants have been made shall
have all rights and remedies for such breach or violation available to it under
the provisions of this Agreement or otherwise, whether at law or in equity,
irrespective of any investigation made by or on behalf of such party on or prior
to the Closing Date.
Section 7.2. Indemnity. The Company hereby agrees to indemnify and hold harmless
the Investor, its Affiliates and their respective officers, directors, partners
and members (collectively, the "Investor Indemnitees"), from and against any and
all losses, claims, damages, judgments, penalties, liabilities and deficiencies
(collectively, "Losses"), and agrees to reimburse the Investor Indemnitees for
all out-of-pocket expenses (including the fees and expenses of legal counsel),
in each case promptly as incurred by the Investor Indemnitees and to the extent
arising out of or in connection with:
1. any misrepresentation, omission of fact or breach of any of the
Company's representations or warranties contained in this Agreement, the
annexes, schedules or exhibits hereto or any instrument, agreement or
certificate entered into or delivered by the Company pursuant to this
Agreement; or
2. any failure by the Company to perform in any material respect
any of its covenants, agreements, undertakings or obligations set forth
in this Agreement, the annexes, schedules or exhibits hereto or any
instrument, agreement or certificate entered into or delivered by the
Company pursuant to this Agreement.
Investor hereby agrees to indemnify and hold harmless the Company,
its Affiliates and their respective officers, directors, partners and members
(collectively, the "Company Indemnitees"), from and against any and all Losses,
and agrees to reimburse the Company Indemnitees for all out-of-pocket expenses
(including the fees and expenses of legal counsel), in each case promptly as
incurred by the Company Indemnitees and to the extent arising out of or in
connection with:
1. any misrepresentation, omission of fact, or breach of any of
Investor's representations or warranties contained in this Agreement, the
annexes, schedules or exhibits hereto or any instrument, agreement or
certificate entered into or delivered by Investor pursuant to this
Agreement; or
2. any failure by Investor to perform in any material respect any
of its covenants, agreements, undertakings or obligations set forth in
this Agreement or any instrument, certificate or agreement entered into
or delivered by Investor pursuant to this Agreement.
19
<PAGE> 20
Section 7.3. Notice. Promptly after receipt by either party hereto seeking
indemnification pursuant to Section 7.2 (an "Indemnified Party") of written
notice of any investigation, claim, proceeding or other action in respect of
which indemnification is being sought (each, a "Claim"), the Indemnified Party
promptly shall notify the party against whom indemnification pursuant to Section
7.2 is being sought (the "Indemnifying Party") of the commencement thereof; but
the omission to so notify the Indemnifying Party shall not relieve it from any
liability that it otherwise may have to the Indemnified Party, except to the
extent that the Indemnifying Party is materially prejudiced and forfeits
substantive rights and defenses by reason of such failure. In connection with
any Claim as to which both the Indemnifying Party and the Indemnified Party are
parties, the Indemnifying Party shall be entitled to assume the defense thereof.
Notwithstanding the assumption of the defense of any Claim by the Indemnifying
Party, the Indemnified Party shall have the right to employ separate legal
counsel and to participate in the defense of such Claim, and the Indemnifying
Party shall bear the reasonable fees, out-of-pocket costs and expenses of such
separate legal counsel to the Indemnified Party if (and only if): (x) the
Indemnifying Party shall have agreed to pay such fees, out-of-pocket costs and
expenses, (y) the Indemnified Party and the Indemnifying Party reasonably shall
have concluded that representation of the Indemnified Party and the Indemnifying
Party by the same legal counsel would not be appropriate due to actual or, as
reasonably determined by legal counsel to the Indemnified Party, potentially
differing interests between such parties in the conduct of the defense of such
Claim, or if there may be legal defenses available to the Indemnified Party that
are in addition to or disparate from those available to the Indemnifying Party,
or (z) the Indemnifying Party shall have failed to employ legal counsel
reasonably satisfactory to the Indemnified Party within a reasonable period of
time after notice of the commencement of such Claim. If the Indemnified Party
employs separate legal counsel in circumstances other than as described in
clauses (x), (y) or (z) above, the fees, costs and expenses of such legal
counsel shall be borne exclusively by the Indemnified Party. Except as provided
above, the Indemnifying Party shall not, in connection with any Claim in the
same jurisdiction, be liable for the fees and expenses of more than one firm of
legal counsel for the Indemnified Party (together with appropriate local
counsel). The Indemnifying Party shall not, without the prior written consent of
the Indemnified Party (which consent shall not unreasonably be withheld), settle
or compromise any Claim or consent to the entry of any judgment that does not
include an unconditional release of the Indemnified Party from all liabilities
with respect to such Claim or judgment.
Section 7.4. Direct Claims. In the event one party hereunder should have a claim
for indemnification that does not involve a claim or demand being asserted by a
third party, the Indemnified Party promptly shall deliver notice of such claim
to the Indemnifying Party. If the Indemnified Party disputes the claim, such
dispute shall be resolved by good faith negotiations of the Indemnified Party
and the Indemnifying Party, and if such parties cannot resolve their dispute
within 30 days, then either party shall be free to seek judicial relief.
20
<PAGE> 21
ARTICLE VIII
DUE DILIGENCE REVIEW; NON-DISCLOSURE OF NON-PUBLIC INFORMATION.
Section 8.1. Due Diligence Review. The Company shall make available for
inspection and review by the Investor, advisors to and representatives of the
Investor (who may or may not be affiliated with the Investor and who are
reasonably acceptable to the Company), any underwriter participating in any
disposition of the Registrable Securities on behalf of the Investor pursuant to
the Registration Statement, any such registration statement or amendment or
supplement thereto or any blue sky, NASD or other filing, all SEC Documents and
other filings with the SEC, and all other publicly available corporate documents
and properties of the Company as may be reasonably necessary for the purpose of
such review, and cause the Company's officers, directors and employees to supply
all such publicly available information reasonably requested by the Investor or
any such representative, advisor or underwriter in connection with such
Registration Statement (including, without limitation, in response to all
questions and other inquiries reasonably made or submitted by any of them),
prior to and from time to time after the filing and effectiveness of the
Registration Statement for the sole purpose of enabling the Investor and such
representatives, advisors and underwriters and their respective accountants and
attorneys to conduct initial and ongoing due diligence with respect to the
Company and the accuracy of the Registration Statement.
Section 8.2. Non-Disclosure of Non-Public Information
(a) The Company shall not disclose non-public information to the
Investor, advisors to or representatives of the Investor unless prior to
disclosure of such information the Company identifies such information as being
non-public information and provides the Investor, such advisors and
representatives with the opportunity to accept or refuse to accept such
non-public information for review. Other than disclosure of any comment letters
received from the SEC staff with respect to the Registration Statement, the
Company may, as a condition to disclosing any non-public information hereunder,
require the Investor's advisors and representatives to enter into a
confidentiality agreement in form reasonably satisfactory to the Company and the
Investor.
(b) Nothing herein shall require the Company to disclose non-public
information to the Investor or its advisors or representatives, and the Company
represents that it does not disseminate non-public information to any investors
who purchase stock in the Company in a public offering, to money managers or to
securities analysts, provided, however, that notwithstanding anything herein to
the contrary, the Company will, as hereinabove provided, immediately notify the
advisors and representatives of the Investor and, if any, underwriters, of any
event or the existence of any circumstance (without any obligation to disclose
the specific event or circumstance) of which it becomes aware, constituting
non-public information (whether or not requested of the Company specifically or
generally during the course of due diligence by such persons or entities),
which, if not disclosed in the prospectus included in the Registration Statement
would cause such prospectus to include a material misstatement or to omit a
material fact required to be stated therein in order to make the statements,
therein in light of the circumstances in which they were made, not misleading.
Nothing contained in this Section 8.2
21
<PAGE> 22
shall be construed to mean that such persons or entities other than the Investor
(without the written consent of the Investor prior to disclosure of such
information) may not obtain non-public information in the course of conducting
due diligence in accordance with the terms of this Agreement and nothing herein
shall prevent any such persons or entities from notifying the Company of their
opinion that based on such due diligence by such persons or entities, that the
Registration Statement contains an untrue statement of a material fact or omits
a material fact required to be stated in the Registration Statement or necessary
to make the statements contained therein, in light of the circumstances in which
they were made, not misleading.
ARTICLE IX
LEGENDS
Section 9.1. Legends. Unless otherwise provided below, each certificate
representing Registrable Securities will bear the following legend or equivalent
(the "Legend"):
THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY OTHER
APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER
SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN
MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED
OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION THAT IS EXEMPT FROM, OR
NOT SUBJECT TO, SUCH REGISTRATION.
Upon the execution and delivery hereof, the Company is issuing to the transfer
agent for its Common Stock (and to any substitute or replacement transfer agent
for its Common Stock upon the Company's appointment of any such substitute or
replacement transfer agent) instructions in substantially the form of Exhibit F
hereto. Such instructions shall be irrevocable by the Company from and after the
date hereof or from and after the issuance thereof to any such substitute or
replacement transfer agent, as the case may be, except as otherwise expressly
provided in the Registration Rights Agreement. It is the intent and purpose of
such instructions, as provided therein, to require the transfer agent for the
Common Stock from time to time upon transfer of Registrable Securities by the
Investor to issue certificates evidencing such Registrable Securities free of
the Legend during the following periods and under the following circumstances
and without consultation by the transfer agent with the Company or its counsel
and without the need for any further advice or instruction or documentation to
the transfer agent by or from the Company or its counsel or the Investor:
(a) at any time after the Effective Date, upon surrender of one or more
certificates evidencing Common Stock that bear the Legend, to the extent
accompanied by a notice requesting the issuance of new certificates free of the
Legend to replace those surrendered;
22
<PAGE> 23
provided that (i) the Registration Statement shall then be effective; (ii) the
Investor confirms to the transfer agent that it has sold, pledged or otherwise
transferred or agreed to sell, pledge or otherwise transfer such Common Stock in
a bona fide transaction to a third party that is not an affiliate of the
Company; and (iii) the Investor confirms to the transfer agent that the Investor
has complied with the prospectus delivery requirement.
(b) at any time upon any surrender of one or more certificates evidencing
Registrable Securities that bear the Legend, to the extent accompanied by a
notice requesting the issuance of new certificates free of the Legend to replace
those surrendered and containing representations that (i) the Investor is
permitted to dispose of such Registrable Securities without limitation as to
amount or manner of sale pursuant to Rule 144(k) under the Securities Act or
(ii) the Investor has sold, pledged or otherwise transferred or agreed to sell,
pledge or otherwise transfer such Registrable Securities in a manner other than
pursuant to an effective registration statement, to a transferee who will upon
such transfer be entitled to freely tradable securities.
Any of the notices referred to above in this Section 9.1 may be sent by
facsimile to the Company's transfer agent.
Section 9.2. No Other Legend or Stock Transfer Restrictions. No legend other
than the one specified in Section 9.1 has been or shall be placed on the share
certificates representing the Common Stock and no instructions or "stop transfer
orders," so called, "stock transfer restrictions," or other restrictions have
been or shall be given to the Company's transfer agent with respect thereto
other than as expressly set forth in this Article IX.
Section 9.3. Investor's Compliance. Nothing in this Article shall affect in any
way the Investor's obligations under any agreement to comply with all
applicable securities laws upon resale of the Common Stock.
ARTICLE X
CHOICE OF LAW
Section 10.1. Governing Law. This Agreement shall be governed by and interpreted
in accordance with the laws of the State of New York, without regard to the
conflicts of law principles of such state. Each of the parties consents to the
jurisdiction of the federal courts whose districts encompass any part of the
City of New York or the state courts of the State of New York sitting in the
City of New York in connection with any dispute arising under this Agreement and
hereby waives, to the maximum extent permitted by law, any objection, including
any objection based on forum non conveniens, to the bringing of any such
proceeding in such jurisdictions.
23
<PAGE> 24
ARTICLE XI
ASSIGNMENT; ENTIRE AGREEMENT
Section 11.1. Assignment. Neither this Agreement nor any rights of the Investor
or the Company hereunder may be assigned by either party to any other person.
Notwithstanding the foregoing, (a) the provisions of this Agreement shall inure
to the benefit of, and be enforceable by, any transferee of any of the Preferred
Stock purchased or acquired by the Investor hereunder with respect to the
Preferred Stock held by such person, and (b) upon the prior written consent of
the Company, which consent shall not unreasonably be withheld or delayed, the
Investor's interest in this Agreement may be assigned at any time, in whole or
in part, to any other person or entity (including any affiliate of the Investor)
who agrees to make the representations and warranties contained in Article III
and who agrees to be bound by the covenants of Article V.
ARTICLE XII
NOTICES
Section 12.1. Notices. All notices, demands, requests, consents, approvals, and
other communications required or permitted hereunder shall be in writing and,
unless otherwise specified herein, shall be (i) personally served, (ii)
deposited in the mail, registered or certified, return receipt requested,
postage prepaid, (iii) delivered by reputable air courier service with charges
prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed
as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or
permitted to be given hereunder shall be deemed effective (a) upon hand delivery
or delivery by facsimile, with accurate confirmation generated by the
transmitting facsimile machine, at the address or number designated below (if
delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered
other than on a business day during normal business hours where such notice is
to be received) or (b) on the second business day following the date of mailing
by reputable courier service, fully prepaid, addressed to such address, or upon
actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be:
If to the Company: Integrated Surgical Systems, Inc.
1850 Research Park Drive
Davis, CA 95616-4884
Attention: Ramesh C. Trivedi
Telephone: (530) 792-2600
Facsimile: (530) 792-2690
with a copy to: Snow Becker Krauss P.C.
(shall not constitute notice) 605 Third Avenue
New York, NY 10158
Attention: Jack Becker
24
<PAGE> 25
Telephone: (212) 687-3860
Facsimile: (212) 949-7052
if to the Investor: As set forth on the signature page hereto.
with a copy to: Joseph A. Smith, Esq.
(shall not constitute notice) Epstein Becker & Green, P.C.
250 Park Avenue
New York, New York
Telephone: (212) 351-4500
Facsimile: (212) 661-0989
Either party hereto may from time to time change its address or facsimile number
for notices under this Section 12.1 by giving at least ten (10) days' prior
written notice of such changed address or facsimile number to the other party
hereto.
ARTICLE XIII
TERMINATION
Section 13.1. Termination by Mutual Written Consent. This Agreement may be
terminated and the transactions contemplated hereby may be abandoned, for any
reason and at any time prior to the Closing Date, by the mutual written consent
of the Company and the Investors.
Section 13.2. Termination by the Company or the Investors. This Agreement may be
terminated and the transactions contemplated hereby may be abandoned by action
of the Company or the Investors if (i) the Closing shall not have occurred at or
prior to 5:00 p.m., New York City time, on August 31, 1998; provided, however,
that the right to terminate this Agreement pursuant to this Section 13.2 shall
not be available to any party whose failure to fulfill any of its obligations
under this Agreement has been the cause of or resulted in the failure of the
Closing to occur at or before such time and date or (ii) any court or public or
governmental authority shall have issued an order, ruling, judgment or writ, or
there shall be in effect any law, restraining, enjoining or otherwise
prohibiting the consummation of any of the transactions contemplated by this
Agreement.
Section 13.3. Termination by the Investors. This Agreement may be terminated and
the transactions contemplated hereby may be abandoned by the Investors at any
time prior to the Closing Date, if (i) the Company shall have failed to comply
in any material respect with any of its covenants or agreements contained in
this Agreement, (ii) there shall have been a breach by the Company with respect
to any representation or warranty made by it in this Agreement or (iii) there
shall be in existence any condition, having or reasonably and forseeably likely
to have a Material Adverse Effect.
Section 13.4. Termination by the Company. This Agreement may be terminated and
the transactions contemplated hereby may be abandoned by the Company at any time
prior to the Closing Date, if (i) the Investors shall have failed to comply in
any material respect with any of
25
<PAGE> 26
their respective covenants or agreements contained in this Agreement or (ii)
there shall have been a breach by the Investors with respect to any
representation or warranty made by them in this Agreement.
Section 13.5. Fees and Expenses of Termination. If this Agreement is terminated
for any reason, the Company shall reimburse the Investors for all of the
Investors' out-of-pocket costs and expenses incurred in connection with the
transactions contemplated by this Agreement (including, but not limited to, the
fees and disbursements of Investors' legal counsel as set forth in Section
14.7).
ARTICLE XIV
MISCELLANEOUS
Section 14.1. Counterparts/ Facsimile/ Amendments. This Agreement may be
executed in multiple counterparts, each of which may be executed by less than
all of the parties and shall be deemed to be an original instrument which shall
be enforceable against the parties actually executing such counterparts and all
of which together shall constitute one and the same instrument. Except as
otherwise stated herein, in lieu of the original documents, a facsimile
transmission or copy of the original documents shall be as effective and
enforceable as the original. This Agreement may be amended only by a writing
executed by all parties.
Section 14.2. Entire Agreement. This Agreement, the Exhibits hereto, which
include, but are not limited to the Warrant, the Escrow Agreement, and the
Registration Rights Agreement, set forth the entire agreement and understanding
of the parties relating to the subject matter hereof and supersedes all prior
and contemporaneous agreements, negotiations and understandings between the
parties, both oral and written relating to the subject matter hereof. The terms
and conditions of all Exhibits to this Agreement are incorporated herein by this
reference and shall constitute part of this Agreement as is fully set forth
herein.
Section 14.3. Survival; Severability. The representations, warranties, covenants
and agreements of the parties hereto shall survive each Closing hereunder. In
the event that any provision of this Agreement becomes or is declared by a court
of competent jurisdiction to be illegal, unenforceable or void, this Agreement
shall continue in full force and effect without said provision; provided that
such severability shall be ineffective if it materially changes the economic
benefit of this Agreement to any party.
Section 14.4. Title and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.
Section 14.5. Reporting Entity for the Common Stock. The reporting entity relied
upon for the determination of the trading price or trading volume of the Common
Stock on any given Trading Day for the purposes of this Agreement shall be
Bloomberg, L.P. or any successor thereto. The written mutual consent of the
Investor and the Company shall be required to employ any other reporting entity.
26
<PAGE> 27
Section 14.6. Replacement of Certificates. Upon (i) receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or
mutilation of a certificate representing the Preferred Stock or any Conversion
Shares or Warrant or any Warrant Shares and (ii) in the case of any such loss,
theft or destruction of such certificate, upon delivery of an indemnity
agreement or security reasonably satisfactory in form and amount to the Company
(which shall not exceed that required by the Company's transfer agent in the
ordinary course) or (iii) in the case of any such mutilation, on surrender and
cancellation of such certificate, the Company at its expense will execute and
deliver, in lieu thereof, a new certificate of like tenor.
Section 14.7. Fees and Expenses. Each of the Company and the Investor agrees to
pay its own expenses incident to the performance of its obligations hereunder,
except that the Company shall pay the fees, expenses and disbursements of
Investor's counsel in an amount not to exceed $20,000 as set forth in the Escrow
Agreement.
Section 14.8. Brokerage. Each of the parties hereto represents that it has had
no dealings in connection with this transaction with any finder or broker who
will demand payment of any fee or commission from the other party except for
Trinity Capital Advisors, Inc. as set forth on the Schedule of Exceptions, whose
fee shall be paid by the Company. The Company on the one hand, and the Investor,
on the other hand, agree to indemnify the other against and hold the other
harmless from any and all liabilities to any person claiming brokerage
commissions or finder's fees on account of services purported to have been
rendered on behalf of the indemnifying party in connection with this Agreement
or the transactions contemplated hereby.
27
<PAGE> 28
IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed by the undersigned, thereunto duly authorized, as of the date
first set forth above.
INTEGRATED SURGICAL SYSTEMS, INC.
By: /s/ Mark Winn
-------------------------------
Mark Winn
Chief Financial Officer
Jurisdiction of Incorporation
of Investor: Panama INVESTOR
Address: c/o Ultra Finance Name: AMRO INTERNATIONAL, S.A.
-------------------------------
Grossmunster Platz 26 By: /s/ R. Klee
------------------------------
Zurich, CH 8022
Telephone: 411 252 8680
Telecopier: 411 262 5515
Amount of investment: $500,000.00
Increased to $1,000,000 per wire
transfer of 9/2/98.
Jurisdiction of Incorporation INVESTOR
of Investor: Citco B.V.I. Ltd.
THE SHAAR FUND LTD.
Address: Citco Building, Wickhams Cay
P.O. Box 662 By: /s/ Declan Quilligan
Road Town, Tortola ----------------------------
B.V.I.
Telephone: (599-9) 284 494 2217
Telecopier: (599-9) 284 494 3917
Amount of investment: $2,520,000
28
<PAGE> 29
AMENDMENT No. 1 to PREFERRED STOCK PURCHASE AGREEMENT
This Amendment No. 1 ("Amendment") dated as of August 28, 1998 amends that
certain Preferred Stock Purchase Agreement dated as of August 25, 1998 among
Integrated Surgical Systems, Inc. and the Investors signatory thereto (the
"Agreement"). All capitalized terms used but not defined in this Amendment shall
have the meanings ascribed to them in the Agreement.
1. The Company and each Investor agrees that the total offering of Preferred
Stock shall be 3,520 shares for a total purchase price of $3,520,000.
2. The Company and each Investor agree that The Shaar Fund Ltd. shall be
entitled to deduct the additional sum of $20,000 from the Purchase Price for its
legal fees and expenses, and that the Company shall accept a net funding from
The Shaar Fund Ltd. of $2,500,000 as payment in full for The Shaar Fund Ltd.'s
subscription for 2,520 shares of Preferred Stock.
3. The number of Warrants to be issued to each Investor shall continue to be
based on the proportion of 50,000 Warrants per 4,000 shares of Preferred Stock.
4. The Certificate of Designations for the Preferred Stock shall state that the
total number of authorized shares of Preferred Stock shall be 3,520.
5. The Escrow Agreement is amended to provide that the $20,000 reserved to
be paid to Epstein Becker & Green, P.C. shall be paid to Weil Gotschal & Manges.
6. Except as set forth in this Amendment, the Agreement remains unmodified and
in full force and effect.
In witness whereof, the undersigned have duly executed the foregoing amendment,
by their duly authorized representatives.
Integrated Surgical Systems, Inc. The Shaar Fund Ltd.
By: /s/ Mark Winn By: /s/ Declan Quilligan
------------------------- --------------------------
AMRO International, S.A.
By: /s/ R. Klee
-------------------------
<PAGE> 1
Exhibit 4.2
CERTIFICATE OF DESIGNATIONS,
PREFERENCES AND RIGHTS OF
SERIES A CONVERTIBLE PREFERRED STOCK OF
INTEGRATED SURGICAL SYSTEMS, INC.
PURSUANT TO SECTION 151 OF THE DELAWARE
GENERAL CORPORATION LAW
Integrated Surgical Systems, Inc., a corporation organized and existing
under and by virtue of the General Corporation Law of the State of Delaware
(hereinafter the "Corporation"), in accordance with the provisions of Section
151(g) thereof, DOES HEREBY CERTIFY that, at a meeting of the Board of Directors
of the Corporation held on August 15, 1998:
FIRST: The following resolution was duly adopted by the Board of
Directors of the Corporation:
"RESOLVED: That pursuant to the authority vested in the Board of
Directors of the Corporation by Article 4 of the Corporation's restated
certificate of incorporation, as amended (the "Certificate of Incorporation"), a
series of Preferred Stock of the Corporation be, and it hereby is, created out
of the authorized but unissued shares of the capital stock of the Corporation,
such series to be designated Series A Convertible Preferred Stock (the "Series A
Convertible Preferred Stock"), to consist of 3,520 shares, par value $0.01 per
share, of which the preferences and relative and other rights, and the
qualifications, limitations or restrictions thereof, shall be as set forth in
the Certificate of Designations annexed hereto:
1. NUMBER OF SHARES OF SERIES A CONVERTIBLE PREFERRED STOCK. Of the
1,000,000 shares of authorized but unissued Preferred Stock, $0.01 par value
("Preferred Stock") of the Corporation, three thousand five hundred and twenty
(3,520) shares shall be designated and known as Series A Convertible Preferred
Stock, par value $0.01 per share ("Series A Convertible Preferred Stock").
2. VOTING.
(a) Unless required by law, no holder of any shares of Series
A Convertible Preferred Stock shall be entitled to vote at any meeting of
stockholders of the Corporation (or any written actions of stockholders in lieu
of meetings) with respect to any matters presented to the stockholders of the
Corporation for their action or consideration. Notwithstanding the foregoing,
the Corporation shall provide each holder of record of Series A Convertible
Preferred Stock with timely
<PAGE> 2
notice of every meeting of stockholders of the Corporation and shall provide
each holder with copies of all proxy materials distributed in connection
therewith.
(b) So long as shares of Series A Convertible Preferred Stock
are outstanding, the Corporation shall not, without first obtaining the approval
(by vote or written consent, as provided by the Delaware General Corporation
Law) of the holders of at least 85% in interest of the then outstanding shares
of Series A Convertible Preferred Stock:
(i) alter or change the rights, preferences or
privileges of the Series A Convertible Preferred Stock;
(ii) create any new class or series of capital stock
having parity with or a preference over the Series A Convertible Preferred Stock
as to distribution of assets upon liquidation, dissolution or winding up of the
Corporation ("Senior Securities") or alter or change the rights, preferences or
privileges of any Senior Securities so as to affect adversely the Series A
Convertible Preferred Stock;
(iii) increase the authorized number of shares of
Series A Convertible Preferred Stock; or
(iv) do any act or thing not authorized or
contemplated by this Certificate of Designations which would result in taxation
of the holders of shares of the Series A Convertible Preferred Stock under
Section 305 of the Internal Revenue Code of 1986, as amended (or any comparable
provision of the Internal Revenue Code as hereafter from time to time amended).
In the event holders of at least 85% in interest of the then
outstanding shares of Series A Convertible Preferred Stock agree to allow the
Corporation to alter or change the rights, preferences or privileges of the
shares of Series A Convertible Preferred Stock, pursuant to subsection (b)
above, so as to affect the Series A Convertible Preferred Stock, then the
Corporation will deliver notice of such approved change to the holders of the
Series A Convertible Preferred Stock that did not agree to such alteration or
change (the "Dissenting Holders") and Dissenting Holders shall have the right
for a period of thirty (30) days to convert any and all shares of then held
Series A Convertible Preferred Stock pursuant to the terms of this Certificate
of Designation as in effect prior to such alteration or change, or else to
continue to hold their shares of Series A Convertible Preferred Stock.
3. DIVIDENDS.
No holder of any shares of Series A Convertible Preferred
Stock shall be entitled to receive any dividends.
4. LIQUIDATION. (a) If the Corporation shall commence a voluntary case
under the Federal bankruptcy laws or any other applicable Federal or State
bankruptcy, insolvency or similar
2
<PAGE> 3
law, or consent to the entry of an order for relief in an involuntary case under
any law or to the appointment of a receiver, liquidator, assignee, custodian,
trustee, sequestrator (or other similar official) of the Corporation or of any
substantial part of its property, or make an assignment for the benefit of its
creditors, or admit in writing its inability to pay its debts generally as they
become due, or if a decree or order for relief in respect of the Corporation
shall be entered by a court having jurisdiction in the premises in an
involuntary case under the Federal bankruptcy laws or any other applicable
Federal or State bankruptcy, insolvency or similar law resulting in the
appointment of a receiver, liquidator, assignee, custodian, trustee,
sequestrator (or other similar official) of the Corporation or of any
substantial part of its property, or ordering the winding up or liquidation of
its affairs, and any such decree or order shall be unstayed and in effect for a
period of thirty (30) consecutive days and, on account of any such event, the
Corporation shall liquidate, dissolve or wind up, or if the Corporation shall
otherwise liquidate, dissolve or wind up (each such event being considered a
"Liquidating Event"), no distribution shall be made to the holders of any shares
of capital stock of the Corporation upon liquidation, dissolution or winding up
unless prior thereto, the holders of shares of Series A Convertible Preferred
Stock shall have received the Liquidation Preference (as defined in Article
4(c)) with respect to each share. If upon the occurrence of a Liquidation Event,
the assets and funds available for distribution among the holders of the Series
A Convertible Preferred Stock and holders of Pari Passu Securities shall be
insufficient to permit the payment to such holders of the preferential amounts
payable thereon, then the entire assets and funds of the Corporation legally
available for distribution to the Series A Convertible Preferred Stock and the
Pari Passu Securities shall be distributed ratably among such shares in
proportion to the ratio that that Liquidation Preference payable on each such
share bears to the aggregate Liquidation Preference payable on all such shares.
(b) At the option of each Holder, the sale,
conveyance of disposition of all or substantially all of the assets of the
Corporation, the effectuation by the Corporation of a transaction or series or
related transactions in which more than 50% of the voting power of the
Corporation is disposed of, or the consolidation, merger or other business
combination of the Corporation with or into any other Person or Persons when the
Corporation is not the survivor shall be deemed to be a liquidation, dissolution
or winding up of the Corporation pursuant to which the Corporation shall be
required to distribute, upon consummation of and as a condition to such
transaction an amount equal to the Liquidation Preference with respect to each
outstanding share of Series A Convertible Preferred Stock held by such Holder in
accordance with and subject to the terms of this Article 4.
(c) The Liquidation Preference shall be the Stated
Value of $1,000 per share of Series A Convertible Preferred Stock.
5. OPTIONAL CONVERSION. The holders of shares of Series A Convertible
Preferred Stock shall have the following conversion rights:
(a) RIGHT TO CONVERT; CONVERSION PRICE. Subject to the terms,
conditions, and restrictions of this Paragraph 5, the holder of any shares of
Series A Convertible Preferred Stock
3
<PAGE> 4
shall have the right to convert each such share of Series A Convertible
Preferred Stock (except that upon any liquidation of the Corporation, the right
of conversion shall terminate at the close of business on the business day fixed
for payment of the amount distributable on the Series A Convertible Preferred
Stock) into an amount of shares of Common Stock equal to the Stated Value of
such share or shares of Series A Convertible Preferred Stock divided by (i) the
lowest price at which a trade of the Common Stock is executed, as reported by
Bloomberg L.P., on the principal market for the Corporation's Common Stock (the
"Principal Market") during the period of five Trading Days ending with the last
Trading Day prior to the date of conversion (the "Conversion Date") (the "Market
Price"), after (ii) discounting the Market Price by 15% to determine the
conversion price (the "Conversion Price"). To illustrate, if the Market Price as
of the Conversion Date is $6.00 and 100 shares of Series A Convertible Preferred
Stock are being converted, the Stated Value for which would be $100,000, then
the Conversion Price shall be $5.10 per share of Common Stock ($6.00 x .85),
whereupon the Stated Value of $100,000 of Series A Convertible Preferred Stock
would entitle the holder thereof to convert the 100 shares of Series A
Convertible Preferred Stock into 19,607 shares of Common Stock ($100,000 divided
by $5.10 equals 19,607). However, in no event shall the Conversion Price be
greater than 150% of Market Price on the Original Issuance Date, as defined in
the next paragraph (the "Maximum Conversion Price"). In addition, if the
Conversion Price on any Conversion Date is less than $6.00, then the Corporation
shall have the option, prior to receipt of a Conversion Notice from the holder
and upon prior written notice to the holder, to pay the holder in shares of
Common Stock as set forth above, or else in cash in an amount equal to (i) the
closing price on the Principal Market on the day prior to the Conversion Date
multiplied by (ii) the number of shares of Common Stock which would otherwise be
issuable to the holder upon such conversion, or any combination of cash and
Common Stock. If notice of the Corporation's election to pay the holder in cash
is not received by the holder prior to the receipt by the Corporation of a
Conversion Notice, the Corporation shall pay the holder in shares of Common
Stock. Unless the Corporation shall have obtained the approval of its voting
stockholders to such issuance in accordance with the rules of the Principal
Market, the Corporation shall not issue shares of Common Stock upon conversion
of any shares of Series A Convertible Preferred Stock if such issuance of Common
Stock, when added to the number of shares of Common Stock previously issued by
the Corporation upon conversion of shares of the Series A Convertible Preferred
Stock, would equal or exceed twenty percent (20%) of the number of shares of the
Corporation's Common Stock which were issued and outstanding on the Original
Issuance Date; and, in such event, the Corporation shall honor such conversion
request in cash in accordance with the previous sentence, irrespective of the
Conversion Price.
(b) CONVERSION DATE. (i) The holder of any shares of Series A
Convertible Preferred Stock may convert: 90 days after the date upon which the
Series A Preferred Stock was originally issued (the "Original Issuance Date"),
25% of the cumulative amount of shares of Series A Convertible Preferred Stock
held by such holder; 120 days after the Original Issuance Date, 50% of the
cumulative amount of shares of Series A Convertible Preferred Stock held by such
holder; 150 days after the Original Issuance Date, 75% of the cumulative amount
of shares of Series A Convertible Preferred Stock held by such holder; and 180
days after the Original Issuance Date,
4
<PAGE> 5
100% of the cumulative amount of shares of Series A Convertible Preferred Stock
held by such holder. In the event that the Market Price exceeds the Maximum
Conversion Price at any time prior to 180 days after the Original Issuance Date,
then all of the shares of Series A Convertible Preferred Stock shall become
immediately convertible.
(ii) The Holder shall not have the right, and the
Company shall not have the obligation, to convert all or any portion of the
Series A Convertible Preferred Stock if and to the extent that the issuance to
the Holder of Common Shares upon such conversion would result in the Holder
being deemed the "beneficial owner" of more than 5% of the then outstanding
shares of Common Stock within the meaning of Section 13(d) of the Securities
Exchange Act of 1934, as amended, and the rules promulgated thereunder. If any
court of competent jurisdiction shall determine that the foregoing limitation is
ineffective to prevent a holder from being deemed the beneficial owner of more
than 5% of the then outstanding shares of Common Stock, then the Corporation
shall redeem so many of such holder's shares of Series A Convertible Preferred
Stock pursuant to Section 7(a) hereof as are necessary to cause such holder to
be deemed the beneficial owner of not more than 5% of the then outstanding
shares of Common Stock.
(c) NOTICE OF CONVERSION. The right of conversion shall be
exercised by the holder thereof by giving written notice (the "Conversion
Notice") to the Corporation, by facsimile or by registered mail or overnight
delivery service, with a copy by facsimile to the Corporation's then transfer
agent for its Common Stock, as designated by the Corporation from time to time,
that the holder elects to convert a specified number of shares of Series A
Convertible Preferred Stock representing a specified Stated Value thereof into
Common Stock and, if such conversion will result in the conversion of all of
such holder's shares of Series A Convertible Preferred Stock, by surrender of a
certificate or certificates for the shares so to be converted to the Corporation
at its principal office (or such other office or agency of the Corporation as
the Corporation may designate by notice in writing to the holders of the Series
A Convertible Preferred Stock) at any time during its usual business hours on
the date set forth in the Conversion Notice, together with a statement of the
name or names (with address) in which the certificate or certificates for shares
of Common Stock shall be issued. The Conversion Notice shall include therein the
Stated Value of shares of Series A Convertible Preferred Stock to be converted,
and a calculation (i) of the Market Price, (ii) the Conversion Price, and (iii)
the number of shares of Common Stock to be issued in connection with such
conversion.
(d) ISSUANCE OF CERTIFICATES; TIME CONVERSION EFFECTED. (i)
Promptly, but in no event more than three business days, after the receipt of
the Conversion Notice referred to in Subparagraph 5(c) and surrender of the
certificate or certificates for the share or shares of Series A Convertible
Preferred Stock to be converted, the Corporation shall issue and deliver, or
cause to be issued and delivered, to the holder, registered in such name or
names as such holder may direct, a certificate or certificates for the number of
whole shares of Common Stock into which such shares of Series A Convertible
Preferred Stock are converted. To the extent permitted by law, such conversion
shall be deemed to have been effected on the date on which such Conversion
Notice shall
5
<PAGE> 6
have been received by the Corporation and at the time specified stated in such
Conversion Notice, which must be during the calendar day of such notice, and at
such time the rights of the holder of such share or shares of Series A
Convertible Preferred Stock shall cease, and the person or persons in whose name
or names any certificate or certificates for shares of Common Stock shall be
issuable upon such conversion shall be deemed to have become the holder or
holders of record of the shares represented thereby. Issuance of shares of
Common Stock issuable upon conversion which are requested to be registered in a
name other than that of the registered holder shall be subject to compliance
with all applicable federal and state securities laws.
(ii) The Corporation understands that a delay in the issuance
of the shares of Common Stock beyond three business days could result in
economic loss to the holder. As compensation to the holder for such loss, the
Corporation agrees to pay late payments to the holder for late issuance of
shares of Common Stock upon conversion in accordance with the following schedule
(where "No. Business Days Late" is defined as the number of business days beyond
three (3) business days from the date of receipt of the Conversion Notice):
<TABLE>
<CAPTION>
No. Business Days Late Late Payment For Each
$5,000 of Liquidation Preference
Amount Being Converted
- --------------------------------------------------------------------------
<S> <C>
1 $100
2 $200
3 $300
4 $400
5 $500
6 $600
7 $700
8 $800
9 $900
10 $1,000
>10 $1,000 + $200 for each Business Day
Late beyond 10 days
</TABLE>
The Corporation shall pay any payments incurred under this Section in
immediately available funds upon demand. Nothing herein shall limit holder's
right to pursue injunctive relief and/or actual damages for the Corporation's
failure to issue and deliver Common Stock to the holder. Furthermore, in
addition to any other remedies which may be available to the holder, in the
event that the Corporation fails for any reason to effect delivery of such
shares of Common Stock within five business days the date of receipt of the
Conversion Notice, the holder will be entitled to revoke the relevant Conversion
Notice by delivering a notice to such effect to the Corporation whereupon the
Corporation and the holder shall each be restored to their respective positions
immediately prior to delivery of such Conversion Notice.
6
<PAGE> 7
(iii) If, at any time (a) the Corporation challenges,
disputes or denies the right of the holder to effect the conversion of the
Series A Convertible Preferred Stock into Common Shares or otherwise dishonors
or rejects any Conversion Notice delivered in accordance with this Section 5 or
(b) any third party who is not and has never been an Affiliate (as defined in
Rule 405 under the Securities Act of 1933, as amended) of the holder commences
any lawsuit or proceeding or otherwise asserts any claim before any court or
public or governmental authority which seeks to challenge, deny, enjoin, limit,
modify, delay or dispute the right of the holder hereof to effect the conversion
of the Series A Convertible Preferred Stock into Common Shares, then the holder
shall have the right, by written notice to the Corporation, to require the
Corporation to promptly redeem the Series A Convertible Preferred Stock for cash
at a redemption price equal to one hundred thirty-five percent (135%) of the
Stated Value thereof (the "Mandatory Purchase Amount"). Under any of the
circumstances set forth above, the Corporation shall be responsible for the
payment of all costs and expenses of the holder, including reasonable legal fees
and expenses, as and when incurred in disputing any such action or pursuing its
rights hereunder (in addition to any other rights of the holder).
(iv) The holder shall be entitled to exercise its
conversion privilege notwithstanding the commencement of any case under 11
U.S.C. Section 101 et seq. (the "Bankruptcy Code"). In the event the Corporation
is a debtor under the Bankruptcy Code, the Corporation hereby waives to the
fullest extent permitted any rights to relief it may have under 11 U.S.C.
Section 362 in respect of the holder's conversion privilege. The Corporation
hereby waives to the fullest extent permitted any rights to relief it may have
under 11 U.S.C. Section 362 in respect of the conversion of the Series A
Convertible Preferred Stock. The Corporation agrees, without cost or expense the
holder, to take or consent to any and all action necessary to effectuate relief
under 11 U.S.C. Section 362.
(e) FRACTIONAL SHARES. No fractional shares shall be issued
upon conversion of Series A Convertible Preferred Stock into Common Stock. All
fractional shares shall be rounded up to the nearest whole share.
(f) REORGANIZATION OR RECLASSIFICATION. If any capital
reorganization or reclassification of the capital stock of the Corporation shall
be effected in such a way that holders of Common Stock shall be entitled to
receive stock, securities or assets with respect to or in exchange for Common
Stock, or, in the case of any consolidation, merger or mandatory share exchange
of the Corporation into any other company, then, as a condition of such
reorganization, reclassification or exchange, lawful and adequate provisions
shall be made whereby each holder of a share or shares of Series A Convertible
Preferred Stock shall thereupon have the right to receive, upon the basis and
upon the terms and conditions specified herein and in lieu of the shares of
Common Stock immediately theretofore receivable upon the conversion of such
share or shares of Series A Convertible Preferred Stock, such shares of stock,
securities or assets as may be issued or payable with respect to or in exchange
for a number of outstanding shares of such Common Stock equal to the number of
shares of such Common Stock immediately theretofore receivable upon such
conversion had such reorganization, reclassification or exchange not taken
place, and in any such
7
<PAGE> 8
case appropriate provisions shall be made with respect to the rights and
interests of such holder to the end that the provisions hereof (including
without limitation provisions for adjustments of the conversion rights) shall
thereafter be applicable, as nearly as may be, in relation to any shares of
stock, securities or assets thereafter deliverable upon the exercise of such
conversion rights.
(g) ADJUSTMENTS FOR SPLITS, COMBINATIONS, ETC. The Conversion
Price and the number of shares of Common Stock into which the Series A
Convertible Preferred Stock shall be convertible shall be adjusted for stock
splits, combinations, or other similar events. Additionally, an adjustment will
be made in the case of an exchange of Common Stock, consolidation or merger of
the Company with or into another corporation or sale of all or substantially all
of the assets of the Company in order to enable the holder of Series A
Convertible Preferred Stock to acquire the kind and the number of shares of
stock or other securities or property receivable in such event by a holder of
the number of shares of Common Stock that might otherwise have been issued upon
the conversion of the Series A Convertible Preferred Stock. No adjustment to the
Conversion Price will be made for dividends (other than stock dividends), if
any, paid on the Common Stock or for securities issued pursuant to exercise for
fair value of options, warrants, or restricted stock.
(h) ADJUSTMENTS TO CONVERSION RATIO. For so long as any shares
of Series A Convertible Preferred Stock are outstanding, but no later than one
year from the effective date of a registration statement registering for resale
by the holders the shares of Common Stock issuable upon conversion of the Series
A Convertible Preferred Stock, if the Corporation (i) issues and sells pursuant
to an exemption from registration under the Securities Act (A) Common Stock at a
purchase price on the date of issuance thereof that is lower than the Conversion
Price at such date (other than shares of Common Stock issued in connection with
the exercise of any warrants or options outstanding on the Original Issuance
Date or pursuant to the Corporation's 1998 Employee Stock Purchase Plan), (B)
warrants or options with an exercise price on the date of issuance of the
warrants or options that is lower than the Conversion Price on such date (other
than options and stock awards granted pursuant to the Corporation's 1995 and
1998 Stock Option Plans), or (C) convertible, exchangeable or exercisable
securities with a right to convert, exchange or exercise at lower than the
Conversion Price on the date of issuance or conversion, as applicable, of such
convertible, exchangeable or exercisable securities (other than options and
stock awards granted pursuant to the Corporation's 1995 and 1998 Stock Option
Plans); and (ii) grants the right to the purchaser(s) thereof to demand that the
Corporation register under the Securities Act such Common Stock issued or the
Common Stock for which such warrants or options may be exercised or such
convertible, exchangeable or exercisable securities may be converted, exercised
or exchanged, then the Conversion Price shall be reduced to a rate equal to the
lowest of any lower rates since the most recently received Conversion Notice,
and such Adjusted Conversion Price shall apply to any future Conversion Notices
received by the Corporation. The Adjusted Conversion Price as it may exist from
time to time shall not apply retroactively to any shares of Series A Convertible
Preferred Stock converted prior to the implementation of such Adjusted
Conversion Price. Notwithstanding the foregoing, the Corporation may issue up to
an aggregate total of Three Hundred Thousand (300,000) shares of Common Stock
(subject to adjustment only for stock splits, stock dividends and reverse
8
<PAGE> 9
stock splits) at any price determined by the Board of Directors, after the
Original Issuance Date, without causing an Adjusted Conversion Price.
6. MANDATORY CONVERSION.
(a) MANDATORY CONVERSION DATE. If on or after August 24, 2001
(such date as selected by the Corporation being the "Mandatory Conversion
Date"), there remain issued and outstanding any shares of Series A Convertible
Preferred Stock, then the Corporation shall be entitled to require all (but not
less than all) holders of shares of Series A Convertible Preferred Stock then
outstanding to convert their shares of Series A Convertible Preferred Stock into
shares of Common Stock or, at the option of the Corporation, to buy out all such
holders in cash, at the then effective Conversion Price pursuant to Subparagraph
5(a). The Corporation shall provide written notice (the "Mandatory Conversion
Notice") to the holders of shares of Series A Convertible Preferred Stock of
such mandatory conversion or such mandatory buy-out. The Mandatory Conversion
Notice shall include (i) the Stated Value of the shares of Series A Convertible
Preferred Stock to be converted or bought out, (ii) the Conversion Price at the
Mandatory Conversion Date, and (iii) the number of shares of the Corporation's
Common Stock to be issued (or the amount of cash to be paid in the event of a
buy-out) upon such mandatory conversion or such mandatory buy-out at the then
applicable Conversion Price. Notwithstanding the foregoing, in no event shall
the Corporation convert that portion of the Series A Convertible Preferred Stock
to the extent that the issuance of Common Stock upon the conversion of such
Series A Convertible Preferred Stock, when combined with shares of Common Stock
received upon other conversions of Series A Convertible Preferred Stock by such
holder and any other holders of Series A Convertible Preferred Stock, would
exceed 19.99% of the Common Stock outstanding on the Original Issuance Date, or
as to any individual holder, make such holder the beneficial owner of 5% or more
of the Company's then-outstanding Common Stock.
(b) SURRENDER OF CERTIFICATES. On or before the Mandatory
Conversion Date, each holder of shares of Series A Convertible Preferred Stock
shall surrender his or its certificate or certificates for all such shares to
the Corporation at the place designated in such Mandatory Conversion Notice (or
an affidavit of lost certificate in form and content reasonably satisfactory to
the Corporation), and shall thereafter receive certificates for the number of
shares of Common Stock to which such holder is entitled or, in the event of a
buy-out by the Corporation, the amount of cash such holder is entitled within
three business days. On the Mandatory Conversion Date, all rights with respect
to the Series A Convertible Preferred Stock so converted, including the rights,
if any, to receive notices and vote, will terminate. All certificates evidencing
shares of Series A Convertible Preferred Stock that are required to be
surrendered for conversion in accordance with the provisions hereof, from and
after the Mandatory Conversion Date, shall be deemed to have been retired and
cancelled, notwithstanding the failure of the holder or holders thereof to
surrender such certificates on or prior to such date. The Corporation may
thereafter take such appropriate action as may be necessary to reduce the
authorized Series A Convertible Preferred Stock accordingly.
9
<PAGE> 10
7. REDEMPTION OF SERIES A CONVERTIBLE PREFERRED STOCK.
(a) RIGHT TO REDEEM SERIES A CONVERTIBLE PREFERRED STOCK. At
any time, and from time to time, on and after the expiration of the earlier of
(i) six months from the Original Issuance Date or (ii) the closing of a
registered firm-commitment underwritten secondary offering of equity securities
by the Corporation for cash, the Corporation may, in its sole discretion, but
shall not be obligated to, redeem, in whole or in part, the then issued and
outstanding shares of Series A Convertible Preferred Stock, at a price equal to
the greater of (i) $1,500 per share of such Series A Convertible Preferred Stock
or (ii) the Market Price of the Common Stock into which such share of Series A
Convertible Preferred Stock could be converted on the date of such notice (the
"Redemption Price").
(b) NOTICE OF REDEMPTION. The Corporation shall provide each
holder of record of the Series A Convertible Preferred Stock being redeemed with
written notice of redemption (the "Redemption Notice") not less than 30 days
prior to any date stipulated by the Corporation for the redemption of the Series
A Convertible Preferred Stock (the "Redemption Date"). The Redemption Notice
shall contain (i) the Redemption Date, (ii) the number of shares of Series A
Convertible Preferred Stock to be redeemed from the holder to whom the
Redemption Notice is delivered, (iii) instructions for surrender to the
Corporation of the certificate or certificates representing the shares of Series
A Convertible Preferred Stock to be redeemed, and (iv) a procedure for the
holder to specify the number of shares of Series A Convertible Preferred Stock
to be converted into Common Stock pursuant to Paragraph 5.
(c) RIGHT TO CONVERT SERIES A CONVERTIBLE PREFERRED STOCK UPON
RECEIPT OF REDEMPTION Notice. Upon receipt of the Redemption Notice, the
recipient thereof shall have the option, at its sole election, to specify what
portion of the Series A Convertible Preferred Stock called for redemption in the
Redemption Notice shall be redeemed as provided in this Paragraph 7 or converted
into Common Stock in the manner provided in Paragraph 5. If the holder of the
Series A Convertible Preferred Stock called for redemption elects to convert any
of such shares, then such conversion shall take place on the Conversion Date
specified by the holder, but in no event after the Redemption Date, in
accordance with the terms of Paragraph 5.
(d) SURRENDER OF CERTIFICATES; PAYMENT OF REDEMPTION PRICE. On
or before the Redemption Date, each holder of the shares of Series A Convertible
Preferred Stock to be redeemed shall surrender the required certificate or
certificates representing such shares to the Corporation, in the manner and at
the place designated in the Redemption Notice, and upon payment to the holder of
the Redemption Price, each such surrendered certificate shall be cancelled and
retired. If payment of such redemption price is not made in full by the
Redemption Date the Holder shall again have the right to convert the Series A
Convertible Preferred Stock as provided in Article 5 hereof. If a certificate is
surrendered and all the shares evidenced thereby are not being redeemed, the
Corporation shall issue new certificates to be registered in the names of the
person(s) whose
10
<PAGE> 11
name(s) appear(s) as the owners on the respective surrendered certificates and
deliver such certificate to such person(s).
8. NOTICES. In case at any time:
(a) the Corporation shall declare any dividend upon its Common
Stock payable in cash or stock or make any other pro rata distribution to the
holders of its Common Stock; or
(b) the Corporation shall offer for subscription pro rata to
the holders of its Common Stock any additional shares of stock of any class or
other rights; or
(c) there shall be any capital reorganization or
reclassification of the capital stock of the Corporation, or a consolidation or
merger of the Corporation with or into, or a sale of all or substantially all
its assets to, another entity or entities; or
(d) there shall be a voluntary or involuntary
dissolution, liquidation or winding up of the Corporation;
then, in any one or more of said cases, the Corporation shall give, by first
class mail, postage prepaid, or by telex or facsimile or by recognized overnight
delivery service to non-U.S. residents, addressed to each holder of any shares
of Series A Convertible Preferred Stock at the address of such holder as shown
on the books of the Corporation, (i) at least 10 days' prior written notice of
the date on which the books of the Corporation shall close or a record shall be
taken for such dividend, distribution or subscription rights or for determining
rights to vote in respect of any such reorganization, reclassification,
consolidation, merger, sale, dissolution, liquidation or winding up and (ii) in
the case of any such reorganization, reclassification, consolidation, merger,
sale, dissolution, liquidation or winding up, at least 10 days' prior written
notice of the date when the same shall take place. Such notice in accordance
with the foregoing clause (i) shall also specify, in the case of any such
dividend, distribution or subscription rights, the date on which the holders of
Common Stock shall be entitled thereto and (ii) shall also specify the date on
which the holders of Common Stock shall be entitled to exchange their Common
Stock for securities or other property deliverable upon such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation or
winding up, as the case may be.
9. STOCK TO BE RESERVED. The Corporation, upon the effective
date of this Certificate of Designations, has a sufficient number of shares of
Common Stock available to reserve for issuance upon the conversion of all
outstanding shares of Series A Convertible Preferred Stock. The Corporation will
at all times reserve and keep available out of its authorized Common Stock,
solely for the purpose of issuance upon the conversion of Series A Convertible
Preferred Stock as herein provided, such number of shares of Common Stock as
shall then be issuable upon the conversion of all outstanding shares of Series A
Convertible Preferred. The Corporation covenants that all shares of Common Stock
which shall be so issued shall be duly and validly issued, fully
11
<PAGE> 12
paid and non-assessable. The Corporation will take all such action as may be so
taken without violation of any applicable law or regulation, or of any
requirement of any national securities exchange upon which the Common Stock may
be listed to have a sufficient number of authorized but unissued shares of
Common Stock to issue upon conversion of the Series A Convertible Preferred
Stock. The Corporation will not take any action which results in any adjustment
of the conversion rights if the total number of shares of Common Stock issued
and issuable after such action upon conversion of the Series A Convertible
Preferred Stock would exceed the total number of shares of Common Stock then
authorized by the Corporation's Certificate of Incorporation, as amended.
10. NO REISSUANCE OF SERIES A CONVERTIBLE PREFERRED STOCK.
Shares of Series A Convertible Preferred Stock which are converted into shares
of Common Stock as provided herein shall not be reissued.
11. ISSUE TAX. The issuance of certificates for shares of
Common Stock upon conversion of Series A Convertible Preferred Stock shall be
made without charge to the holder for any United States issuance tax in respect
thereof, provided that the Corporation shall not be required to pay any tax
which may be payable in respect of any transfer involved in the issuance and
delivery of any certificate in a name other than that of the holder of the
Series A Convertible Preferred Stock which is being converted.
12. CLOSING OF BOOKS. The Corporation will at no time close
its transfer books against the transfer of any Series A Convertible Preferred
Stock or of any shares of Common Stock issued or issuable upon the conversion of
any shares of Series A Convertible Preferred Stock in any manner which
interferes with the timely conversion of such Series A Convertible Preferred
Stock, except as may otherwise be required to comply with applicable securities
laws.
13. DEFINITIONS. As used in this Certificate of Designations,
the term "Common Stock" shall mean and include the Corporation's authorized
Common Stock, $0.01 par value, as constituted on the date of filing of these
terms of the Series A Convertible Preferred Stock, and shall also include any
capital stock of any class of the Corporation thereafter authorized which shall
neither be limited to a fixed sum or percentage of par value in respect of the
rights of the holders thereof to participate in dividends nor entitled to a
preference in the distribution of assets upon the voluntary or involuntary
liquidation, dissolution or winding up of the Corporation; provided that the
shares of Common Stock receivable upon conversion of shares of Series A
Convertible Preferred Stock shall include only shares designated as Common Stock
of the Corporation on the date of filing of this instrument, or in case of any
reorganization, reclassification, or stock split of the outstanding shares
thereof, the stock, securities or assets provided for in Subparagraph 5(f) and
(g). Any capitalized terms used in this Certificate of Designations but not
defined herein shall have the meanings set forth in that certain Preferred Stock
Purchase Agreement dated as of August 25, 1998 among the Corporation and the
other
12
<PAGE> 13
persons signatory thereto, a copy of which will be provided to any stockholder
of the Corporation upon request to the Secretary of the Corporation, without
charge.
14. LOSS, THEFT, DESTRUCTION OF PREFERRED STOCK. Upon receipt
of evidence satisfactory to the Corporation of the loss, theft, destruction or
mutilation of certificates representing shares of Series A Convertible Preferred
Stock and, in the case of any such loss, theft or destruction, upon receipt of
indemnity or security reasonably satisfactory to the Corporation, or, in the
case of any such mutilation, upon surrender and cancellation of the Series A
Convertible Preferred Stock certificate, the Corporation shall make, issue and
deliver, in lieu of such lost, stolen, destroyed or mutilated certificates for
Series A Convertible Preferred Stock, new certificates for Series A Convertible
Preferred Stock of like tenor. The Series A Convertible Preferred Stock shall be
held and owned upon the express condition that the provisions of this Section 14
are exclusive with respect to the replacement of mutilated, destroyed, lost or
stolen shares of Series A Preferred Stock and shall preclude any and all other
rights and remedies notwithstanding any law or statue existing or hereafter
enacted to the contrary with respect to the replacement of negotiable
instruments or other securities without the surrender thereof.
15. WHO DEEMED ABSOLUTE OWNER. The Corporation may deem the
person in whose name the Series A Convertible Preferred Stock shall be
registered upon the registry books of the Corporation to be, and may treat it
as, the absolute owner of the Series A Convertible Preferred Stock for the
purpose of conversion of the Series A Convertible Preferred Stock and for all
other purposes, and the Corporation shall not be affected by any notice to the
contrary. All such payments and such conversion shall be valid and effectual to
satisfy and discharge the liability upon the Series A Convertible Preferred
Stock to the extent of the sum or sums so paid or the conversion so made.
16. REGISTER. The Corporation shall keep at its principal
office a register in which the Corporation shall provide for the registration of
the Series A Convertible Preferred Stock. Upon any transfer of the Series A
Convertible Preferred Stock in accordance with the provisions hereof, the
Corporation shall register such transfer on the Series A Convertible Preferred
Stock register.
17. WITHHOLDING. To the extent required by applicable law, the
Corporation may withhold amounts for or on account of any taxes imposed or
levied by or on behalf of any taxing authority in the United States having
jurisdiction over the Corporation from any payments made pursuant to the Series
A Convertible Preferred Stock.
18. HEADINGS. The headings of the Sections of this Certificate
of Designations are inserted for convenience only and do not constitute a part
of this Certificate of Designations.
13
<PAGE> 14
IN WITNESS WHEREOF, Mark Winn, Chief Financial Officer of the
Corporation, under penalties of perjury, does hereby declare and certify that
this is the act and deed of the Corporation and the facts stated herein are true
and accordingly has signed this Certificate of Designations as of this 25th day
of August, 1998.
INTEGRATED SURGICAL SYSTEMS, INC.
By: /s/Mark Winn
------------
Mark Winn
Chief Financial Officer
14
<PAGE> 1
EXHIBIT 4.3
NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN
REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE
"COMMISSION") OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN
EXEMPTION FROM REGISTRATION UNDER REGULATION D PROMULGATED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THIS WARRANT SHALL NOT
CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION OF AN OFFER TO BUY THE WARRANT
OR THE SHARES ISSUABLE UPON EXERCISE HEREOF IN ANY JURISDICTION IN WHICH SUCH
OFFER OR SOLICITATION WOULD BE UNLAWFUL.
NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF MAY BE SOLD,
PLEDGED, TRANSFERRED OR ASSIGNED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS,
OR IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE PROVISIONS OF
THE SECURITIES ACT AND UNDER PROVISIONS OF APPLICABLE STATE SECURITIES LAWS;
AND IN THE CASE OF AN EXEMPTION, ONLY IF THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION OF THE WARRANT OR
SUCH SHARES, WHICH OPINION AND WHICH COUNSEL SHALL BE SATISFACTORY TO THE
COMPANY IN ITS SOLE DISCRETION.
STOCK PURCHASE WARRANT
To Purchase Shares of Common Stock of
INTEGRATED SURGICAL SYSTEMS, INC.
THIS CERTIFIES that, for value received, (the
"Holder"), is entitled, upon the terms and subject to the conditions
hereinafter set forth, at any time on or after March 4, 1999 and on or prior
to March 3, 2002 (the "Termination Date") but not thereafter, to subscribe for
and purchase from INTEGRATED SURGICAL SYSTEMS, INC., a corporation incorporated
in Delaware (the "Company"), ( ) shares
(the "Warrant Shares") of Common Stock, par value US $0.01 per share of the
Company (the "Common Stock"). The purchase price of one share of Common Stock
(the "Exercise Price") under this Warrant shall be equal to One Hundred Thirty
(130%) percent of the Market Price on the Closing Date (as those terms are
defined in the Preferred Stock Purchase Agreement dated as of August 25, 1998
("Agreement"), between the Company and the Holder), as reported by Bloomberg,
L.P. The Exercise Price and the number of shares for which the Warrant is
exercisable shall be subject to adjustment as provided herein. This Warrant is
being issued in connection with the Agreement and is subject to its terms and
conditions. In the event of any conflict between the terms of this Warrant and
the Agreement, the Agreement shall control.
<PAGE> 2
1. Title of Warrant. Prior to the expiration hereof and subject to
compliance with applicable laws, this Warrant and all rights hereunder are
transferable, in whole or in part, at the office or agency of the Company by the
holder hereof in person or by duly authorized attorney, upon surrender of this
Warrant together with the Assignment Form annexed hereto properly endorsed.
2. Authorization of Shares. The Company covenants that all shares of
Common Stock which may be issued upon the exercise of rights represented by this
Warrant will, upon exercise of the rights represented by this Warrant, be duly
authorized, validly issued, fully paid and nonassessable and free from all
taxes, liens and charges in respect of the issue thereof (other than taxes in
respect of any transfer occurring contemporaneously with such issue).
3. Exercise of Warrant. (a) Except as provided in Section 4 herein,
exercise of the purchase rights represented by this Warrant may be made at any
time or times, before the close of business on the Termination Date, or such
earlier date on which this Warrant may terminate as provided in this Warrant, by
the surrender of this Warrant and the Notice of Exercise Form annexed hereto
duly executed, at the office of the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered holder
hereof at the address of such holder appearing on the books of the Company) and
upon payment of the Exercise Price of the shares thereby purchased by cash,
check or bank draft payable to the Company or by wire transfer or cashier's
check drawn on a United States bank; whereupon the holder of this Warrant shall
be entitled to receive a certificate for the number of shares of Common Stock so
purchased. Certificates for shares purchased hereunder shall be delivered to the
holder hereof within three (3) business days after the date on which this
Warrant shall have been exercised as aforesaid. Payment of the Exercise Price of
the shares may be by certified check or cashier's check or by wire transfer to
an account designated by the Company in an amount equal to the Exercise Price
multiplied by the number of Warrant Shares. This Warrant shall be deemed to have
been exercised and such certificate or certificates shall be deemed to have been
issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such shares for all purposes, as
of the date the Warrant has been exercised by payment to the Company of the
Warrant purchase price and all taxes required to be paid by Holder, if any,
pursuant to Section 5 prior to the issuance of such shares have been paid. If
this Warrant shall have been exercised in part, the Company shall, at the time
of delivery of the certificate or certificates representing Warrant Shares,
deliver to Holder a new Warrant evidencing the rights of Holder to purchase the
unpurchased shares of Common Stock called for by this Warrant, which new Warrant
shall in all other respects be identical with this Warrant.
(b) The holder shall be entitled to exercise the Warrant
notwithstanding the commencement of any case under 11 U.S.C. Section 101 et seq.
(the "Bankruptcy Code"). In the event the Company is a debtor under the
Bankruptcy Code, the Company hereby waives to the fullest extent permitted any
rights to relief it may have under 11 U.S.C. Section 362 in respect of the
Holder's exercise right. The Company hereby waives to the fullest extent
permitted any rights to relief it may have under 11 U.S.C. Section 362 in
respect of the exercise of the Warrant. The Company agrees, without cost or
expense to the Holder, to take or consent to any and all action necessary to
effectuate relief under 11 U.S.C. Section 362.
2
<PAGE> 3
4. No Fractional Shares or Scrip. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which Holder would otherwise be entitled
to purchase upon such exercise, the Company shall pay a cash adjustment in
respect of such final fraction in an amount equal to the same fraction of the
Market Price per share of Common Stock as of the Closing Date.
5. Charges, Taxes and Expenses. Issuance of certificates for shares of
Common Stock upon the exercise of this Warrant shall be made without charge to
the holder hereof for any issue or transfer tax or other incidental expense in
respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name
of the holder of this Warrant or in such name or names as may be directed by the
holder of this Warrant; provided, however, that in the event certificates for
shares of Common Stock are to be issued in a name other than the name of the
holder of this Warrant, this Warrant when surrendered for exercise shall be
accompanied by the Assignment Form attached hereto duly executed by the holder
hereof; and provided further, that upon any transfer involved in the issuance or
delivery of any certificates for shares of Common Stock, the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it
for any transfer tax incidental thereto.
6. Closing of Books. The Company will not close its shareholder books
or records in any manner which prevents the timely exercise of this Warrant.
7. Transfer, Division and Combination. (a) Subject to compliance with
any applicable securities laws, transfer of this Warrant and all rights
hereunder, in whole or in part, shall be registered on the books of the Company
to be maintained for such purpose, upon surrender of this Warrant at the
principal office of the Company, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required, such payment,
the Company shall execute and deliver a new Warrant or Warrants in the name of
the assignee or assignees and in the denomination specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the
portion of this Warrant not so assigned, and this Warrant shall promptly be
cancelled. A Warrant, if properly assigned, may be exercised by a new Holder for
the purchase of shares of Common Stock without having a new Warrant issued.
(b) This Warrant may be divided or combined with other Warrants upon
presentation hereof at the aforesaid office of the Company, together with a
written notice specifying the names and denominations in which new Warrants are
to be issued, signed by Holder or its agent or attorney. Subject to compliance
with Section 7(a), as to any transfer which may be involved in such division or
combination, the Company shall execute and deliver a new Warrant or Warrants in
exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice.
<PAGE> 4
(c) The Company shall prepare, issue and deliver at its own expense
(other than transfer taxes) the new Warrant or Warrants under this Section 7.
(d) The Company agrees to maintain, at its aforesaid office, books for
the registration and the registration of transfer of the Warrants.
8. No Rights as Shareholder until Exercise. This Warrant does not entitle
the holder hereof to any voting rights or other rights as a shareholder of the
Company prior to the exercise thereof. Upon the surrender of this Warrant and
the payment of the aggregate Exercise Price, the Warrant Shares so purchased
shall be and be deemed to be issued to such holder as the record owner of such
shares as of the close of business on the later of the date of such surrender
or payment.
9. Loss, Theft, Destruction or Mutilation of Warrant. The Company
represents and warrants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this
Warrant certificate or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it, and upon surrender and cancellation of such Warrant or
stock certificate, if mutilated, the Company will make and deliver a new
Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.
10. Saturdays, Sundays, Holidays, etc. If the last or appointed day for
the taking of any action or the expiration of any right required or granted
herein shall be a Saturday, Sunday or a legal holiday, then such action may be
taken or such right may be exercised on the next succeeding day not a Saturday,
Sunday or legal holiday.
11. (a) Adjustments of Exercise Price and Number of Warrant Shares. The
number and kind of securities purchasable upon the exercise of this Warrant and
the Exercise Price shall be subject to adjustment from time to time upon the
happening of any of the following. In case the Company shall (i) declare or pay
a dividend in shares of Common Stock or make a distribution in shares of Common
Stock to holders of its outstanding Common Stock, (ii) subdivide its
outstanding shares of Common Stock, (iii) combine its outstanding shares of
Common Stock into a smaller number of shares of Common Stock or (iv) issue any
shares of its capital stock in a reclassification of the Common Stock, then the
number of Warrant Shares purchasable upon exercise of this Warrant immediately
prior thereto shall be adjusted so that the holder of this Warrant shall be
entitled to receive the kind and number of Warrant Shares or other securities
of the Company which he would have owned or have been entitled to receive had
such Warrant been exercised in advance thereof. Upon each such adjustment of
the kind and number of Warrant Shares or other securities of the Company which
are purchasable hereunder, the holder of this Warrant shall thereafter be
entitled to purchase the number of Warrant Shares or other securities resulting
from such adjustment at an Exercise Price per such Warrant Share or other
security obtained by multiplying the Exercise Price in effect immediately prior
to such adjustment by the number of Warrant Shares purchasable pursuant hereto
immediately prior to such adjustment and dividing by the number of Warrant
Shares or other securities of the Company resulting from such adjustment. An
adjustment made pursuant to this paragraph shall become effective immediately
after the effective date of such event retroactive to the record date, if any,
for such event.
4
<PAGE> 5
(b) Reorganization, Reclassification, Merger, Consolidation or
Disposition of Assets. In case the Company shall reorganize its capital,
reclassify its capital stock, consolidate or merge with or into another
corporation (where the Company is not the surviving corporation or where there
is a change in or distribution with respect to the Common Stock of the
Company), or sell, transfer or otherwise dispose of all or substantially all
its property, assets or business to another corporation and, pursuant to the
terms of such reorganization, reclassification, merger, consolidation or
disposition of assets, shares of common stock of the successor or acquiring
corporation, or any cash, shares of stock or other securities or property of
any nature whatsoever (including warrants or other subscription or purchase
rights) in addition to or in lieu of common stock of the successor or
acquiring corporation ("Other Property"), are to be received by or distributed
to the holders of Common Stock of the Company, then Holder shall have the right
thereafter to receive, upon exercise of the Warrant, the number of shares of
common stock of the successor or acquiring corporation or of the Company, if it
is the surviving corporation, and Other Property receivable upon or as a result
of such reorganization, reclassification, merger, consolidation or disposition
of assets by a holder of the number of shares of Common Stock for which this
Warrant is exercisable immediately prior to such event. In case of any such
reorganization, reclassification, merger, consolidation or disposition of
assets, the successor or acquiring corporation (if other than the Company)
shall expressly assume the due and punctual observance and performance of each
and every covenant and condition of this Warrant to be performed and observed
by the Company and all the obligations and liabilities hereunder, subject to
such modifications as may be deemed appropriate (as determined by resolution of
the Board of Directors of the Company) in order to provide for adjustments of
shares of Common Stock for which this Warrant is exercisable which shall be as
nearly equivalent as practicable to the adjustments provided for in this
Section 11. For purposes of this Section 11, "common stock of the successor or
acquiring corporation" shall include stock of such corporation of any class
which is not preferred as to dividends or assets over any other class of stock
of such corporation and which is not subject to redemption and shall also
include any evidences of indebtedness, shares of stock or other securities
which are convertible into or exchangeable for any such stock, either
immediately or upon the arrival of a specified date or the happening of a
specified event and any warrants or other rights to subscribe for or purchase
any such stock. The foregoing provisions of this Section 11 shall similarly
apply to successive reorganizations, reclassifications, mergers, consolidations
or disposition of assets.
(c) Certain Limitations. Notwithstanding anything herein to the
contrary, the Company agrees not to enter into any transaction which, by reason
of any adjustment hereunder, would cause the Exercise Price to be less than the
par value per share of Common Stock.
12. Voluntary Adjustment by the Company. The Company may at any time
during the term of this Warrant, reduce the then current Exercise Price to any
amount and for any period of time deemed appropriate by the Board of Directors
of the Company.
13. Notice of Adjustment. Whenever the number of Warrant Shares or number
or kind of securities or other property purchasable upon the exercise of this
Warrant or the Exercise Price is adjusted, as herein provided, the Company
shall promptly mail by registered or certified mail, return receipt requested,
to the holder of this Warrant notice of such adjustment or adjustments setting
forth the number of Warrant Shares (and other securities or property)
5
<PAGE> 6
purchasable upon the exercise of this Warrant and the Exercise Price of such
Warrant Shares (and other securities or property) after such adjustment, setting
forth a brief statement of the facts requiring such adjustment and setting forth
the computation by which such adjustment was made. Such notice, in absence of
manifest error, shall be conclusive evidence of the correctness of such
adjustment.
14. Notice of Corporate Action. If at any time
(a) the Company shall take a record of the holders of its Common Stock
for the purpose of entitling them to receive a dividend or other distribution,
or any right to subscribe for or purchase any evidences of its indebtedness, any
shares of stock of any class or any other securities or property, or to receive
any other right, or
(b) there shall be any capital reorganization of the Company, any
reclassification or recapitalization of the capital stock of the Company or any
consolidation or merger of the Company with, or any sale, transfer or other
disposition of all or substantially all the property, assets or business of the
Company to, another corporation or,
(c) there shall be a voluntary or involuntary dissolution, liquidation
or winding up of the Company;
then, in any one or more of such cases, the Company shall give to Holder (i) at
least 30 days' prior written notice of the date on which a record date shall be
selected for such dividend, distribution or right or for determining rights to
vote in respect of any such reorganization, reclassification, merger,
consolidation, sale, transfer, disposition, liquidation or winding up, and (ii)
in the case of any such reorganization, reclassification, merger, consolidation,
sale, transfer, disposition, dissolution, liquidation or winding up, at least 30
days' prior written notice of the date when the same shall take place. Such
notice in accordance with the foregoing clause also shall specify (i) the date
on which any such record is to be taken for the purpose of such dividend,
distribution or right, the date on which the holders of Common Stock shall be
entitled to any such dividend, distribution or right, and the amount and
character thereof, and (ii) the date on which any such reorganization,
reclassification, merger, consolidation, sale, transfer, disposition,
dissolution, liquidation or winding up is to take place and the time, if any
such time is to be fixed, as of which the holders of Common Stock shall be
entitled to exchange their shares of Common Stock for securities or other
property deliverable upon such disposition, dissolution, liquidation or winding
up. Each such written notice shall be sufficiently given if addressed to Holder
at the last address of Holder appearing on the books of the Company and
delivered in accordance with Section 17(d).
15. Authorized Shares. The Company covenants that during the period the
Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant
Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of executing stock
certificates to execute and issue the necessary certificates for the Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such
Warrant Shares may be issued as
6
<PAGE> 7
provided herein without violation of any applicable law or regulation, or of any
requirements of NASDAQ or any domestic securities exchange upon which the Common
Stock may be listed.
The Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization,
transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, but will at all times in
good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder
against impairment. Without limiting the generality of the foregoing, the
Company will (a) not increase the par value of any shares of Common Stock
receivable upon the exercise of this Warrant above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (b) take
all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable shares of Common
Stock upon the exercise of this Warrant, and (c) use its best efforts to obtain
all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof as may be necessary to enable the Company to
perform its obligations under this Warrant.
Upon the request of Holder, the Company will at any time during the
period this Warrant is outstanding acknowledge in writing, in form reasonably
satisfactory to Holder, the continuing validity of this Warrant and the
obligations of the Company hereunder.
Before taking any action which would cause an adjustment reducing the
current Exercise Price below the then par value, if any, of the shares of
Common Stock issuable upon exercise of the Warrants, the Company shall take any
corporate action which may be necessary in order that the Company may validly
and legally issue fully paid and non-assessable shares of such Common Stock at
such adjusted Exercise Price.
Before taking any action which would result in an adjustment in the
number of shares of Common Stock for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions
thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.
16. Required Registration. Pursuant to the terms and conditions set forth
in the Registration Rights Agreement entered into between the Company and the
Holders as of the date of issuance of this Warrant, the Company shall prepare
and file with the Commission not later than the 45th day after the Closing Date,
a Registration Statement relating to the offer and sale of the Common Stock
issuable upon exercise of the Warrants and shall use its best efforts to cause
the Commission to declare such Registration Statement effective under the
Securities Act as promptly as practicable but no later than 90 days after the
closing date (or 120 days after the Closing Date if such Registration Statement
is not permitted to be filed on Form S-3).
17. Miscellaneous.
(a) Issue Date; Jurisdiction. The provisions of this Warrant shall be
construed and shall be given effect in all respects as if it had been issued and
delivered by the
7
<PAGE> 8
Company on the date hereof. This Warrant shall be binding upon any successors
or assigns of the Company. This Warrant shall constitute a contract under the
laws of New York without regard to its conflict of law, principles or rules,
and be subject to arbitration pursuant to the terms set forth in the Agreement.
(b) Restrictions. The holder hereof acknowledges that the Warrant
Shares acquired upon the exercise of this Warrant, if not registered, will have
restrictions upon resale imposed by state and federal securities laws.
(c) Nonwaiver and Expenses. No course of dealing or any delay or
failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice Holder's rights, powers or
remedies, notwithstanding all rights hereunder terminate on the Termination
Date. If the Company fails to make, when due, any payments provided for
hereunder, or fails to comply with any other provision of this Warrant, the
Company shall pay to Holder such amounts as shall be sufficient to cover any
costs and expenses including, but not limited to, reasonable attorneys' fees,
including those of appellate proceedings, incurred by Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers
or remedies hereunder.
(d) Notices. Any notice, request or other document required or
permitted to be given or delivered to the holder hereof by the Company shall be
delivered in accordance with the notice provisions of the Agreement.
(e) Limitation of Liability. No provision hereof, in the absence of
affirmative action by Holder to purchase shares of Common Stock, and no
enumeration herein of the rights or privileges of Holder hereof, shall give
rise to any liability of Holder for the purchase price of any Common Stock or
as a stockholder of the Company, whether such liability is asserted by the
Company or by creditors of the Company.
(f) Remedies. Holder, in addition to being entitled to exercise all
rights granted by law, including recovery of damages, will be entitled to
specific performance of its rights under this Warrant. The Company agrees that
monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of the provisions of this Warrant and hereby agrees to
waive the defense in any action for specific performance that a remedy at law
would be adequate.
(g) Successors and Assigns. Subject to applicable securities laws,
this Warrant and the rights evidenced hereby shall inure to the benefit of and
be binding upon the successors of the Company and the successors and assigns of
Holder. The provisions of this Warrant are intended to be for the benefit of
all Holders from time to time of this Warrant and shall be enforceable by any
such Holder or holder of Warrant Stock.
(h) Cooperation. The Company shall cooperate with Holder in supplying
such information as may be reasonably necessary for Holder to complete and file
any information reporting forms presently or hereafter required by the
Commission as a condition to the availability of an exemption from the
Securities Act for the sale of any Warrant or Restricted Common Stock.
8
<PAGE> 9
(i) Indemnification. The Company agrees to indemnify and hold harmless
Holder from and against any liabilities, obligations, losses, damages,
penalties, actions, judgments, suits, claims, costs, attorneys' fees, expenses
and disbursements of any kind which may be imposed upon, incurred by or asserted
against Holder in any manner relating to or arising out of any failure by the
Company to perform or observe in any material respect any of its covenants,
agreements, undertakings or obligations set forth in this Warrant; provided,
however, that the Company will not be liable hereunder to the extent that any
liabilities, obligations, losses, damages, penalties, actions, judgments, suits,
claims, costs, attorneys' fees, expenses or disbursements are found in a final
non-appealable judgment by a court to have resulted from Holder's negligence,
bad faith or willful misconduct in its capacity as a stockholder or
warrantholder of the Company.
(j) Amendment. This Warrant and all other Warrants may be modified or
amended or the provisions hereof waived with the written consent of the Company
and the Holder.
(k) Severability. Wherever possible, each provision of this Warrant
shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Warrant shall be prohibited by or
invalid under applicable law, such provision shall be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such
provisions or the remaining provisions of this Warrant.
(l) Headings. The headings used in this Warrant are for the
convenience of reference only and shall not, for any purpose, be deemed a part
of this Warrant.
IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by
its officer thereunto duly authorized.
Dated: September 10, 1998
INTEGRATED SURGICAL SYSTEMS, INC.
By: Ramesh C. Trivedi
_________________________________
CFO, Authorized Signatory
9
<PAGE> 10
NOTICE OF EXERCISE
To: INTEGRATED SURGICAL SYSTEMS, INC.
(1) The undersigned hereby elects to purchase shares of Common
Stock, par value $0.01 per share (the "Common Stock"), of INTEGRATED SURGICAL
SYSTEMS, INC. pursuant to the terms of the attached Warrant, and tenders
herewith payment of the exercise price in full, together with all applicable
transfer taxes, if any.
(2) Please issue a certificate or certificates representing said shares of
Common Stock in the name of the undersigned or in such other name as is
specified below:
------------------------------------
(Name)
------------------------------------
(Address)
------------------------------------
Dated:
-------------------------------
Signature
<PAGE> 11
ASSIGNMENT FORM
(To assign the foregoing warrant, execute
this form and supply required information.
Do not use this form to exercise the warrant.)
FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to
- ------------------------------------------------------------- whose address is
- -------------------------------------------------------------------------------.
- --------------------------------------------------------------------------------
Dated: ---------------,
Holder's Signature: -----------------------------
Holder's Address: -------------------------------
-------------------------------
Signature Guaranteed: ----------------------------------------------------------
NOTE: The signature to this Assignment Form must correspond with the name as it
appears on the face of the Warrant, without alteration or enlargement or any
change whatsoever, and must be guaranteed by a bank or trust company. Officers
of corporations and those acting in an fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing
Warrant.
2
<PAGE> 1
EXHIBIT 4.4
REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS AGREEMENT, dated as of the 25th day of August, 1998,
between the persons signatory hereto (each referred to as the "Holder"), and
INTEGRATED SURGICAL SYSTEMS, INC., a corporation incorporated under the laws of
the State of Delaware, and having its principal place of business at 1850
Research Park Drive, Davis, California 95616-4884 (the "Company").
WHEREAS, simultaneously with the execution and delivery of
this Agreement, the Holder is purchasing from the Company, pursuant to a
Preferred Stock Purchase Agreement dated the date hereof (the "Purchase
Agreement"), ($ ) Dollars worth of shares of Series A
Convertible Preferred Stock, $0.01 par value and a Warrant to purchase
shares of the Company's Common Stock (terms not defined herein shall have the
meanings ascribed to them in the Purchase Agreement); and
WHEREAS, the Company desires to grant to the Holder the
registration rights set forth herein with respect to the shares of Common Stock
issuable upon conversion of the Series A Convertible Preferred Stock and shares
of Common Stock underlying the Warrant (hereinafter referred to as the "Stock"
or "Securities" of the Company).
NOW, THEREFORE, the parties hereto mutually agree as follows:
Section 1. Registrable Securities. As used herein the term
"Registrable Security" means the Securities; provided, however, that with
respect to any particular Registrable Security, such security shall cease to be
a Registrable Security when, as of the date of determination, (i) it has been
effectively registered under the Securities Act of 1933, as amended (the "1933
Act") and disposed of pursuant thereto, (ii) registration under the 1933 Act is
no longer required for the immediate public distribution of such security
without limitation as to volume as a result of the provisions of Rule 144
promulgated under the 1933 Act, or (iii) it has ceased to be outstanding. The
term "Registrable Securities" means any and/or all of the securities falling
within the foregoing definition of a "Registrable Security." In the event of any
merger, reorganization, consolidation, recapitalization or other change in
corporate structure affecting the Common Stock, such adjustment shall be deemed
to be made in the definition of "Registrable Security" as is appropriate in
order to prevent any dilution or enlargement of the rights granted pursuant to
this Agreement.
Section 2. Restrictions on Transfer. The Holder acknowledges
and understands that prior to the registration of the Securities as provided
herein, the Securities are "restricted securities" as defined in Rule 144
promulgated under the Act. The Holder understands that no disposition or
transfer of the Securities may be made by Holder in the absence of (i) an
opinion of counsel to the Holder that such transfer may be made without
registration under the 1933 Act or (ii) such registration.
1
<PAGE> 2
With a view to making available to the Holder the
benefits of Rule 144 under the Securities Act or any other similar rule or
regulation of the Commission that may at any time permit the Holder to sell
securities of the Company to the public without registration ("Rule 144"), the
Company agrees to:
(a) comply with the provisions of paragraph (c)(1) of
Rule 144; and
(b) file with the Commission in a timely manner all
reports and other documents required to be filed by the Company pursuant to
Section 13 or 15(d) under the Exchange Act; and, if at any time it is not
required to file such reports but in the past had been required to or did file
such reports, it will, upon the request of any Holder, make available other
information as required by, and so long as necessary to permit sales of, its
Registrable Securities pursuant to Rule 144.
Section 3. Registration Rights.
(a) The Company agrees that it will prepare and file
with the Securities and Exchange Commission ("Commission"), within forty five
(45) days after the Subscription Date, a registration statement (on Form S-3, or
other appropriate registration statement) under the 1933 Act (the "Registration
Statement"), at the sole expense of the Company (except as provided in Section
3(c) hereof), in respect of all holders of Registrable Securities, so as to
permit a public offering and resale of the Registrable Securities under the Act.
The Company shall use its best efforts to cause the
Registration Statement to become effective within ninety (90) days from the
Subscription Date. In the event that the Commission decides to review the
Registration Statement or deems that registration of the Registrable Securities
on a Form S-3 is not acceptable, the Company shall use its best efforts to cause
the Registration Statement to become effective within one hundred twenty (120)
days from the Subscription Date. The number of shares designated in the
Registration Statement to be registered shall include all the Warrant Shares and
the number of shares of Common Stock which would be issued assuming a Market
Price of $2.00 per share of Common Stock, and shall include appropriate language
regarding reliance upon Rule 416 to the extent permitted by the Commission. The
Company will notify Holder of the effectiveness of the Registration Statement
within one business day of such event.
(b) The Company will maintain the Registration
Statement or post-effective amendment filed under this Section 3 hereof current
under the 1933 Act until the earlier of (i) the date that all of the Registrable
Securities have been sold pursuant to the Registration Statement, (ii) the date
the holders thereof receive an opinion of counsel to the Company, which counsel
shall be reasonably acceptable to the Holder, that the Registrable Securities
may be sold under the provisions of Rule 144 without limitation as to volume,
(iii) all Registrable Securities have been otherwise transferred to Holders who
may trade such shares without restriction under the Securities Act, and the
Company has delivered a new certificate or other evidence of ownership for such
securities not bearing a restrictive legend, or (iv) all Registrable Securities
may be sold without any time, volume or manner limitations pursuant to Rule
144(k) or any
2
<PAGE> 3
similar provision then in effect under the Securities Act in the opinion of
counsel to the Company, which counsel shall be reasonably acceptable to the
Holder.
(c) All fees, disbursements and out-of-pocket
expenses and costs incurred by the Company in connection with the preparation
and filing of the Registration Statement under subparagraph 3(a) and in
complying with applicable securities and Blue Sky laws (including, without
limitation, all attorneys' fees) shall be borne by the Company. The Holder shall
bear the cost of underwriting discounts and commissions, if any, applicable to
the Registrable Securities being registered and the fees and expenses of its
counsel. The Holder and its counsel shall have a reasonable period, not to
exceed three (3) business days, to review the proposed Registration Statement or
any amendment thereto, prior to filing with the Commission, and the Company
shall provide each Holder with copies of any comment letters received from the
Commission with respect thereto. The Company shall make reasonably available for
inspection by Holder, any underwriter participating in any disposition pursuant
to the Registration Statement, and any attorney, accountant or other agent
retained by such Holder or any such underwriter all relevant financial and other
records, pertinent corporate documents and properties of the Company and its
subsidiaries, and cause the Company's officers, directors and employees to
supply all information reasonably requested by such Holder or any such
underwriter, attorney, accountant or agent in connection with the Registration
Statement, in each case, as is customary for similar due diligence examinations;
provided, however, that all records, information and documents that are
designated in writing by the Company, in good faith, as confidential,
proprietary or containing any material non-public information shall be kept
confidential by such Holder and any such underwriter, attorney, accountant or
agent (pursuant to an appropriate confidentiality agreement in the case of any
such Holder or agent), unless such disclosure is made pursuant to judicial
process in a court proceeding (after first giving the Company an opportunity
promptly to seek a protective order or otherwise limit the scope of the
information sought to be disclosed) or is required by law, or such records,
information or documents become available to the public generally or through a
third party not in violation of an accompanying obligation of confidentiality;
and provided further that, if the foregoing inspection and information gathering
would otherwise disrupt the Company's conduct of its business, such inspection
and information gathering shall, to the maximum extent possible, be coordinated
on behalf of the Holder and the other parties entitled thereto by one firm of
counsel designed by and on behalf of the majority in interest of Holder and
other parties. The Company shall qualify any of the securities for sale in such
states as such Holder reasonably designates and shall furnish indemnification in
the manner provided in Section 6 hereof. However, the Company shall not be
required to qualify in any state which will require an escrow or other
restriction relating to the Company and/or the sellers. The Company at its
expense will supply the Holder with copies of the Registration Statement and the
prospectus or offering circular included therein and other related documents in
such quantities as may be reasonably requested by the Holder.
(d) The Company shall not be required by this Section
3 to include a Holder's Registrable Securities in any Registration Statement
which is to be filed if, in the opinion of counsel for both the Holder and the
Company (or, should they not agree, in the opinion of another counsel
experienced in securities law matters acceptable to counsel for the Holder and
the Company) the proposed offering or other transfer as to which such
registration is requested is exempt from applicable federal and state securities
laws and would result in all
3
<PAGE> 4
purchasers or transferees obtaining securities which are not "restricted
securities", as defined in Rule 144 under the 1933 Act.
(e) In the event that (i) the Registration Statement
to be filed by the Company pursuant to Section 3(a) above is not filed with the
Commission within forty five (45) days from the Subscription Date and/or the
Registration Statement is not declared effective by the Commission within ninety
(90) days from the Subscription Date (or within one hundred twenty (120) days
from the Subscription Date if the Commission decides to review the Registration
Statement or deems that registration of the Registrable Securities on a Form S-3
is not acceptable), (ii) the Registration Statement is not maintained as
effective by the Company for the period set forth in Section 3(b) above or (iii)
an amendment to the Registration Statement was not filed by the Company with the
Commission and declared effective by the Commission on a timely basis to include
any additional number of shares of Stock as described in Section 3(i), if
necessary, then the Company will pay Holder (pro rated on a daily basis), as
liquidated damages for such failure and not as a penalty, two (2%) percent of
the purchase price of the then outstanding Securities for the first thirty (30)
days, and in the event of late filing, three percent (3%) percent of the
purchase price of the Securities for every thirty (30) day period thereafter
until the Registration Statement has been filed and in the event of late
effectiveness, one percent (1%) of the purchase price of the Securities for
every thirty (30) day period thereafter until the Registration Statement has
been declared effective. Such payment of the liquidated damages shall be made to
the Holder in cash, immediately upon demand, provided, however, that the payment
of such liquidated damages shall not relieve the Company from its obligations to
register the Securities pursuant to this Section.
Notwithstanding the above, if the Registration
Statement covering the Additional Registrable Securities (as defined in Section
3(i) hereof) required to be filed by the Company pursuant to Section 3(i) hereof
is not filed with the Commission within 45 days after the Market Price declines
to $2.00, the Company shall be in default of this Registration Rights Agreement.
If the Company does not remit the damages to the
Holder as set forth above, the Company will pay the Holder reasonable costs of
collection, including attorneys fees, in addition to the liquidated damages. The
registration of the Securities pursuant to this provision shall not affect or
limit Holder's other rights or remedies as set forth in this Agreement.
(f) No provision contained herein shall preclude the
Company from selling securities pursuant to any Registration Statement in which
it is required to include Registrable Securities pursuant to this Section 3.
(g) If at any time or from time to time after the
effective date of the Registration Statement, the Company notifies the Holder in
writing of the existence of a Potential Material Event (as defined in Section
3(h) below), the Holder shall not offer or sell any Registrable Securities or
engage in any other transaction involving or relating to Registrable Securities,
from the time of the giving of notice with respect to a Potential Material Event
until such Holder receives written notice from the Company that such Potential
Material Event either has been disclosed to the public or no longer constitutes
a Potential Material Event; provided,
4
<PAGE> 5
however, that the Company may not so suspend the right to such holders of
Securities for more than twenty (20) days in the aggregate during any twelve
month period, during the periods the Registration Statement is required to be in
effect. If a Potential Material Event shall occur prior to the date the
Registration Statement is filed, then the Company's obligation to file the
Registration Statement shall be delayed without penalty for not more than twenty
(20) days. The Company must give Holder notice in writing at least two (2)
business days prior to the first day of the blackout period.
(h) "Potential Material Event" means any of the
following: (a) the possession by the Company of material information not ripe
for disclosure in a registration statement, which shall be evidenced by
determinations in good faith by the Chief Executive Officer or the Board of
Directors of the Company that disclosure of such information in the Registration
Statement would be detrimental to the business and affairs of the Company; or
(b) any material engagement or activity by the Company which would, in the good
faith determination of the Chief Executive Officer or the Board of Directors of
the Company, be adversely affected by disclosure in a registration statement at
such time, which determination shall be accompanied by a good faith
determination by the Chief Executive Officer or the Board of Directors of the
Company that the Registration Statement would be materially misleading absent
the inclusion of such information.
(i) In the event the Market Price declines to $2.00
or less (the "Decline Date"), the Company shall, to the extent required by the
Securities Act (because the additional shares were not covered by the
Registration Statement filed pursuant to Section 3(a)), as reasonably determined
by the Holder, file an additional Registration Statement with the Commission for
such additional number of Registrable Securities as would be issuable upon
conversion of the Preferred Stock (the "Additional Registrable Securities"), in
addition to those previously registered, assuming a Market Price of $1.00 per
share. The Company shall prepare and file with the Commission not later than the
30th day after the Decline Date, a registration statement relating to the offer
and sale of such Additional Registrable Securities (the "Additional Registration
Statement") and shall use its best efforts to cause the Commission to declare
such Additional Registration Statement effective under the Securities Act as
promptly as practicable but not later than 60 days thereafter. If the Additional
Registration Statement is not (i) filed with the commission by the 30th day
after the Decline Date or (ii) declared effective by the Commission within 90
days after the Decline Date (either of which, without duplication, an
"Additional Registration Date"), then the Company shall make payments to the
Holder as set forth in Section 3(e).
Section 4. Cooperation with Company. Holder will cooperate
with the Company in all respects in connection with this Agreement, including
timely supplying all information reasonably requested by the Company and
executing and returning all documents reasonably requested in connection with
the registration and sale of the Registrable Securities and entering into and
performing its obligations under any underwriting agreement, if the offering is
an underwritten offering, in usual and customary form, with the managing
underwriter or underwriters of such underwritten offering.
5
<PAGE> 6
Section 5. Registration Procedures. If and whenever the
Company is required by any of the provisions of this Agreement to effect the
registration of any of the Registrable Securities under the Act, the Company
shall (except as otherwise provided in this Agreement), as expeditiously as
possible:
(a) (i) prepare and file with the Commission such
amendments and supplements to the Registration Statement and the prospectus used
in connection therewith as may be necessary to keep such registration statement
effective and to comply with the provisions of the Act with respect to the sale
or other disposition of all securities covered by such registration statement
whenever the Holder of such securities shall desire to sell or otherwise dispose
of the same (including prospectus supplements with respect to the sales of
securities from time to time in connection with a registration statement
pursuant to Rule 415 promulgated under the Act) and (ii) take all lawful action
such that each of (A) the Registration Statement and any amendment thereto does
not, when it becomes effective, contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to
make the statements therein, not misleading and (B) the Prospectus forming part
of the Registration Statement, and any amendment or supplement thereto, does not
at any time during the Registration Period include an untrue statement of a
material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading.
(b) (i) prior to the filing with the Commission of
any Registration Statement (including any amendments thereto) and the
distribution or delivery of any prospectus (including any supplements thereto),
provide draft copies thereof to the Holders and reflect in such documents all
such comments as the Holders (and their counsel) reasonably may propose
respecting the Selling Shareholders and Plan of Distribution sections (or
equivalents) and (ii) furnish to each Holder such numbers of copies of a
prospectus including a preliminary prospectus or any amendment or supplement to
any prospectus, in conformity with the requirements of the Act, and such other
documents, as such Holder may reasonably request in order to facilitate the
public sale or other disposition of the securities owned by such Holder;
(c) register and qualify the securities covered by
the Registration Statement under such other securities or blue sky laws of such
jurisdictions as the Holder shall reasonably request (subject to the limitations
set forth in Section 3(d) above), and do any and all other acts and things which
may be necessary or advisable to enable each Holder to consummate the public
sale or other disposition in such jurisdiction of the securities owned by such
Holder, except that the Company shall not for any such purpose be required to
qualify to do business as a foreign corporation in any jurisdiction wherein it
is not so qualified or to file therein any general consent to service of
process;
(d) list such securities on the NASDAQ Small Cap
Stock Market or other national securities exchange on which any securities of
the Company are then listed, if the listing of such securities is then permitted
under the rules of such exchange or NASDAQ;
(e) enter into and perform its obligations under an
underwriting agreement, if the offering is an underwritten offering, in usual
and customary form, with the
6
<PAGE> 7
managing underwriter or underwriters of such underwritten offering, including,
but not limited to, the following:
(i) making such representations and
warranties to the Holder participating in such underwritten offering and to the
managers, in form, substance and scope as are customarily made by the Company to
underwriters in secondary underwritten offerings;
(ii) obtaining opinions of counsel to the
Company (which counsel and opinions (in form, scope and substance) shall be
reasonably satisfactory to the managers) addressed to the underwriters, covering
such matters as are customarily covered in opinions requested in secondary
underwritten offerings (it being agreed that the matters to be covered by such
opinions shall include, without limitation, as of the date of the opinion and as
of the Effective Time of the Registration Statement or most recent
post-effective amendment thereto, as the case may be, the absence from the
Registration Statement and the Prospectus, including any documents incorporated
by reference therein, of an untrue statement of a material fact or the omission
of a material fact required to be stated therein or necessary to make the
statements therein (in the case of the Prospectus, in light of the circumstances
under which they were made) not misleading, subject to customary limitations);
(iii) obtaining "cold comfort" letters and
updates thereof from the independent public accountants of the Company (and, if
necessary, from the independent public accountants of any subsidiary of the
Company or of any business acquired by the Company, in each case for which
financial statements and financial data are, or are required to be, included in
the Registration Statement), addressed to each underwriter participating in such
underwritten offering (if such underwriter has provided such letter,
representations or documentation, if any, required for such cold comfort letter
to be so addressed), in customary form and covering matters of the type
customarily covered in "cold comfort" letters in connection with secondary
underwritten offerings; and
(iv) delivering such documents and
certificates as may be reasonably required
by the managers, if any;
(f) notify each Holder of Registrable Securities
covered by the Registration Statement, at any time when a prospectus relating
thereto covered by the Registration Statement is required to be delivered under
the Act, of the happening of any event of which it has knowledge as a result of
which the prospectus included in the Registration Statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material
fact required to be stated therein or necessary to make the statements therein
not misleading in the light of the circumstances then existing, and the Company
shall prepare and file a curative amendment under Section 5(a) as quickly as
commercially possible;
(g) as promptly as practicable after becoming aware
of such event, notify each Holder who holds Registrable Securities being sold
(or, in the event of an underwritten offering, the managing underwriters) of the
issuance by the Commission of any stop order or other suspension of the
effectiveness of the Registration Statement at the earliest
7
<PAGE> 8
possible time and take all lawful action to effect the withdrawal, recession or
removal of such stop order or other suspension;
(h) cooperate with the Holders who hold Registrable
Securities being offered to facilitate the timely preparation and delivery of
certificates for the Registrable Securities to be offered pursuant to the
Registration Statement and enable such certificates for the Registrable
Securities to be in such denominations or amounts, as the case may be, as the
Holders reasonably may request and registered in such names as the Holder may
request; and, within three business days after a Registration Statement which
includes Registrable Securities is declared effective by the Commission, deliver
and cause legal counsel selected by the Company to deliver to the transfer agent
for the Registrable Securities (with copies to the Holders whose Registrable
Securities are included in such Registration Statement) an appropriate
instruction and, to the extent necessary, an opinion of such counsel;
(i) take all such other lawful actions reasonably
necessary to expedite and facilitate the disposition by the Holders of their
Registrable Securities in accordance with the intended methods therefor provided
in the prospectus which are customary under the circumstances;
(j) make generally available to its security holders
as soon as practicable, but in any event not later than 18 months after (i) the
effective date (as defined in Rule 158(c) under the Securities Act) of the
Registration Statement, and (ii) the effective date of each post-effective
amendment to the Registration Statement, as the case may be, an earnings
statement of the Company and its subsidiaries complying with Section 11(a) of
the Securities Act and the rules and regulations of the commission thereunder
(including, at the option of the Company, Rule 158);
(k) in the event of an underwritten offering,
promptly include or incorporate in a Prospectus supplement or post-effective
amendment to the Registration Statement such information as the managers
reasonably agree should be included therein and to which the Company does not
reasonably object and make all required filings of such Prospectus supplement or
post-effective amendment as soon as practicable after it is notified of the
matters to be included or incorporated in such Prospectus supplement or
post-effective amendment; and
(l) maintain a transfer agent and registrar for its
Common Stock.
Section 6. Indemnification.
(a) The Company agrees to indemnify and hold harmless
the Holder and each person, if any, who controls the Holder within the meaning
of the 1933 Act ("Distributing Holder") against any losses, claims, damages or
liabilities, joint or several (which shall, for all purposes of this Agreement,
include, but not be limited to, all reasonable costs of defense and
investigation and all reasonable attorneys' fees), to which the Distributing
Holder may become subject, under the 1933 Act or otherwise, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out
of or are based upon any untrue statement or alleged untrue statement of any
material fact contained in the Registration Statement, or any
8
<PAGE> 9
related preliminary prospectus, final prospectus, offering circular,
notification or amendment or supplement thereto, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading;
provided, however, that the Company will not be liable in any such case to the
extent that any such loss, claim, damage or liability arises out of or is based
upon an untrue statement or alleged untrue statement or omission or alleged
omission made in the Registration Statement, preliminary prospectus, final
prospectus, offering circular, notification or amendment or supplement thereto
in reliance upon, and in conformity with, written information furnished to the
Company by the Distributing Holder, specifically for use in the preparation
thereof. This Section 6(a) shall not inure to the benefit of any Distributing
Holder with respect to any person asserting such loss, claim, damage or
liability who purchased the Registrable Securities which are the subject thereof
if the Distributing Holder failed to send or give (in violation of the 1933 Act
or the rules and regulations promulgated thereunder) a copy of the prospectus
contained in such Registration Statement to such person at or prior to the
written confirmation to such person of the sale of such Registrable Securities,
where the Distributing Holder was obligated to do so under the 1933 Act or the
rules and regulations promulgated thereunder. This indemnity agreement will be
in addition to any liability which the Company may otherwise have.
(b) Each Distributing Holder agrees that it will
indemnify and hold harmless the Company, and each officer, director of the
Company or person, if any, who controls the Company within the meaning of the
1933 Act, against any losses, claims, damages or liabilities (which shall, for
all purposes of this Agreement, include, but not be limited to, all reasonable
costs of defense and investigation and all reasonable attorneys' fees) to which
the Company or any such officer, director or controlling person may become
subject under the 1933 Act or otherwise, insofar as such losses, claims, damages
or liabilities (or actions in respect thereof; arise out of or are based upon
any untrue statement or alleged untrue statement of any material fact contained
in the Registration Statement, or any related preliminary prospectus, final
prospectus, offering circular, notification or amendment or supplement thereto,
or arise out of or are based upon the omission or the alleged omission to state
therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, but in each case only to the extent that such
untrue statement or alleged untrue statement or omission or alleged omission was
made in the Registration Statement, preliminary prospectus, final prospectus,
offering circular, notification or amendment or supplement thereto in reliance
upon, and in conformity with, written information furnished to the Company by
such Distributing Holder, specifically for use in the preparation thereof. This
indemnity agreement will be in addition to any liability which the Distributing
Holder may otherwise have.
(c) Promptly after receipt by an indemnified party
under this Section 6 of notice of the commencement of any action, such
indemnified party will, if a claim in respect thereof is to be made against the
indemnifying party under this Section 6, notify the indemnifying party of the
commencement thereof; but the omission so to notify the indemnifying party will
not relieve the indemnifying party from any liability which it may have to any
indemnified party except to the extent of actual prejudice demonstrated by the
indemnifying party. In case any such action is brought against any indemnified
party, and it notifies the indemnifying party of the commencement thereof, the
indemnifying party will be entitled to participate in, and, to the extent that
it may wish, jointly with any other indemnifying party
9
<PAGE> 10
similarly notified, assume the defense thereof, subject to the provisions herein
stated and after notice from the indemnifying party to such indemnified party of
its election so to assume the defense thereof, the indemnifying party will not
be liable to such indemnified party under this Section 6 for any legal or other
expenses subsequently incurred by such indemnified party in connection with the
defense thereof other than reasonable costs of investigation, unless the
indemnifying party shall not pursue the action to its final conclusion. The
indemnified party shall have the right to employ separate counsel in any such
action and to participate in the defense thereof, but the fees and expenses of
such counsel shall not be at the expense of the indemnifying party if the
indemnifying party has assumed the defense of the action with counsel reasonably
satisfactory to the indemnified party; provided that if the indemnified party is
the Distributing Holder, the fees and expenses of such counsel shall be at the
expense of the indemnifying party if (i) the employment of such counsel has been
specifically authorized in writing by the indemnifying party, or (ii) the named
parties to any such action (including any impleaded parties) include both the
Distributing Holder and the indemnifying party and the Distributing Holder shall
have been advised by such counsel that there may be one or more legal defenses
available to the indemnifying party different from or in conflict with any legal
defenses which may be available to the Distributing Holder (in which case the
indemnifying party shall not have the right to assume the defense of such action
on behalf of the Distributing Holder, it being understood, however, that the
indemnifying party shall, in connection with any one such action or separate but
substantially similar or related actions in the same jurisdiction arising out of
the same general allegations or circumstances, be liable only for the reasonable
fees and expenses of one separate firm of attorneys for the Distributing Holder,
which firm shall be designated in writing by the Distributing Holder). No
settlement of any action against an indemnified party shall be made without the
prior written consent of the indemnified party, which consent shall not be
unreasonably withheld.
Section 7. Contribution. In order to provide for just and
equitable contribution under the 1933 Act in any case in which (i) the
indemnified party makes a claim for indemnification pursuant to Section 6 hereof
but is judicially determined (by the entry of a final judgment or decree by a
court of competent jurisdiction and the expiration of time to appeal or the
denial of the last right of appeal) that such indemnification may not be
enforced in such case notwithstanding the fact that the express provisions of
Section 6 hereof provide for indemnification in such case, or (ii) contribution
under the 1933 Act may be required on the part of any indemnified party, then
the Company and the applicable Distributing Holder shall contribute to the
aggregate losses, claims, damages or liabilities to which they may be subject
(which shall, for all purposes of this Agreement, include, but not be limited
to, all reasonable costs of defense and investigation and all reasonable
attorneys' fees), in either such case (after contribution from others) on the
basis of relative fault as well as any other relevant equitable considerations.
The relative fault shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information
supplied by the Company on the one hand or the applicable Distributing Holder on
the other hand, and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
The Company and the Distributing Holder agree that it would not be just and
equitable if contribution pursuant to this Section 7 were determined by pro rata
allocation or by any other method of allocation which does not take account of
the equitable considerations
10
<PAGE> 11
referred to in this Section 7. The amount paid or payable by an indemnified
party as a result of the losses, claims, damages or liabilities (or actions in
respect thereof) referred to above in this Section 7 shall be deemed to include
any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending any such action or claim. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the 1933 Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation.
Notwithstanding any other provision of this Section 7, in no event shall any (i)
Holder be required to undertake liability to any person under this Section 7 for
any amounts in excess of the dollar amount of the proceeds to be received by
such Holder from the sale of such Holder's Registrable Securities (after
deducting any fees, discounts and commissions applicable thereto) pursuant to
any Registration Statement under which such Registrable Securities are to be
registered under the Securities Act and (ii) underwriter be required to
undertake liability to any person hereunder for any amounts in excess of the
aggregate discount, commission or other compensation payable to such underwriter
with respect to the Registrable Securities underwritten by it and distributed
pursuant to the Registration Statement.
Section 8. Notices. All notices, demands, requests, consents,
approvals, and other communications required or permitted hereunder shall be in
writing and, unless otherwise specified herein, shall be (i) personally served,
(ii) deposited in the mail, registered or certified, return receipt requested,
postage prepaid, (iii) delivered by reputable air courier service with charges
prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed
as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or
permitted to be given hereunder shall be deemed effective (a) upon hand delivery
or delivery by facsimile, with accurate confirmation generated by the
transmitting facsimile machine, at the address or number designated below (if
delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered
other than on a business day during normal business hours where such notice is
to be received) or (b) on the second business day following the date of mailing
by reputable courier service, fully prepaid, addressed to such address, or upon
actual receipt of such mailing, whichever shall first occur.
The addresses for such communications shall be:
If to the Company: Integrated Surgical Systems, Inc.
1850 Research Park Drive
Davis, CA 95616-4884
Attention: Ramesh C. Trivedi
Telephone: (530) 792-2600
Facsimile: (530) 792-2690
11
<PAGE> 12
with a copy to: Snow Becker Krauss P.C.
(shall not constitute notice) 605 Third Avenue
New York, NY 10158
Attention: Jack Becker
Telephone: (212) 687-3860
Facsimile: (212) 949-7052
If to the Investor: As set forth in the
signature page of the
Purchase Agreement.
with a copy to: Joseph A. Smith, Esq.
(shall not constitute notice) Epstein Becker & Green, P.C.
250 Park Avenue
New York, New York
Telephone: (212) 351-4500
Facsimile: (212) 661-0989
Either party hereto may from time to time change its address or facsimile number
for notices under this Section 8 by giving at least ten (10) days' prior written
notice of such changed address or facsimile number to the other party hereto.
Section 9. Assignment. This Agreement is binding upon and
inures to the benefit of the parties hereto and their respective heirs,
successors and permitted assigns. The rights granted the Holder under this
Agreement may be assigned to any purchaser of substantially all of the
Registrable Securities (or the rights thereto) from Holder. In the event of a
transfer of the rights granted under this Agreement, the Holder agrees that the
Company may require that the transferee comply with reasonable conditions as
determined in the discretion of the Company.
Section 10. Additional Covenants of the Company. The Company
agrees that at such time as it meets all the requirements for the use of
Securities Act Registration Statement on Form S-3 it shall file all reports and
information required to be filed by it with the Commission in a timely manner
and take all such other action so as to maintain such eligibility for the use of
such form.
Section 11. Counterparts/Facsimile. This Agreement may be
executed in two or more counterparts, each of which shall be constitute an
original, but all of which, when together shall constitute but one and the same
instrument, and shall become effective when one or more counterparts have been
signed by each party hereto and delivered to the other party. In lieu of the
original, a facsimile transmission or copy of the original shall be as effective
and enforceable as the original.
12
<PAGE> 13
Section 12. Termination of Registration Rights. The rights
granted pursuant to this Agreement shall terminate as to each Holder (and
permitted transferees or assignees ) upon the occurrence of any of the
following:
(a) all Holder's securities subject to this Agreement have
been registered and sold;
(b) such Holder's securities subject to this Agreement may be
sold without such registration pursuant to Rule 144 promulgated by the SEC
pursuant to the Securities Act;
(c) such Holder's securities subject to this Agreement can be
sold pursuant to Rule 144(k).
Section 13. Remedies. The remedies provided in this Agreement
are cumulative and not exclusive of any remedies provided by law. If any term,
provision, covenant or restriction of this Agreement is held by a court of
competent jurisdiction to be invalid, illegal, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired
or invalidated, and the parties hereto shall use their best efforts to find and
employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is
hereby stipulated and declared to be the intention of the parties that they
would have executed the remaining terms, provisions, covenants and restrictions
without including any of such that may be hereafter declared invalid, illegal,
void or unenforceable.
Section 14. Conflicting Agreements. The Company shall not
enter into any agreement with respect to its securities that is inconsistent
with the rights granted to the holders of Registrable Securities in this
Agreement or otherwise conflicts with the provisions hereof. Without limiting
the generality of the foregoing, without the written consent of the Holders of a
majority in interest of the Registrable Securities, the Company shall not grant
to any person the right to request it to register any of its securities under
the Securities Act unless the rights so granted are subject in all respect to
the prior rights of the holders of Registrable Securities set forth herein, and
are not otherwise in conflict or inconsistent with the provisions of this
Agreement. The restrictions on the Company's rights to grant registration rights
under this paragraph shall terminate on the date of the Registration Statement
to be filed pursuant to Section 3(a) is declared effective by the Commission.
Section 15. Headings. The headings in this Agreement are for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
Section 16. Governing Law, Arbitration. This Agreement shall
be governed by and construed in accordance with the laws of the State of New
York applicable to contracts made in New York by persons domiciled in New York
City and without regard to its principles of conflicts of laws. Any dispute
under this Agreement or any Exhibit attached hereto shall be submitted to
arbitration under the American Arbitration Association (the "AAA") in New York
City, New York, and shall be finally and conclusively determined by the decision
of a board of
13
<PAGE> 14
arbitration consisting of three (3) members (hereinafter referred to as the
"Board of Arbitration") selected as according to the rules governing the AAA.
The Board of Arbitration shall meet on consecutive business days in New York
City, New York, and shall reach and render a decision in writing (concurred in
by a majority of the members of the Board of Arbitration) with respect to the
amount, if any, which the losing party is required to pay to the other party in
respect of a claim filed. In connection with rendering its decisions, the Board
of Arbitration shall adopt and follow the laws of the State of New York. To the
extent practical, decisions of the Board of Arbitration shall be rendered no
more than thirty (30) calendar days following commencement of proceedings with
respect thereto. The Board of Arbitration shall cause its written decision to be
delivered to all parties involved in the dispute. Any decision made by the Board
of Arbitration (either prior to or after the expiration of such thirty (30)
calendar day period) shall be final, binding and conclusive on the parties to
the dispute, and entitled to be enforced to the fullest extent permitted by law
and entered in any court of competent jurisdiction. The non-prevailing party to
any arbitration (as determined by the Board of Arbitration) shall pay the
expenses of the prevailing party, including reasonable attorneys' fees, in
connection with such arbitration.
Section 17. Severability. If any provision of this Agreement
shall for any reason be held invalid or unenforceable, such invalidity or
unenforceability shall not affect any other provision hereof and this Agreement
shall be construed as if such invalid or unenforceable provision had never been
contained herein. Terms not otherwise defined herein shall be defined in
accordance with the Agreement.
Section 18. Capitalized Terms. All capitalized terms not
otherwise defined herein shall have the meaning assigned to them in the Purchase
Agreement.
IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be duly executed, on the day and year first above written.
INTEGRATED SURGICAL SYSTEMS, INC.
By: ________________________________
Mark Winn
Chief Financial Officer
HOLDER:
_______________________________________________
By:____________________________________________
Authorized Signatory
14
<PAGE> 1
Exhibit 5.1
SNOW BECKER KRAUSS P.C.
605 Third Avenue
New York, New York 10158
Phone: (212) 687-3860
Fax: (212) 949-7052
October 22, 1998
Board of Directors
Integrated Surgical Systems, Inc.
1850 Research Park Drive
Davis, California 95616-4884
Ladies and Gentlemen:
You have requested our opinion, as counsel for Integrated
Surgical Systems, Inc., a Delaware corporation (the "Company"), in connection
with the registration statement on Form S-3 (the "Registration Statement"),
under the Securities Act of 1933, filed by the Company with the Securities and
Exchange Commission for the sale of 1,809,000 shares (the "Registered Shares")
of common stock, $.01 par value (the "Common Stock"), by the selling
securityholders named in the Registration Statement, including (i) up to
1,805,000 shares that they may acquire upon conversion of the Company's Series A
Convertible Preferred Stock (the "Series A Preferred Stock") and upon exercise
of warrants (the "Warrants") to purchase an aggregate of 440,000 shares of
Common Stock and (ii) 5,000 shares of Common Stock (the "Shares") issued in
connection with the issuance and sale of the Series A Preferred Stock, as
described in the Registration Statement.
We have examined such records and documents and made such
examinations of law as we have deemed relevant in connection with this opinion.
Based upon the foregoing, it is our opinion that:
1. The Company has been duly organized, is validly existing and
in good standing under the laws of the State of Delaware.
2. All of the Registered Shares have been duly authorized.
3. The Shares have been legally issued and are fully paid and
nonassessable.
4. The Registered Shares issuable upon conversion of the Series A
Preferred Stock or upon the exercise of the Warrants, when
issued in accordance with the terms of the Certificate of
Designations authorizing the issuance of the Series A
Preferred Stock or upon payment of the exercise price
specified in the Warrants, as the case may be, will be legally
issued, fully paid and nonassesable.
We hereby consent to the filing of this opinion as an exhibit
to the Registration Statement and to the reference to our firm under the caption
"Legal Matters" in the Registration Statement. In so doing, we do not admit that
we are in the category of persons whose consent is required under Section 7 of
the Act or the rules and regulations of the Securities and Exchange Commission
promulgated thereunder.
Very truly yours,
s/ SNOW BECKER KRAUSS P.C.
<PAGE> 1
Exhibit 23.2
CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
We consent to the reference to our firm under the caption
"Experts" in the Registration Statement (Form S-3) and related Prospectus of
Integrated Surgical Systems, Inc. for the registration of 1,809,000 shares of
its common stock and to the incorporation by reference therein of our report
dated February 26, 1998, with respect to the consolidated financial statements
of Integrated Surgical Systems, Inc. included in its Annual Report (Form 10-KSB)
for the year ended December 31, 1997, filed with the Securities and Exchange
Commission.
ERNST & YOUNG LLP
Sacramento, California
October 23, 1998
